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Abstract
The mechanisms by which the release of acetylcholine from cholinergic neurones in the heart is
regulated are not well understood. A reliable and sensitive assay for acetylcholine is lacking.
Most studies of cardiac parasympathetic neurotransmission have used indirect methods such
as changes in heart rate and contractility.
A novel high pressure liquid chromatography (HPLC) method (electrochemical
detection) was adopted to assay acetylcholine overflow from the in situ, perfused, innervated
rat heart. Sample concentrations of 20 nM and above could be accurately measured
(inter-assay coefficient of variation, 6 %). Bilateral vagal nerve stimulations (15 Hz, 60 s,
0.8 mA) in the presence of neostigmine, produced the expected negative inotropic and
chronotropic effects which were reversibly abolished by 1 jiM atropine. Acetylcholine was not
detected in coronary effluent. Neostigmine, 50 jiM, inhibited over 91 % of the in vitro
myocardial acetylcholinesterase activity. Infused acetylcholine, 200 nM, was quantitatively
recovered. These results suggested that the concentration of acetylcholine released from the
parasympathetic neuroeffector junction was below the detection limit for the assay. Increasing
the frequency and voltage of the vagal nerve stimulation to cause asystole did not produce a
detectable amount of acetylcholine. Neither did the presence of atropine, which has been
reported to quadruple the acetylcholine overflow from the perfused chicken heart. Bioassay of
acetylcholine, using the leech dorsal muscle preparation, was twice as sensitive as the HPLC
method, but still failed to detect acetylcholine.
An HPLC method was also set up for the measurement of noradrenaline in coronary
effluent samples from perfused, innervated rat hearts. The sensitivity was 0.5 nM
noradrenaline (inter-assay coefficient of variation, 4.9 %). Four repeated left stellate ganglion
stimulations (5 Hz, 60s, 0.8mA), S1-S4, separated by a 15 min recovery period,
demonstrated a progressive decline in noradrenaline overflow. The influence of duration of
ganglion stimulation (30 or 60s) and coronary flow rate (5 or 10mlg"1 min"1) on the
noradrenaline overflow and functional response to four consecutive sympathetic ganglion
stimulations, was examined. Baseline (pre-stimulation) mechanical performance of the
preparation was stable. Lactate production was low and did not vary significantly between the
groups. Stimulation induced changes in heart rate and left ventricular pressure were stable
throughout the four stimulations (coronary flow rate 5 ml g"1 min'1). Noradrenaline overflow
and contractility, however, showed a progressive decline from SI to S4 (p< 0.05). Reducing
the stimulus duration from 60 to 30 s delayed the onset of the decline in noradrenaline
x
overflow and +dP/dt, while preventing the decline in the magnitude of the -dP/dt response.
Increasing the coronary flow rate, completely prevented the decline in the response to nerve
stimulation.
Perfusing the heart with very large amounts of catecholamines may protect against
prolonged ischaemia (so-called ischaemic preconditioning). The ability of sympathetic nerve
stimulation (5 Hz, 5 min) to precondition the rat heart against dysfunction and tissue enzyme
depletion after a 30 min period of stop-flow ischaemia was investigated. Noradrenaline and
lactate release, left ventricular pressure, heart rate and contractility during the first 30 min of
reperfusion were not altered by preconditioning. Tissue creatine kinase levels after 4 hours
reperfusion also did not differ. Recovery of coronary perfusion, however, was slightly
improved in the preconditioned groups (p < 0.05).
In conclusion, vagal stimulation of the perfused, innervated rat heart results in marked
negative inotropic and chronotropic changes, without detectable acetylcholine overflow.
Repeated left stellate ganglion stimulation (S1-S4) results in reduced noradrenaline overflow
and haemodynamic effects, that can be prevented using a coronary perfusion flow rate of
10 ml g"1 min"1. Left stellate ganglion stimulation does not confer a protective effect against
ischaemia. Future studies of the role of the parasympathetic nervous system require more
sensitive methods to detect acetylcholine.
xi
CHAPTER 1
Introduction and literature review
1.1 The cardiac autonomic nervous system
The autonomic nervous system and its control of cardiac function has long been a subject of
interest by investigators. In 1921, Loewi performed his classic, and much quoted experiment
on frog heart which was the first demonstration of chemical neurotransmission. A profusion of
experiments followed, during which the principles of chemical neurotransmission were
elucidated. More recently, the importance of autonomic nerve function in determining the
outcome of acute cardiac ischaemia or infarction has been investigated.
Sudden cardiac death following acute myocardial ischaemia remains one of the highest
causes ofmortality in the western world (Bennett, 1996; Immonen-RSM et al., 1996). Death
commonly occurs within minutes of the onset of severe chest pain or heart attack, in many
cases, before the patient has reached hospital. In a study by Armstrong, in which patients were
followed up for 4 weeks after suffering a myocardial infarction, 45 % of the deaths over this
period, occurred within an hour of the onset of symptoms (Armstrong et al., 1972). Holter
monitoring has shown that the majority of such deaths result from the onset of ventricular
fibrillation, often preceded by episodes of ventricular tachycardia (Nikolic et al., 1982),
generated through a re-entrant mechanism (Janse et al., 1980; Janse and Wit, 1989).
Evidence of autonomic activation is common during the first hour of an episode of
acute myocardial ischaemia. In an important study by Webb and colleagues (Webb et al.,
1972), over 80 % of patients admitted to hospital suffering from the advent of their first
myocardial infarction showed symptoms of autonomic overactivity during the first hour of the
ischaemic event. Experimental studies have demonstrated an important role for the autonomic
nervous system in the genesis of arrhythmias. In general, sympathetic neural influences are
thought to facilitate the formation of arrhythmias in the ischaemic and non-ischaemic
myocardium (Sheridan et al., 1980; Verrier and Lown, 1984; Penny, 1984; Schwartz et al.,
1976a and b; Schwartz, 1985; Schwartz et al., 1985), while parasympathetic influences are
thought to oppose this (Ferrari et al., 1992; Billman, 1989; De Ferrari, 1987; Das and
Bhattacharya, 1972; Hohnloser et al., 1986).
Evidence that the cardiac autonomic nervous system may contribute to
arrhythmogenesis during myocardial ischaemia in the in vivo situation, comes from studies of
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parasympathetic tone using the methods of heart rate variability and baroreflex sensitivity
testing (see section 1.1.6 for detailed description). These techniques have shown that where
parasympathetic responses are impaired, as indicated by a reduced heart rate variability or
baroreflex sensitivity, the myocardium is more vulnerable to the onset of ventricular
arrhythmias (Schwartz et al., 1988a). The degree of impahment of parasympathetic neural
function is a good predictor of outcome following myocardial infarction, both in animals
(Schwartz et al., 1988a; Hull et al., 1990) and humans (La Rovere et al., 1988; Kleiger et al.,
1987; Odemuyiwa et al., 1994). Furthermore, the strength of pre-infarction parasympathetic
reflexes may be able to identify those individuals at greater risk from arrhythmias in the event
of an episode of acute ischaemia (Schwartz et al., 1988a; Adamson et al., 1994).
Understanding the behaviour of the cardiac autonomic nervous system during acute
ischaemia may therefore, lead to the development of interventions to both identify and treat
those at greatest risk from arrhythmias. In order to understand and interpret the effect of
changes in autonomic nerve function during ischaemia, however, it is important to first
understand the behaviour of the autonomic nervous system under normal conditions.
1.1.1 Anatomy of cardiac autonomic innervation
There are two limbs of the autonomic nervous system - sympathetic and parasympathetic. In
control of cardiac function, these two limbs generally (although not always) have opposing
effects. Sympathetic nerve activation causes increases in heart rate, force of contraction and
automaticity. Parasympathetic nerve activity leads to decreases in all of the above. In some
respects, however, the two systems do have synergistic effects. For example, both
noradrenaline and acetylcholine shorten action potential duration and thus reduce the
refractory period.
Although both obey the same principles of stimulus secretion coupling, the anatomy of
the two systems is different (for review see Corr et al., 1986; Loffelholz and Pappano, 1985).
Sympathetic efferent preganglionic neurones have their cell bodies in the lateral hom of the
grey matter in the cervical-thoracic vertebrae. Fibres leave the spinal cord in the spinal nerves.
Once outside the spinal cord, they exit the spinal nerves and run to the paravertebral
sympathetic chain - an interconnected chain of sympathetic ganglia which lie on either side of
the spinal column. Cardiac sympathetic nerves synapse in the left and right stellate ganglia (the
product of a fusion between the inferior cervical and first thoracic ganglia).
Efferent sympathetic impulses are transmitted to the heart via ansae subclaviae -
branches of the right and left stellate ganglia. Postganglionic axons primarily enter the
myocardium following the coronary arteries. Although overlap does exist, left sided cardiac
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nerves mainly innervate the anterior aspect of the ventricles and the AV node, whereas the
right-sided cardiac nerves innervate the sinus node and the posterior portion of the ventricles.
The parasympathetic cardiac innervation originates from the dorsal vagal nuclei in the
medulla and is conducted to the heart in the left and right branches of the vagus nerve. Ganglia
are located in the cardiac vagal plexus or the atrial walls. Postganglionic neurones are much
shorter than those of the sympathetic system and infiltrate the atria and nodal tissues along
blood vessels. It was once thought that there was no vagal innervation to the ventricular
myocardium. Acetylcholine (Brown, 1976), choline acetyltransferase (Roskoski et al., 1975)
and muscarinic receptors (Fields et al., 1978) have all, however, been shown to exist in
ventricular tissue. It is now known that some postganglionic axons enter the ventricular
myocardium via the AV groove. Although the density of parasympathetic innervation in the
ventricles is substantially less than that in the atria, vagal nerve stimulation is able to exert
important effects on ventricular automaticity and repolarization, both through an interaction
with the sympathetic nervous system and also through direct electrophysiological actions
(Rardon and Bailey, 1983).
1.1.2 Physiology of the parasympathetic nervous system
a) Synthesis and storage ofacetylcholine
Acetylcholine is synthesised within the axoplasm of cholinergic nerve terminals (for review see
Ldffelholz et al., 1984). The acetyl moiety from acetyl coenzyme A is transferred to choline in
a reaction catalysed by the enzyme, choline acetyltransferase. The original source of the acetyl
groups has not been determined in the heart, although in brain tissue, they are derived from
pyruvate. In comparison, much more is known about the second precursor, choline.
Choline is a charged polar molecule which cannot easily cross the cell membrane. Its
transfer into the nerve cell is the rate limiting step in acetylcholine synthesis. Choline for the
reaction is taken up from the interstitial space by a high affinity choline uptake (HACU)
carrier (Wetzel and Brown, 1983). The carrier molecule is sodium dependent and activated by
stimulation of the vagus nerves. Plasma levels of choline in mammalian species are of the
order of 5-10 |iM (Bligh, 1952). Under normal physiological conditions, this is sufficient to
maintain adequate acetylcholine synthesis (Wetzel and Brown, 1983; Dieterich et al., 1978).
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Acetylcholine is synthesised locally by choline acetyltransferase (ChAT) and stored in small, clear vesicles.
Acetylcholine release is triggered by depolarisation. At the end-plate, acetylcholine acts on both presynaptic and
postsynaptic muscarinic-m2 receptors. The presynaptic m2 receptors inhibit acetylcholine release - an effect
which is shared by both Y2 purinergic and C*2 adrenergic receptors. Released acetylcholine is degraded by the
membrane-bound enzyme, acetylcholinesterase into choline and acetate. Choline may be taken up into the
presynaptic terminal by a high affinity choline uptake carrier (HACU) where it is reincorporated into
acetylcholine.
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Hydrolysis of released acetylcholine by acetylcholinesterase inactivates acetylcholine
and also liberates choline into the extracellular space. A certain amount of this choline is
reuptaken into the nerve terminal although this is likely to be a relatively unimportant source
of choline for acetylcholine synthesis (LOffelholz and Pappano, 1985). A further supply of
extracellular free choline is obtained from the breakdown of phospholipids -
glycerophosphocholine and phosphorylated choline. This accounts for the choline efflux
evident in unstimulated isolated hearts, perfused with choline free medium (Corradetti et al.,
1982).
The formation of acetylcholine is catalysed by choline acetyltransferase - a cytosolic
enzyme. The distribution of choline acetyltransferase within the heart has been mapped, and
supports observations by histologists that postganglionic cholinergic innervation is low in
mammalian ventricles (Slavikovd and Tucek, 1981) compared to the atria.
Following synthesis, the acetylcholine is packaged into synaptic storage vesicles inside
which, the concentration of the transmitter can be as high as 800 mM (Zimmermann, 1988).
b) Acetylcholine release
Release of acetylcholine from the vesicles is triggered either by the arrival of an action
potential or by high extracellular potassium levels (for review see Kilbinger, 1988). The exact
mechanism of the release has not been elucidated, but it is dependent on an influx of
extracellular calcium. Agents which affect interneuronal calcium influx can modify
acetylcholine release. Magnesium, cobalt and manganese ions all inhibit acetylcholine release
by interfering with the slow inward calcium current in the neurone (Ginsborg and Jenkinson,
1976; Glitsch and Pott, 1978). Likewise, barbiturates have been reported to reduce the release
of cardiac acetylcholine. Pentobarbital infused into the isolated, perfused chicken heart caused
a substantial inhibition of stimulation induced acetylcholine release (Lindmar et al., 1979).
Acetylcholine release can also be modulated by a variety of endogenous agents
(Wetzel and Brown, 1985; Wetzel et al., 1985). Mechanisms of presynaptic modulation of
neurotransmitter release by endogenous substances are discussed in the next section.
Following its release from the presynaptic membrane, acetylcholine diffuses across the
synaptic cleft to the postsynaptic membrane where it combines with muscarinic receptors.
Despite the existence of several different species of the muscarinic acetylcholine receptor
(Kubo et al., 1986; Bonner et al., 1987), only receptors of the m2 subtype have been identified
in mammalian cardiac tissue (Deighton et al., 1990; Maeda et al., 1988). The density of
receptors is highest in areas with the greatest parasympathetic innervation.
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Postsynaptic muscarinic receptors are coupled to a variety of ion channels and second
messenger systems, through a range of G proteins. Different subclasses of the m2 receptor,
with different affinities for acetylcholine, have been hypothesised to be coupled to the same
effector via different G proteins, allowing fine control of the response (Ikegaya et al., 1990).
Among its other actions, acetylcholine or cholinergic agonists binding to cardiac
postsynaptic muscarinic receptors can inhibit adenylate cyclase and the production of
3',5'-cyclic adenosine monophosphate (cAMP) (Delhaye et al., 1984; Hescheler et al., 1986;
Breitweiser and Szabo, 1985), stimulate the production of cyclic guanosine monophosphate
(cGMP) (Cramb et al., 1987; George et al., 1970), open potassium channels (Szabo and
Otero, 1990; Pfaffinger et al., 1985) and interact with the PI cycle (Cockroft, 1987).
c) Presynaptic modulation ofneurotransmitter release
Mechanisms of presynaptic modulation of neurotransmitter release can be classified into four
groups. Presynaptic mechanisms affecting both the parasympathetic and the sympathetic
postganglionic nerve terminals are discussed below.
i) Feedback modulation
Receptors located on the presynaptic neurone, allow neurotransmitter, present in the synaptic
cleft, to influence its own release. The best characterised example of feedback modulation
occurs when noradrenaline released from the neuroeffector junction, acts at presynaptic
(X2-adrenoceptors on sympathetic nerves to inhibit the further release of noradrenaline (Starke,
1987; Haass et al., 1989). The mechanism of this effect is an inhibition of voltage-gated
calcium channels (Rand et al., 1987). It appears that acetylcholine is able to similarly
influence its own release from the cholinergic neuroeffector junction. Pharmacological
blockade of muscarinic receptors with atropine causes an increase in the stimulation-evoked
release of acetylcholine (Ldffelholz et al., 1984). Although the mechanism has not been
investigated in the heart, in other tissues which have been examined, such as the guinea pig
ileum and the cat urinary bladder, presynaptic muscarinic receptors cause inhibition of N-type
calcium channels (Wessler, 1996).
ii) Axo-axonal modulation
Neurotransmitters released from adjacent nerves of a different type, have presynaptic receptors
on their neighbouring nerves. In the heart, the best example of this is the reciprocal
arrangement which exists between parasympathetic and sympathetic postganglionic nerves.
Cholinergic agonists or vagal stimulation inhibits stimulated noradrenaline overflow from
isolated, perfused rat hearts (LOffelholz and Muscholl, 1969; Fuder et al., 1985; Levy, 1984;
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Lavalkie et al., 1978). Similarly, acetylcholine release from incubated rat atria, evoked by
either field stimulation or high potassium, was significantly inhibited by a-adrenoceptor
agonists (Wetzel et al., 1985; McGrattan et al., 1987). As yet, it has not been demonstrated
that noradrenaline release evoked by sympathetic nerve stimulation is able to inhibit the
overflow of vagally mediated acetylcholine overflow. Although, in the dog heart in vivo,
sympathetic nerve stimulation reduces heart rate variability, the effect is mediated through the
adrenergic co-transmitter neuropeptide Y and not through presynaptic a-adrenoceptors
(Warner and Levy, 1989; Potter, 1987; Hall and Potter, 1990).
iii) Trans-synaptic (retrograde) modulation
Released neurotransmitter binding to postsynaptic receptors on the effector cell, may stimulate
the release of a substance which is able to diffuse back and interact with presynaptic
exocytotic mechanisms. Examples of such substances include: adenosine, bradykinin,
histamine, serotonin and prostaglandins. Thus, adenosine which is released from myocardial
cells following sympathetic stimulation (Fredholm and Sollevi, 1981), acts at presynaptic
Ai-adenosine receptors on the sympathetic nerves and inhibits further release of noradrenaline
(Haass et al., 1989).
iv) Neurohormonal modulation
Autacoids or hormones produced by remote tissues are carried in the blood and influence
neurotransmitter released at presynaptic autonomic nerves. Examples would be the facilitation
of noradrenaline release by adrenaline acting at presynaptic (^-adrenoceptors on cardiac
sympathetic nerves (Adler-Graschinsky and Langer, 1975; Yamaguchi et al, 1977). Also, the
inhibition of presynaptic acetylcholine release from parasympathetic nerves by circulating
noradrenaline acting at ct2-adrenoceptors. Other substances in this category include angiotensin
II, histamine, dopamine, enkephalines and serotonin (Corr et al., 1986).
d) Electrophysiological and metabolic effects ofmyocardial acetylcholine
General parasympathetic effects on cardiac electrophysiology include negative inotropic and
chronotropic changes, decreased automaticity and pacemaker activity, decreased duration of
action potential and refractory period. The rate of electrical conduction through the
myocardium may also be slowed. These changes are effected through alterations to the
membrane ionic conductances, particularly potassium, which occur during the five phases of
the cardiac action potential.
For example, acetylcholine exerts its negative chronotropic effect, primarily by
opening inwardly rectifying potassium channels Ik(ach) during phase 4 of the action potential in
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the nodal tissues (Boyett et al., 1995; Spear et al., 1979). This effect opposes the spontaneous
depolarisation mediated by If (DiFrancesco and Tromba, 1988) and increases the time taken
to reach the pacemaker potential. Acetylcholine is coupled to the potassium channel through
m2-muscarinic activation of a heterotrimeric, pertussis toxin sensitive G protein (Kurachi
etal., 1992; Pfaffinger et al., 1985). Through its actions on inwardly rectifying potassium
channels, acetylcholine is also able to hyperpolarise the cell membrane and depress the
pacemaker potential, making the heart less excitable and less prone to the induction of
re-entrant arrhythmias (Baumgarten and Fozzard, 1986; Mubagwa and Carmeliet, 1983).
In addition to its negative chronotropic effect, acetylcholine is able to antagonise the
positive inotropic effect of (^-adrenergic stimulation, mediated by increased inward calcium
influx during the plateau phase of the action potential (Josephson and Sperelakis, 1982). As
discussed later (see section 1.1.3c), the (^-adrenergic effect is mediated by cyclic AMP and
m2-muscarinic receptor activation is coupled to adenylate cyclase activity by an inhibitory G
protein. The muscarinic stimulation of guanylate cyclase activity and cGMP (George et al.,
1970) may also play a role in this inhibition (Beavo et al., 1971; Endoh, 1979). Acetylcholine
also increases the repolarising inward potassium current during phase 3 of the action potential,
resulting in lengthening of the refractory period.
In addition to the acute effects on ionic conductance, acetylcholine acting at
muscarinic receptors can also exert more long-term effects through alteration of membrane
phospholipid metabolism. Stimulation of muscarinic receptors causes the 'PI effect* - an
increase in the breakdown of phosphatidylinositol (Cockroft, 1987; Brown and Brown, 1983;
Quist, 1982). Changes in the phospholipid metabolism may be directly linked to effector sites
through mechanisms involving alterations to physical properties of the membrane (fluidity
etc.). Furthermore, although the muscarinic stimulation of myoinositol-D-l,4,5-trisphosphate
(IP3) formation is thought to be physiologically unimportant in the mammalian heart
(Hawthorne and Simmonds, 1989), formation of the second metabolite, diacylglycerol, and the
subsequent activation of protein kinase C, may play a role in the modulation of contractility
over the longer term. Protein kinase C is proposed to achieve this through desensitisation of
(3-adrenergic receptors (Limas and Limas, 1985), and phosphorylation of sarcoplasmic
reticulum to enhance the calcium transport ATPase (Limas, 1980).
e) Inactivation of released acetylcholine
Clearance of acetylcholine from the synaptic cleft in the heart is by both enzymatic hydrolysis
and diffusion / washout (for reviews, see Ldffelholz et al., 1984; LOffelholz and Pappano,
1985). During the former, acetylcholine is hydrolysed into its constituent parts by the enzyme
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acetylcholinesterase. Acetylcholinesterase is located on the basement membrane, past which
the acetylcholine must diffuse to reach the postsynaptic membrane. This process is relatively
slow within the mammalian heart and allows much of the released acetylcholine to diffuse out
of the extracellular space and into the vascular lumen from where it is washed out. Even so,
the use of cholinesterase inhibitors markedly potentiates the actions of acetylcholine within the
mammalian heart (Ostenieder et al., 1981; Glitsch and Pott, 1978), leading to a 2-3 fold
increase in the evoked output (Dieterich et al., 1977). In the perfused chicken heart, the mean
extracellular concentration of acetylcholine following a short burst of vagal stimulation was
found to decline in a multiexponential fashion. The concentration was reduced by 50 % after
only 2.5 seconds (Lindmar et al., 1982) although 20 % of the acetylcholine remained
unhydrolysed after a further 20 seconds. In contrast to the mammalian heart, acetylcholine
overflow is readily detectable in the coronary effluent of perfused, vagally stimulated avian
hearts, even in the absence of cholinesterase inhibition (Kilbinger and LOffelholz, 1976;
Dieterich et al., 1977). The avian ventricle has a much more extensive parasympathetic
innervation than its mammalian counterpart (LOffelholz and Pappano, 1985) and vagal
stimulation results in a much larger acetylcholine overflow.
1.1.3 Physiology of the sympathetic nervous system
a) Synthesis and storage ofnoradrenaline
Noradrenaline is synthesised within the cytosol of the adrenergic nerve terminals (for a detailed
review, see Knight et al., 1989; Philippu and Matthaei, 1988). There are several enzymatic
steps in the process, the first of which is rate limiting and involves the
hydroxylation of L-tyrosine by tyrosine hydroxylase. The resulting DOPA is acted on by
DOPA decarboxylase to form dopamine, which is then converted to noradrenaline by
dopamine p-hydroxylase.
Storage of noradrenaline is in both small and large dense cored vesicles within the
nerve terminal. Very little noradrenaline is present in the cytosol, but the concentration in the
vesicles is very high (0.3 - 1.0 M). A reserpine sensitive active transport system carries the
noradrenaline across the vesicular membrane. Inside the vesicles, noradrenaline is complexed
to a protein, chromogranin A, and ATP, which reduces the osmolality of the vesicle contents
and helps to prevent the noradrenaline from leaking out. Neuropeptide Y (NPY), a
co-transmitter, is also stored within the large dense cored vesicles and released at the same
time as noradrenaline, ATP and chromogranin A.
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b) Noradrenaline release
Noradrenaline release from adrenergic nerve terminals is triggered in much the same way as
acetylcholine from cholinergic nerve terminals. Depolarisation caused either by an action
potential or high extracellular potassium concentration allows an influx of calcium into the
postganglionic adrenergic nerve terminal through voltage sensitive calcium channels. This
stimulates synaptic storage vesicles to fuse with the presynaptic membrane by a mechanism
which has yet to be fully elucidated. Noradrenaline release is accompanied by release of the
co-transmitters NPY and ATP, which themselves may modulate further exocytotic release via
presynaptic Y2 and P2y receptors respectively (Lundberg, 1996). The presynaptic modulation
of exocytotic noradrenaline release is discussed in more detail in section 1.1.2c (see
Figure 1.2).
c) Effects of released noradrenaline on cardiac electrophysiology and metabolism
There are five distinct types of adrenoceptor, and at least four of them are present in the
cardiac junctional tissues. Of the four, oti, pi and p2 receptors are located postsynaptically,
whereas a2 receptors are found prejunctionally. (^-adrenoceptors are expressed in adipose
tissue, where they play a role in the modulation of lipolysis (Barbe et al., 1996), and the
alimentary tissues, where they mediate muscle relaxation (De Boer et al., 1995). Their
presence in the heart has yet to be confirmed (Kaumann and Molenaar, 1996).
Stimulation of ai-adrenoceptors causes an increase in cytosolic free calcium levels
(Bylund et al., 1994). This is achieved by triggering the release of calcium from intracellular
calcium stores (Charest et al., 1983) through the G protein-mediated activation of
phospholipase C (Bylund et al, 1994). The calcium binds to calmodulin and the resulting
complex acts as a second messenger, ai-adrenoceptors have also been linked to a variety of
other signal transduction mechanisms, including the activation of phospholipases A2 and D,
and effects on cyclic nucleotides (Minneman, 1988). In the myocardium, ai-adrenoceceptor
stimulation leads to increased inotropy, reduced automaticity of pacemaker cells, lengthening
of the action potential and increased glucose uptake (Clark and Patten, 1984).
Cardiac beta-adrenoceptors are divided into two subtypes - (3i and (32. Both subtypes
are present in human cardiac tissue, although Pi appears to predominate (Stiles et al., 1983).
Myocardial P-adrenergic stimulation leads to positive inotropic and chronotropic changes,
shortening of action potential duration, increased automaticity of pacemaker cells and
increased conduction velocity.
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Figure 1.2 Schematic illustration of the major pre- and postsynaptic interactions at the
adrenergic nerve terminal
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Noradrenaline is synthesised locally in nerve endings and stored in both small and large dense-cored vesicles.
The co-transmitter, neuropeptide Y (NPY) is also stored in the large dense-cored vesicles, along with ATP
which is present in both vesicle types. Depolarization causes the vesicles to migrate and fuse with the
presynaptic membrane, releasing their contents. Following release, noradrenaline activates a variety of
postjunctional a and fl-adrenoceptors. In addition, it activates prejunctional (X2 adrenoceptors, inhibiting calcium
entry and thereby reducing noradrenaline release. Active reuptake of noradrenaline into the presynaptic nerve
terminal occurs via uptakei. Following reuptake, noradrenaline is repackaged into storage vesicles. The co-
transmitters NPY and ATP also possess both pre- and post-synaptic receptors. ATP acts postsynaptically at P2*
purinergic receptors. It also acts on presynaptic P2y purinergic receptors to inhibit noradrenaline release, and can
be degraded by ecto-ATPase to form adenosine which has similar actions at presynaptic Ai adenosine receptors.
NPY also has an inhibitory effect on noradrenaline release through its actions at presynaptic Y2 neuropeptide
receptors, and acetylcholine diffusing from adjacent cholinergic nerve terminals activates presynaptic m2
muscarinic receptors to achieve the same result.
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All three p-adrenoceptor subtypes are linked to adenylate cyclase activity through a
stimulatory G protein, Gs (Pelzer et al., 1990). There is no evidence for subtype variability in
this mechanism (Tate et al., 1991). When an agonist such as noradrenaline binds to a
P-adrenoceptor, adenylate cyclase activity is stimulated through the action of G„ resulting in
increased levels of intracellular cAMP. Cyclic AMP exerts a variety of intracellular effects
through phosphorylation of a range of cAMP-dependent protein kinases. These have targets at
calcium and potassium channels, sarcolemmal proteins such as phospholamban, contractile
proteins and metabolic enzymes responsible for glycogenolysis and lipolysis.
Cyclic AMP-dependent protein kinase A, phosphorylates components of voltage-gated
calcium channels, allowing increased calcium influx during the early part of the action
potential (Kameyama et al., 1996). This increased calcium influx is responsible for the
positive inotropic changes which are characteristic of P-adrenergic stimulatioa
There is evidence that Gs is able to regulate calcium, potassium and sodium ion
channels directly, even when the cAMP pathways are blocked (Brown and Birnbaumer, 1988;
Yatani et al, 1988; Pelzer et al., 1990). Although still controversial, the effect is very rapid
and has been proposed to allow beat to beat regulation of ion currents by sympathetic
stimulation of the heart (Pelzer et al., 1990).
In addition to its effects on myocardial contractility and action potential duration,
P-adrenoceptor stimulation exerts a positive chronotropic effect. This is achieved by
increasing the rate of spontaneous depolarisation of atrial pacemaker cells during phase 4 of
the action potential through an increase in the pacemaker current (Noble, 1984).
Alpha2-adrenoceptors too, are able to regulate adenylate cyclase activity. They have
an inhibitory effect on adenylate cyclase activity via a pertussis toxin sensitive G protein, Gj
(Limbird, 1988). Presynaptic <X2-adrenoceptors are located on both parasympathetic and
sympathetic postganglionic neurones, where they inhibit the overflow of neurotransmitter
(Farnebo and Hamberger, 1971; Kirkepar and Puig, 1971; Paton and Vizi, 1969). The
inhibition is mediated by a reduction in the calcium influx through voltage-gated calcium
channels, following depolarisation of the synaptic membrane. In the past, this was thought to
be mediated through a reduction in adenylate cyclase activity. The failure of inactivation of Gi
with pertussis toxin, to reliably abolish the a2-mediated inhibition of neurotransmitter release
called this into question (Nichols et al., 1988). Recently, a cGMP-dependent protein kinase
mechanism has been proposed (Haddad et al., 1995).
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d) Deactivation and clearance of released noradrenaline
Unlike acetylcholine, there is no synaptic enzyme whose specific purpose is to inactivate
noradrenaline. Instead, under normal physiological conditions, the majority of the released
noradrenaline is removed from the synaptic cleft by two uptake systems, uptakei and uptake2.
Uptake i is relatively more important in the clearance of noradrenaline from the
synaptic cleft (Iversen, 1973; Goldstein et al., 1988; Dart et al., 1984b) and carries
noradrenaline back across the synaptic membrane. It is an active transport system that is
powered by the electrochemical Na+ gradient. Its action is blocked by cocaine,
phenoxybenzamine, amphetamines and tricyclic antidepressants such as desipramine.
Blockade of uptakei causes an increased overflow of noradrenaline (Dart et al., 1983) and
increased haemodynamic response during sympathetic nerve stimulation (Dart et al., 1984a).
Although uptakei has a high affinity for noradrenaline (it does not transport the (3 agonist
isoprenaline), it has a low maximum rate. Once inside the axoplasm, the majority of
noradrenaline is repackaged into storage vesicles. A small amount is metabolised by
monoamine-oxidase (MAO) into the inactive metabolite 3,4-dihydroxy-phenyl-ethyl-glycol.
Uptake2 is located in the postsynaptic membrane and transports noradrenaline into the
extra-neuronal cells. Inside the cells, noradrenaline is degraded by the enzyme
catechol-O-methyl transferase (COMT), producing the metabolite nor-metanephrine. Although
uptake2 has a high maximum rate in comparison to uptake^ it has a much lower affinity for
noradrenaline, and so plays a less important role in its clearance (Iversen, 1973; Goldstein
et al., 1988; Dart et al., 1984b). Uptake2 has a higher affinity for adrenaline and isoprenaline,
both of which can also be methylated by the enzyme COMT. Uptake2 is blocked by
corticosteroids but is not sensitive to any of the compounds that inhibit uptakei.
Washout of noradrenaline from the synaptic cleft into the circulation also occurs (Dart
et al., 1983) although reuptake is quantitatively more important at low flow rates. In the
presence of uptake blockade, washout becomes the principal method of synaptic clearance of
noradrenaline. Studies on the isolated rat heart, perfused at 5 ml g'1 min"1 in the presence of
desipramine, have shown that following a 1 minute sympathetic nerve stimulation, 98 % of the
noradrenaline overflow appears in the coronary effluent within the first minute (Du, Ph.D
thesis, 1991). Sensitive and robust methods exist for the analysis of noradrenaline and have
been successfully applied to direct measurement of the neurotransmitter in coronary effluent
from isolated hearts. This has proved to be a useful indicator of sympathetic activity and has
provided important insights into the behaviour of the sympathetic nervous system and the
process of chemical neurotransmission during cardiac ischaemia (Dart and Du, 1993).
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1.1.4 Parasympathetic / sympathetic interactions
Interaction of the two halves of the autonomic nervous system occurs at all levels, permitting
the fine control of its actions. In general, the interactions can be classified as presynaptic or
postsynaptic mechanisms.
a) Presynaptic interactions
Interaction of sympathetic and parasympathetic nerves occurs in the control of
neurotransmitter release from presynaptic storage vesicles (see section 1.1.2c). The
presynaptic sympathetic nerve terminals express muscarinic receptors, and parasympathetic
terminals express a-adrenoceptors. In both cases, the presynaptic receptors have been shown
to be capable of reducing the overflow of neurotransmitter from the nerve terminal. As already
discussed, this type of modulation is known as axo-axonal modulation. Trans-synaptic
modulation may also occur where for example, stimulation of the sympathetic nerves causes
the effector cell to release a substance such as adenosine or a prostaglandin, which diffuses to
a specific receptor on the presynaptic parasympathetic terminal and affects acetylcholine
release.
b) Postsynaptic interactions
Postjunctional interaction of the two branches of the autonomic nervous system is indicated by
the ability of acetylcholine to antagonise the effects of noradrenaline infusion (Dempsey and
Cooper, 1969).
Interaction can occur at any of the post-receptor stages beyond G protein activation.
For example, (^-adrenergic receptors are coupled to adenylate cyclase via a G protein (Gs).
Binding of noradrenaline to a (3-adrenergic receptor will stimulate adenylate cyclase activity
and cause an increase in the cytosolic concentration of cyclic AMP. This in turn, activates
cyclic AMP-dependent protein kinase which is involved in the cleavage and regulation of key
metabolic enzymes and the control of certain ion channels. The simultaneous stimulation of
cholinergic, muscarinic receptors acts to oppose the adrenergic effects at more than one level.
First, muscarinic receptors are coupled to an inhibitory G protein (Gi), which inhibits
adenylate cyclase activity and therefore reduces the build up of cyclic AMP. In addition,
muscarinic receptors are coupled to guanylate cyclase activity, stimulating the production of
cyclic GMP which has been shown to antagonise the actions of cyclic AMP (Hartzell and
Fischmeister, 1986).
Interaction of the autonomic nervous system at both the presynaptic and postsynaptic
levels allows the two halves to be in equilibrium with each other. Direct measurement of
Introduction and literature review 14
acetylcholine overflow from stimulated rat heart preparations would allow further
investigation and understanding of the mechanisms of presynaptic modulation of acetylcholine
overflow and the effect of ischaemia on these mechanisms.
1.1.5 Autonomic activation during myocardial ischaemia
Signs of autonomic activation are common during acute myocardial infarction. Acute
ischaemia or infarction and reperfusion is able to trigger cardiac reflexes (Sleight, 1964; Webb
et al., 1972) by the stimulation of both chemosensitive and mechanosensitive receptors. In a
study by Webb and colleagues, the incidence of autonomic disturbance was recorded in
patients within the first hour of the onset of symptoms of their first episode of acute
myocardial infarction. Subjects were excluded if they had suffered a previous myocardial
infarction, had experienced ventricular arrhythmic events or received therapy with either beta
blockers or digitalis. Sinus bradycardia, AV block or transient hypotension were taken as
evidence of parasympathetic hyperactivity, whereas sinus tachycardia and transient
hypertension denoted sympathetic hyperactivity. Within 30 minutes, most patients showed
signs of either parasympathetic or sympathetic overactivity, with the former being more
frequent in cases of inferior infarction. Symptoms of excessive sympathetic activation were the
more usual outcome in cases of anterior infarction (Webb et al., 1972; Ninomiya et al., 1986;
Thames et al., 1978). These site-specific effects of ischaemia are thought to reflect the greater
extent of vagal innervation and density of vagal afferent receptors located in the
infero-posterior wall of the left ventricle (Inoue and Zipes, 1987a).
There is also evidence that both branches of the autonomic nervous system can be
activated simultaneously during myocardial ischaemia. Circulating levels of plasma
catecholamines are raised during the 48 hours following myocardial infarction (Nadeau and de
Champlain, 1979; Forfar et al., 1984; Goldstein, 1981). Catecholamines are released from the
peripheral tissues in response to pain, distress and anxiety, resulting in a high sympathetic
drive. A simultaneously enhanced parasympathetic tone may override this sympathetic activity
(Lombardi et al., 1984). Atropine treatment caused subjects who had previously displayed
bradycardia and symptoms of parasympathetic overactivity to become tachyarrhythmic,
indicating a coexisting sympathetic overactivity (Webb et al., 1972).
In contrast to the above studies, some investigators have observed that ischaemia or
infarction can inhibit normal cardiac reflex activity soon after the onset of coronary occlusion
(Barber et al., 1985; Inoue et al., 1988). In addition, the local effects of ischaemia, such as
tissue acidosis and potassium efflux may lead to the interruption of normal neural function,
both within the ischaemic territory and at sites apical to it which are served by axons lying
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within the ischaemic zone. In one study (Inoue and Zipes, 1988), heterogeneous loss of
functional efferent sympathetic innervation in non-infarcted apical sites occurred as early as
5-20 minutes after the onset of transmural ischaemia created by coronary occlusion. The
extent of this acute denervation was found to increase with time. Following chronic
experimental denervation, either chemically with 6-hydroxy-dopamine, or surgically, the
affected tissue becomes hyper-responsive to certain agonists. This phenomenon is known as
denervation supersensitivity and has been documented for both the sympathetic and
parasympathetic nervous systems (Cannon, 1939). A postsynaptic mechanism appears to be
involved (Vatner et al„ 1985). Sympathetic supersensitivity is characterised by an exaggerated
shortening of the refractory period in response to adrenergic agonist infusion. Shortening of the
refractory period is pro-arrhythmic, particularly when the electrophysiological changes are
heterogeneous across the myocardium (Herre et al., 1988; Inoue and Zipes, 1987b). Likewise,
electrophysiological inhomogeneities caused by vagal denervation, may be arihythmogenic too.
Whether ischaemia triggers or inhibits cardiac reflexes may depend on a number of
factors. The severity of the ischaemia and degree of collateral circulation, the size and position
of the ischaemic zone and whether it is transmural or not may all be important in determining
the outcome. Different time courses may also be involved.
1.1.6 Autonomic nervous system and sudden cardiac death
Under experimental conditions, increased sympathetic neural input during ischaemia is
recognised to be pro-arrhythmic, causing ventricular tachyarrhythmias and lowering of the
threshold to precipitate VF. Furthermore, sympathetic denervation or (3 blockade can protect
the ischaemic myocardium against arrhythmias (Schwartz and Zaza, 1986; Schwartz and
Stone, 1980). Traditionally, parasympathetic influences have been regarded as antiarrhythmic,
an action which is thought to be due to their anti-adrenergic property rather than any direct
antiarrhythmic effect.
With the introduction of two non-invasive methods to measure parasympathetic tone,
the relationship between autonomic nerve function in vivo, and the development of lethal
arrhythmias following myocardial infarction has been examined more closely in humans too.
Tonic vagal activity can be determined by the analysis of heart rate variability from
24 hour ECG recordings. Small variations in the beat to beat length of the R-R interval are
measured. The variability increases with increasing parasympathetic tone. Frequency analysis
of the ECG recordings can also be accomplished. When the frequencies are divided into 4
bands - from high to ultra low, each band is thought to represent different components of the
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autonomic nervous system. The high frequency band (0.15 - 0.4 Hz) is thought to reflect tonic
parasympathetic activity (Berger et al., 1986).
Parasympathetic reflex activity can also be assessed by evaluating baroreflex
sensitivity in the control of heart rate. Arterial baroreceptors are stimulated by increasing the
blood pressure with graded doses of a vasoconstrictor such as phenylephrine. Reflex
sympathetic tone can be gauged in the same way, using a vasodilator to lower blood pressure.
Measurement of both heart rate variability and baroreflex sensitivity have been found
to be useful in predicting the outcome after myocardial infarction in experimental and clinical
situations (for review see Barron and Lesh, 1996). Experimentally, the canine model of sudden
cardiac death has been most extensively studied. Myocardial infarction is surgically induced
and then one month later, the dogs are run on a treadmill at the same time as transient
ischaemia is induced by inflation of a surgically implanted balloon. Those that develop VF are
classified as 'susceptible' and the others as 'resistant'. One month after infarction, both
parasympathetic tonic (Hull et al., 1990; Adamson et al., 1994) and reflex (Schwartz et al.,
1988b) activity measured by heart rate variability and baroreflex sensitivity respectively, have
been shown to be significantly more impaired in the susceptible as opposed to resistant dogs.
In Adamson's study, pre-infarction heart rate variability was not different in the two
groups of dogs (Adamson et al., 1994). Beta blockade, however, caused a much greater
increase in heart rate variability in those animals which later were shown to be resistant to the
development of VF. Confounding variables, such as the extent of the collateral circulation,
were also not different in the two groups.
Pre-infarction differences in baroreflex sensitivity too may be present (Schwartz et al.,
1988a). Baroreflex sensitivity and heart rate variability are reduced after a myocardial
infarction, but steadily improve over a period of about 3 months back to control levels
(Schwartz et al., 1988b; Lombardi et al., 1987). This time period appears to fit the window in
which post-infarction patients are at most risk of sudden cardiac death (Myerburg et al.,
1992).
Several investigators have examined the predictive value of baroreflex sensitivity and
heart rate variability testing in patients who have suffered an infarction. Both depressed heart
rate variability and baroreflex sensitivity are associated with increased risk of sudden death in
the period following an infarction (Kleiger et al., 1987; La Rovere et al., 1988). The strength
of the association is greatly diminished after 6 months post-infarction (Odemuyiwa et al.,
1994).
Studies comparing the prognostic value of the two tests have found that baroreflex
sensitivity carries the greatest predictive power (Farrell et al., 1992). La Rovere and
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colleagues studied a group of 78 patients suffering their first myocardial infarction (La Rovere
et al., 1988). The follow up period was 2 years. Baroreflex sensitivity of less than
3.0ms/mm Hg carried a 50 % mortality rate, compared to only 3 % in patients with a
baroreflex sensitivity greater than 3.0 ms /mm Hg.
The superiority of baroreflex sensitivity testing over heart rate variability in
determining arrhythmic risk is probably due to the nature of the two tests. Whereas heart rate
variability measures tonic parasympathetic activity, baroreflex sensitivity measures the ability
of the parasympathetic system to respond to increased sympathetic activity in the
cardiovascular system. Thus, parasympathetic reflex activity is more likely to be an important
factor in limiting the potentially dangerous electrophysiological changes which occur when the
already destabilised myocardium is put under stress.
1.1.7 Catecholamine release in the ischaemic myocardium
Despite the widely held view that myocardial ischaemia induces neuronal noradrenaline
release, investigators have found difficulty in demonstrating an enhanced noradrenaline
overflow from the ischaemic tissue without reperfusion (Riemersma and Forfar, 1982). In
studies of stop flow ischaemia, where the duration of ischaemia is longer than 10 minutes,
reperfusion causes the overflow of noradrenaline. The amount of released noradrenaline is
related to the duration of the ischaemia. The kinetics of this overflow fits a single compartment
model and suggests that the noradrenaline accumulates in the extracellular space during
ischaemia and is not released by reperfusion itself. For shorter ischaemic episodes, reperfusion
overflow of noradrenaline cannot be demonstrated, possibly due to increased neuronal
reuptake which occurs during early myocardial ischaemia (Riemersma and Forfar, 1982).
Two mechanisms of noradrenaline overflow from acutely ischaemic myocardium have
been proposed. During the first few minutes of ischaemia, the activation of sympathetic
reflexes is postulated to result in limited local release of noradrenaline. Activation of cardiac
sympathetic efferents has been demonstrated within seconds of the onset of coronary artery
occlusion (Malliani et al., 1969). Noradrenaline overflow, however, was not measured. Indeed,
increased noradrenaline overflow from the ischaemic tissue, corresponding to this activity has
been hard to demonstrate both in dogs (Forfar et al., 1983; McGrath et al., 1981), and in man
undergoing balloon angioplasty (SchOmig et al., 1990). Increased neuronal reuptake during
early ischaemia may have removed any noradrenaline that was released before it could wash
out (Richardt et al., 1990). When neuronal reuptake was taken into consideration, McCance
and Forfar could document enhanced spillover of noradrenaline in patients during episodes of
angina (McCance and Forfar, 1989). Evidence that reflex sympathetic activation during early
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ischaemia causes neuronal catecholamine release also comes from denervation studies. In the
in vivo conscious dog model, left stellectomy or left stellate ganglion blockade protected the
acutely ischaemic heart from VF. This was presumably by preventing the deleterious release
ofmyocardial catecholamines (Schwartz and Stone, 1980), although the results of denervation
studies should be interpreted with care. Denervation may also reduce the rate of potassium
efflux from the ischaemic zone (Martin and Meesmann, 1985) and chronic or chemical
denervation facilitates the development of preexisting collaterals (Jones et al., 1978; ROmer
etal., 1981) both of which are antiarrhythmic. In addition to the above evidence of
sympathetic activation, cAMP levels are raised within 3 minutes of the onset of ischaemia and
coincide with the appearance of ventricular arrhythmias (Opie et al., 1982). Reflex induced
endogenous noradrenaline release occurs by calcium dependent exocytosis and is sensitive to
calcium channel blockers (Gothert et al., 1979).
The overflow of noradrenaline after longer periods of ischaemia (between 15 and 40
minutes duration) has been easier to demonstrate both with reperfusion (Abrahamsson et al.,
1984;) and histochemical studies (Holmgren et al., 1981). This noradrenaline overflow has
been demonstrated in isolated heart preparations, and is proposed to be due to a
non-exocytotic, non-calcium dependent mechanism (Kurtz et al., 1995a and b; Schdmig et al.,
1985). The above authors have hypothesised that the compromised energy state of the tissue
allows noradrenaline to leak out of the vesicles and into the cytoplasm. Provision of glucose in
the perfusion medium delays the noradrenaline release, presumably by improving the energy
supply (Abrahamsson et al., 1983; SchOmig et al., 1987). The sodium ion gradient is reversed
in the ischaemic cells and it is proposed that this reverses the normal direction of the uptake i
carrier, causing it to pump noradrenaline out of the cell and into the extracellular space
(SchOmig et al., 1985). Desipramine, the uptakei blocker, has been shown to prevent this
release (Kurtz et al., 1995a; SchOmig et al., 1987; Carlsson, 1987). This noradrenaline release
occurs in the absence of extracellular calcium (Abrahamsson et al., 1984), and has also been
shown to occur without the concurrent release of the co-transmitter NPY, which would be
expected, were an exocytotic mechanism responsible.
The physiological significance of this non-exocytotic noradrenaline release has yet to
be established. In the isolated rat heart, suppression of non-exocytotic noradrenaline release
with desipramine (1 (iM) reduced the incidence of VF during ischaemia (Kurz et al., 1995a).
In the in vivo situation, however, the release occurs at a time when the plasma levels of
catecholamines are already raised due to enhanced release from sympathetic nerves and
adrenal medulla (Goldstein, 1981; Nadeau and de Champlain, 1979). The effect of any local
release from the ischaemic tissue at this time may be overwhelmed by the effect from the high
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circulating catecholamine concentration. Furthermore, differentiating between the two sources
of noradrenaline in the in vivo, un-anaesthetized situation is likely to be impossible.
1.1.8 Contribution of the sympathetic nervous system to arrhythmogenesis
Three principal arrhythmogenic mechanisms have been identified during ischaemia; re-entry,
enhanced automaticity and triggered automaticity. The autonomic nervous system is able to
influence all three (for review see Janse and Wit, 1989).
Re-entrant mechanisms are proposed to underlie the majority of serious ventricular
arrhythmias during ischaemia in the clinical as well as the experimental setting (Janse et al.,
1980). Conduction occurs through a loop of tissue in a circular motion. A unidirectional
conduction block must be present in part of the loop. Under these conditions, an impulse
entering from outside can only travel in one direction around the conduction loop. Normally,
the impulse would die out after a single circuit, as it would not be able to reexcite the
refractory tissue in the first half of the loop. During ischaemia, slow conduction velocity and
shortened refractory periods may allow the impulse to continue propagating and generate a
circus movement, or re-entrant rhythm. Interventions which increase the inhomogeneity of
conduction velocity or repolarisation within the myocardium, facilitate the formation of
re-entrant circuits. Sympathetic activation is proposed to do this, as the innervation is not
homogeneous throughout the myocardium. Sympathetic nerve stimulation was observed to
increase the dispersion of refractoriness in the myocardium (Schwartz and Zaza, 1986),
whereas a slow infusion of a low dose of exogenous noradrenaline was found to have the
opposite effect (Han and Moe, 1964).
Enhanced or abnormal automaticity of Purkinje or ventricular myocardial cells, as a
result of myocardial infarction, has also been proposed to lead to the genesis of arrhythmias
(for a detailed review see Gilmour and Zipes, 1986). Under noimoxic conditions, automaticity
only occurs in pacemaker cells as a result of a spontaneous depolarisation during phase 4 of
the action potential. Electrophysiological studies have demonstrated the presence of
spontaneous activity in depolarised specimens of diseased human ventricle (Singer et al.,
1981; Gilmour et al., 1983). Such cells may provide an ectopic focus within the infarction
zone and, particularly under the influence of catecholamines which increase the firing rate
(Imanishi and Surawicz, 1976), contribute to the genesis of re-entrant arrhythmias. This
mechanism of arrhythmogenesis has never been proved to occur in vivo. It is deemed to be an
unlikely mechanism by some investigators, owing to the fact that the automaticity should be
suppressed in ischaemic tissue by the elevated potassium concentrations which are present
(Janse and Wit, 1989).
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The third mechanism of arrhythmogenesis during ischaemia, is triggered activity due
to delayed after-depolarisations. Delayed after-depolarisations are small oscillations in the
membrane potential which occur at the end of the action potential, when the membrane has
returned to its resting state. They are caused by fluctuations of calcium ions (Ducceschi et al.,
1996) and are generally sub-threshold in magnitude. Under certain conditions, such as
ischaemia, the amplitude of the oscillations can increase above the threshold level and an
action potential is triggered. A tachyarrhythmia results if the process is repeated.
Catecholamines increase the influx of calcium ions, increasing the amplitude of the oscillations
and facilitating the development of triggered activity (Roden, 1993).
Autonomic mechanisms are also involved in the pathology of long QT syndrome, a
hereditary condition which is characterised by an abnormally long QT interval on ECG. Those
affected have a high risk of sudden death due to the onset of lethal ventricular arrhythmias.
Prolongation of the surface QT interval is believed to reflect imbalance of the ventricular
autonomic innervation, resulting in increased dispersion of refractoriness and increased
vulnerability to re-entrant arrhythmias. Left stellectomy, either alone or in conjunction with
(3 blocker therapy, can protect against the onset of lethal ventricular arrhythmias in sufferers
of the syndrome (Schwartz, 1985).
1.1.9 Contribution of the parasympathetic nervous system to arrhythmogenesis
It is well documented that the parasympathetic nervous system can protect the myocardium
against the formation of serious ventricular arrhythmias during the early phase of acute
myocardial ischaemia. During experimental ischaemia, vagal nerve stimulation raised the VF
threshold (Kent et al., 1973) and reduced the incidence of ventricular arrhythmias (Myers et
al., 1974; Scherlag et al., 1970). Likewise, cholinesterase inhibitors protected against
arrhythmias (Das and Bhattacharya, 1972; Harrison et al., 1974), an effect which was
abolished by atropine (Harrison et al., 1974). The antiarrhythmic effect of cholinergic
stimulation is more pronounced during the early stages of experimental myocardial ischaemia.
Parasympathetic nerve stimulation was ineffective, or even exacerbated the genesis of
arrhythmias after experimental myocardial ischaemia had progressed beyond the first few
hours (Scherlag et al., 1974; Kerzner et al., 1973). This pro-arrhythmic effect may have
resulted from vagally-mediated slowing of the atrial pacemaker rate, thus abolishing the
overdrive pacing of areas of enhanced automaticity in the ventricles. Ventricular cells
exhibiting enhanced automaticity may contribute to the formation of re-entrant arrhythmias
(see section 1.1.8). Mortality owing to the sudden onset of malignant ventricular arrhythmias,
is at its highest during the first hour of acute myocardial ischaemia (Webb et al., 1972). In a
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recent study, muscarinic agonists protected against ventricular arrhythmias during an episode
of transient ischaemia in conscious dogs one month after a previous myocardial infarction
(De Ferrari et al., 1993). In the same model, superior vagal reflexes have been linked to a
decreased risk of sudden death (De Ferrari et al., 1991).
The parasympathetic nervous system is proposed to exert its antiarrhythmic effect,
primarily through its antiadrenergic actions. This includes the presynaptic inhibition of
noradrenaline release (Lbffelholz and Muscholl, 1969; Levy and Blattberg, 1976) and
antagonism of the postsynaptic effects of noradrenaline. In opposing the effects of the
sympathetic nervous system, the parasympathetic system exhibits the phenomenon of
accentuated antagonism (Levy, 1971). In other words, vagal effects are more powerful when
there is a coexisting sympathetic drive. Thus vagal stimulation opposes the tendency of
catecholamines to facilitate the genesis of re-entrant and triggered arrhythmias as described in
the preceding section.
In addition to its antiadrenergic actions, various investigators support a role for a
more direct antiarrhythmic action on myocardial electrophysiology. Blair and colleagues
demonstrated that in vivo, atropine shortened the effective refractory period in feline ventricle,
even after sympathectomy (Blair et al., 1980). Similarly, Prystowsky's group showed the
same effect of atropine in humans treated with the (3 blocker propanolol (Prystowsky et al.,
1981). For many years, studies on preparations of ventricular myocardium, in vitro, were
unable to demonstrate a significant effect of exogenous acetylcholine application on action
potential characteristics (Hoffman et al., 1953). Recent work has demonstrated that while
acetylcholine prolongs effective refractory periods in canine epicardium, it is without effect in
endocardial tissues (Litovsky and Anzelvitch, 1990). Previous studies in which a direct effect
of acetylcholine on ventricular refractoriness was not found, had all used endocardial
preparations. Similar results have now been reported in feline ventricular tissues
(Rosenshtraukh et al., 1994). The mechanism of this direct action of acetylcholine on
ventricular refractory period appears to be via activation Ikcaoo (Koumi et al., 1995; Yang
et al., 1996). Lengthening of the effective refractory period opposes the formation of re-entrant
arrhythmias.
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1.2 Ischaemic preconditioning
Brief episodes of ischaemia and reperfusion which themselves do not cause myocardial
damage, prior to a longer sustained period of myocardial ischaemia delay the onset and
decrease the severity of lethal cell injury in the ischaemic tissue (for reviews see: Cohen and
Downey, 1996; Losano et al., 1996). This unexpected phenomenon was first described by
Murry and co-workers in the dog heart (Murry et al., 1986). Four 5 minute circumflex
coronary occlusions interspersed with 5 minute periods of reperfusion immediately before a 40
minute occlusion, reduced the infarct size to 25 % of that produced in the control group by a
single 40 minute occlusion. They described the phenomenon as ischaemic preconditioning and
noted that it was not effective when the episode of sustained ischaemia was extended to
3 hours duration. Since these initial experiments were published, ischaemic preconditioning
has been observed in both in vivo and in vitro preparations of all the species which have been
studied. These include rabbit (Thornton et al., 1990; Liu et al., 1991), rat (Liu and Downey,
1992; Yellon et al., 1992), dog (Murry et al., 1986; Li et al., 1990), and pig hearts (Schott
etal., 1990). But ischaemic preconditioning is not limited to intact preparations. The
phenomenon has also been demonstrated in isolated ventricular myocytes (Armstrong et al.,
1994).
Various preconditioning protocols have been described. The minimum duration of
ischaemia which has been reported to be effective in an animal model is a single episode of
2 minutes duration (Baneijee et al., 1993). Although a duration of 90 seconds may be
sufficient to cause protection in humans undergoing angioplasty (Deutsch et al., 1990). More
commonly, single or multiple episodes of 5 minutes duration have been used in conjunction
with periods of 5 minutes of reperfusion. Only a few studies have ever been designed to
investigate the relative efficacy of different preconditioning protocols and most investigators
have chosen to use a protocol which has previously been successful in that model. In one such
study by Miura and co-workers, the infarct size-limiting effect of single or multiple episodes of
5 minutes of ischaemia interspersed with 5 minutes of reperfusion were compared. Multiple
episodes of preconditioning ischaemia were not more effective than a single episode at limiting
infarct size (Miura et al., 1992). In the dog, a single episode of 5 minutes of preconditioning
ischaemia was as effective as either six or twelve 5 minute episodes (Li et al., 1990).
In addition to its effect on infarct size, ischaemic preconditioning improves functional
recovery after global ischaemia (Cave, 1995) and reduces the number of serious ventricular
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arrhythmias during reperfusion (Podzuweit et al., 1989; Komori et al., 1990; Parratt and
Vegh, 1994).
1.2.1 Proposed mechanisms of ischaemic preconditioning
At the time when the experiments for this thesis were carried out, efforts were being made to
elucidate the mechanism of ischaemic preconditioning. Initial experiments explored several
different potential targets for preconditioning. An effect on collateral flow was ruled out early
on (Murry et al., 1986), as were effects on mitochondrial function (Vander Heide et al., 1991)
and stimulation of endogenous antioxidants (Turrens et al., 1992). Other avenues of
investigation have explored the possibility of effects on: ischaemia-induced osmotic swelling
(Armstrong et al., 1994), ATP-dependent potassium channels (Grover et al., 1990; Gross and
Auchampach, 1992), neutrophil accumulation (Mizamura et al., 1995), haemodynamic
function (Schjott et al., 1994; Goto et al., 1993) or the rate of ATP utilisation in the ischaemic
myocardium (Murry et al., 1990). Currently, the end effector for ischaemic preconditioning
remains to be elucidated. In recent years, however, progress has been made to identify the
pathways involved in triggering the preconditioning response. It was postulated that
substances such as adenosine, released by the ischaemic tissue, might be the first step in the
process. Infusions (5 min) of adenosine or a specific adenosine Ai receptor agonist in rabbit
heart, were indeed found to mimic ischaemic preconditioning (Liu et al., 1991). Furthermore,
adenosine antagonists were able to abolish the infarct reducing effect of ischaemic
preconditioning (Liu et al., 1991). The involvement of adenosine in the preconditioning
response was also reported in dog (Grover et al., 1992; Hoshida et al., 1994), pig (Yokota
et al., 1995) and subsequently in human hearts (Claeys et al., 1996). These results seem to
support the existence of a common pathway to trigger the preconditioning response in all these
species. The mechanism of preconditioning in the rat heart, however, appears to be
independent of adenosine (Asimakis et al., 1993; Li and Kloner, 1993).
Myocardial adenosine receptors are coupled to the intracellular protein kinase C
second messenger system (Cohen and Downey, 1996; Henry et al., 1996). Early studies to
examine a possible link between protein kinase C activation and ischaemic preconditioning
found that activators of protein kinase C such as phorbol esters and water-soluble
diacylglycerol compounds could mimic preconditioning (Mitchell et al., 1993). Inhibitors of
protein kinase C, such as staurosporine and polymyxin B, abolished the expected response
(Ytrehus et al., 1994). A variety of other myocardial receptors are coupled to protein kinase C
including bradykinin (Minshall et al., 1995), angiotensin II (Sadoshima and Izumo, 1993),
endothelin (Irons et al., 1993) and ai-adrenergic receptors (Kaku et al., 1991). It now appears
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that there may be a number of different triggers for the ischaemic preconditioning response,
which are all coupled to the end effector via a common second messenger system.
1.22 Catecholamines and Ischaemic Preconditioning
At the time when the experiments for this thesis were undertaken, very few investigations of
the potential role of catecholamines in the mechanism of ischaemic preconditioning had been
carried out. One of the first publications described how exogenous noradrenaline infusion in
the rat heart, acting through ai-adrenergic receptors, could mimic ischaemic preconditioning
(Baneijee et al., 1993). Reseipine pre-treatment or oci-adreneigic blockade abolished
ischaemic preconditioning, leading the authors to conclude that ischaemic preconditioning is
mediated through ai-adrenoceptor activation. At around the same time, Thornton's group
published the results of their work in rabbits. They used tyramine infusions to release
endogenous catecholamines and found that this could mimic preconditioning in the rabbit heart
in vivo (Thornton et al., 1993). The ability of tyramine to mimic ischemic preconditioning
could be blocked by both an ai-adrenergic receptor antagonist or by a nonselective adenosine
receptor antagonist. The (^-adrenergic antagonist was, however, unable to abolish the effect of
ischaemic preconditioning to limit infarct size. They concluded that although catecholamines
could cause a preconditioning effect in the rabbit, they were not implicated in the mechanism
of ischaemic preconditioning. They postulated that the catecholamine release caused increased
oxygen demand and metabolic stress, provoking adenosine release and leading to the
preconditioning response. Adenosine overflow, however, was not measured.
One explanation for the discrepancy in the results of the above two studies, was that
the mechanism of ischaemic preconditioning in the rat heart differs from that in the rabbit.
Experiments with adenosine in the two species at the time supported this view (Liu et al.,
1994; Li and Kloner, 1993; Asimakis et al., 1993). The results of a third study (Toombs
etal., 1993), however, did not. They reported that the infarct-limiting effect of ischaemic
preconditioning was abolished in reserpinized rabbit preparations in vivo, leading to the
conclusion that endogenous noradrenaline is involved in the genesis of the ischaemic
preconditioning response.
All these investigations used large pharmacological interventions. Where exogenous
noradrenaline infusions were carried out (Baneijee et al., 1993; Bankwala et al., 1994)
unphysiologically high concentrations of noradrenaline were used (up to 30 nmol kg"1 min"1).
Whether endogenous noradrenaline release, induced by sympathetic nerve activation, could
result in the preconditioning of the rat heart remains to be seen. This is an important question
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since repeated episodes of chest pain, accompanied by increased cardiac sympathetic activity,
could result in a preconditioning effect clinically.
1.2.3 Potential clinical applications of ischaemic preconditioning
To date, ischaemic preconditioning remains a mainly laboratory phenomenon. Various authors
have discussed the potential applications of preconditioning in the clinical or surgical setting
(Cohen and Downey, 1996). Evidence now exists that patients who experience episodes of
anginal pain in the period before a major coronary event, have a better outcome than those
whose first symptom is the pain of a myocardial infarction (Kloner et al, 1995). Clinically,
the ultimate aim would be to be able to render a patient in a chronically preconditioned state.
This would provide an alternative treatment for those deemed to be at risk from coronary
thrombosis in whom surgery or angioplasty was not appropriate, or whilst waiting for these
elective procedures. In the event of severe myocardial ischaemia, it would delay the onset of
irreversible cell damage and lengthen the time when effective thrombolytic therapy could be
given to achieve myocardial salvage. In the clinical setting, preconditioning the heart with
ischaemia is far from ideal. In addition to the dangers associated with inducing even transient
ischaemia, the efficacy of ischaemic preconditioning to cause myocardial protection is
short-lived. The initial window of protection was generally reported to be less than 2 hours
long (Van Winkle et al., 1991; Sack et al., 1993). A second window of protection may
develop up to 4 days later (Sack et al., 1993), but this too is likely to have a finite length.
Ideally, a pharmacological agent would be developed which would overcome both the
necessity of inducing transient ischaemia and the temporary nature of the protection. Recently,
investigators were unable to maintain rabbits in a chronically preconditioned state using either
repetitive episodes of ischaemia or adenosine Aj-selective analogue administration (Tsuchida
et al., 1994; Cohen et al., 1994). Tolerance developed to both interventions within 36 hours.
Potentially, there is much larger scope for the routine use of ischaemic preconditioning in the
surgical as opposed to the clinical environment. Either transient ischaemia or a
pharmacological agent could be used to reduce the risk of complications during surgery and
the recovery from bypass procedures. Encouragingly, experiments during heart surgery have
indicated a benefit of several brief episodes of aortic cross-clamping preceding the principal
ischaemic episode, on the recovery from heart bypass or transplant procedures (Yellon et al.,
1993).
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1.3 Summary of objectives
The experiments detailed in this thesis aimed to investigate the following:
1) Can a novel, sensitive HPLC method be used to quantify acetylcholine overflow from the
in situ, innervated perfused rat heart preparation following vagal nerve stimulation?
2) To what extent does the severity or duration of global ischaemia affect the vagally mediated
overflow of acetylcholine?
3) Which of the concomitants of ischaemia such as reduced oxygen supply, reduced glucose
supply and extent of tissue acidosis, have the greatest effect on vagally mediated
acetylcholine overflow?
4) In the normoxically perfused rat heart, does the coronary flow rate affect the stimulation
evoked overflow of autonomic transmitters: acetylcholine and noradrenaline?
5) How do different severities and durations of global ischaemia affect the presynaptic
interaction of the parasympathetic and sympathetic nervous systems with respect to the
overflow of acetylcholine and noradrenaline?
6) Does noradrenaline infusion or sympathetic ganglion stimulation improve functional
recovery following global ischaemia in the rat heart?
7) Do pre-ischaemic noradrenaline infusion or sympathetic ganglion stimulation reduce the
post-ischaemic reperfusion washout of noradrenaline from the rat heart?





Male, Sprague Dawley rats (200 - 300 g) were used (Bantin and Kingman, Hull, UK). They
were housed in an area with a 12 hour light / dark cycle. The temperature was maintained at
20 °C, the humidity was controlled at 60 ± 5 %, and food and water were available ad libitum.
A standard rat and mouse laboratory chow diet was fed (Bantin and Kingman), and between
two and four animals were kept in each cage.
2.1.2 Langendorff Perfusion
An in situ, perfused, innervated rat heart model was used (Dart et al., 1984b). Rats were
anaesthetised with pentobarbitone sodium (60 mg kg"1 ip) and heparinised (200 units rat'1 iv)
via the femoral vein. The animal was immobilised, ventral surface uppermost. The chest wall
was removed and the ascending aorta was cannulated with a stainless steel cannula (internal
diameter, 0.8 mm), which was tied into place for Langendorff perfusion. The time from the
first incision into the chest wall to the commencement of perfusion was not more than 60 s.
Coronary effluent was drained from the right atrium via a polythene cannula (internal
diameter, 0.86 mm), which was introduced via the inferior vena cava and tied into position
such that it did not irritate the atrial wall. Recovery of the coronary effluent was maximised by
tying off the right and left pulmonary vessels, and also the superior vena cava. After occlusion
of the pulmonary vessels, the lungs were removed.
The perfusate was a Krebs-Henseleit solution (see Table 2.1 for composition), which
was continuously gassed with a mixture of oxygen / carbon dioxide in the ratio 95 to 5. The
temperature of the perfusate as it entered the aorta was 37 °C. Mean (± SD) pH, p02 and
pC02 at the beginning of each experiment were as follows:
pH 7.3910.03
p02 579 111 mm Hg
pC02 44.3 ±0.4 mm Hg
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During the nerve stimulation experiments, the flow rate was controlled with a peristaltic pump
(model 202U, Watson Marlow) and was set at 5 or 10 ml g"1 min"1, depending on the
experiment.
A free flow model of perfusion was, however, used for the series of preconditioning
experiments - in line with what had been used by other investigators. In this model, the
coronary perfusion pressure is held constant. The level of perfusate in the perfusion column
was maintained at a constant level of 100 cm above the heart by the use of two peristaltic
pumps an inflow - and a faster outflow pump (MHRE 200, Watson Marlow) which returned
fluid to the reservoir.
Each preparation was allowed to equilibrate for 35 or 45 minutes (depending on the
protocol) and, during this time, the amount of coronary effluent collected per minute was
determined.
Preparations were excluded if they were found to have:
a) Percentage recovery of coronary effluent lower than 80 % (or 7.5 ml min"1 for free flow).
b) Persistent arrhythmias during the equilibration period,
c) An insufficient response to nerve stimulation (less than 15 % increase in heart rate and
dP/dt),
d) Poor contractile function (dP/dt less than 2500 mm Hg s"1).
In those experiments with a fixed flow rate, the mean percentage recovery of coronary
effluent was 93.1 ± 2.5 %. Any preparations in which it was less than 80 % were discarded
(5 out of 50 experiments).
In free flow experiments, the mean coronary flow rate after the 45 min equilibration
period was 9.6 ± 1.0 ml g"1 min"1 (n = 27). Preparations with a coronary flow rate of less than
7.5 ml g"1 min"1 were discarded (2 out of 29 experiments).
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2.13 Measurement ofFunctional Parameters
Heart rate, dP/dt and left ventricular pressure were continuously measured via a pressure
transducer (model E.M. 751, Elcomatic) connected to a polythene cannula (length 2.5 cm,
internal diameter, 0.8 mm) which was carefully introduced into the left ventricular cavity
through a small hole in the apex. The frequency-response curve for the system was flat and
deviated by less than 5 % at 40 Hz.
The coronary perfusion pressure was monitored with an identical pressure transducer
connected to a side arm in the aortic cannula. Under normal conditions, the coronary perfusion
pressure at a flow rate of 5 ml g'1 min"1 was approximately 44 mm Hg.
Information from the transducers was relayed to a polygraph (Department of Medical
Physics, Royal Infirmary Edinburgh) which was connected in series to a multichannel recorder
(Gould TA 2000, Gould). The equipment was calibrated between 0 and 100 mm Hg once a
week using a pneumatic transducer tester (DPM-1B, Bio Tek). An electronic calibration was
carried out at the start of each preparation, using the mechanism built into the polygraph. This
calibration was also from 0-100 mm Hg.
Figure 2.1 Typical trace of left ventricular pressure (LVP), heart rate (HR), dPIdt and
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2.1.4 Nerve Stimulations
Once the heart was perfused, the cervicothoracic vagal nerves and the left stellate ganglion
were exposed, and superfusion with warmed oxygenated buffer commenced to prevent the
nerves from becoming either hypoxic or hypothermic. The nerves were continuously
superfused throughout the experiment, except during periods of nerve stimulation when, to
isolate the stimulus from the surrounding tissue, the nerves and surrounding tissues were
gently blotted dry.
Nerve stimulations, of either 30 or 60 s duration, were carried out with a dual channel
stimulator (S 48, Grass) connected to a signal isolating unit (SIU 7, Grass).
• vagus nerves
Bilateral vagus nerves were dissected free at the cervicothoracic level. A ligature was placed
around them at the anterior end and the nerves were severed anterior to the ligature in order to
abolish any vagal reflexes. A bipolar, platinum, stimulating electrode was placed under the
nerves with the cathode closest to the heart. The stimulus was a square wave pulse of 0.8 mA
amplitude and 2.0 ms duration.The stimulation frequency was 15 Hz.
• sympathetic nerves
Sympathetic nerve stimulation was carried out through the left cervicothoracic stellate
ganglion, which was exposed with the help of a surgical microscope (Wild M7A, Wild UK
Ltd) at the level of the first rib (Dart et al., 1983). Preganglionic fibres were cut and a bipolar
platinum electrode was positioned under the ganglion with the help of a micromanipulator
(Prior of England). The stimulus was a square wave pulse of 0.8 mA amplitude and 2.0 ms
duration.The stimulation frequency was 5 Hz.
2.2 Lactate
Lactate concentrations in the coronary effluent were assayed spectrophotometrically using a
centrifugal analyser (Cobas Bio, Roche Diagnostics) and an enzymatic lactate assay kit (Kit
number 256 773, Boehringer Mannheim).
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2.2.1 Reaction Principle
Lactate reacts with NAD+ in the presence of lactate dehydrogenase, to form pyruvate, NADH
and H+. The NADH formed is measured spectrophotometrically and is proportional to the
amount of lactate which has reacted. The conversion of lactate is incomplete as the equilibrium
lies far to the left. Complete conversion of lactate cannot therefore be achieved. The removal
of pyruvate through a second reaction moves the equilibrium for the initial reaction to the right
and so allows all the lactate to be reacted quantitatively:
LDH
a) L-Lactate + NAD+^— > Pyruvate + NADH + H+
GPT
b) Pyruvate + L-Glutamate < > L-Alanine + a-Oxoglutarate
2.2.2 Method
Measurements were carried out at a wavelength of 340 nm. Aliquots of sample or standard
(30 pi) were analysed with 250 pi of reagent, 60 pi of diluent and 5 pi of enzyme solution.
The incubation temperature was 37 °C, and Precinorm S (880 pM lactate, Boehringer
Mannheim) was used as the quality control. The standard was 1 mM L-lactate (Boehringer
Mannheim). Samples were analysed in duplicate.
The inter- and intra-assay coefficients of variation for the analysis of Precinorm S
were 3.7 (n = 29) and 0.2 % (n = 10) respectively.
2.3 Creatine kinase
Creatine kinase (CK) activity was assayed in freshly prepared ventricular homogenates (see
below) diluted 1:40 (v/v) with 2 % bovine serum albumin (A6003 Sigma) containing 10 mM
Tris, pH 7.4.
The assay was carried out spectrophotometrically using a Cobas Bio centrifugal
analyser (Roche) and an enzymatic CK assay kit (Unimate 3CK, Roche).
2.3.1 Tissue Homogenisation
Excised hearts were dropped into ice cold homogenisation buffer (0.25 M sucrose containing
1 mM disodium EDTA and 0.1 mM dithiothreitol, pH 7.4). The hearts were trimmed to
remove the atria, major blood vessels and excess fat or connective tissue, and the wet weight
of the ventricles was recorded.
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Using scissors, the tissue was finely minced on ice and placed into a Potter Elvjehem
glass homogeniser (50 ml, Jencons) kept on ice. Homogenisation buffer, 25 ml per gram of
tissue, was measured out and divided into two portions, one of which was added to the glass
homogeniser with the tissue. Ten strokes of a well fitting teflon plunger were used to break up
the tissue. The resulting homogenate was poured into a centrifuge tube and the remaining
portion of homogenisation buffer was used to rinse the homogeniser.
The homogenate was spun in a centrifuge (Centra7R, IEC) at lOOOg, 4 °C, for
10 min. The supernatent was poured off into an ice cold beaker, the pellet was resuspended in
a second aliquot of homogenisation buffer and the spin was repeated.
The two supernatents were combined and used for the determination of creatine kinase
activity (and protein concentration).
2.3.2 Reaction Principle
CK was activated by N-acetylcysteine and measured by the photometric determination of
NADPH formation. The rate of NADPH formation through the following reactions, was
directly related to the CK activity:
CK
a) Creatine Phosphate + ADP > Creatine + ATP
HK
b) ATP + D-Glucose < > ADP + D-Glucose-6 Phosphate
G6P-DH
c) D-Glucose-6 Phosphate + NADP + c > D-Gluconate-6Phosphate + NADPH + H+
Samples were assayed in duplicate.
The quality control was Precinorm C (BoehringerMannheim).
Results were expressed in Units mg'1 protein.
The inter- and intra-assay coefficients of variation for the analysis of Precinorm C were 3.4
(n = 29) and 0.75 (n = 10) % respectively.
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2.4 Protein
Measurement of membrane protein concentration in myocardial homogenates was carried out
on the Cobas Bio centrifugal analyser using the method of Lowry et al. (1951) as modified by
Clifton et al. (1988). The assay utilises a colour change following the reduction of Folin and
Ciocalteu's phenol reagent (1927), measured at 750 nm.
The main reagent, made up fresh each day, was a cocktail of the following three stock
solutions and double distilled water.
A) 10 % (w/v) Na2C03 in 0.5 M NaOH
B) 1 % (w/v) CuS04.5H20
C) 2 % (w/v) Na+/K+tartrate
The volume ratio of the components (A:B:C:water) in the final mixture was 10:0.5:0.5:40. A
1:3 dilution (v/v with double distilled water) of the Folin Ciocalteu's phenol reagent (Roche)
was used as the start reagent for the reaction.
The protein standard solution was bovine serum albumin, fraction V (A6003, Sigma)
dissolved in homogenisation buffer. Standards of 0, 50, 100, 200, 300 and 400 mg L'1 were
run with each estimation. Sample protein concentration was calculated from the non-linear
calibration curve, using the DENS (data evaluation of non-linear standard curves) mode.
Samples were run in duplicate.
The inter-assay coefficient of variation, calculated from the 300 mg L"1 standard, was
3.4 % (n = 5). The intra-assay coefficient of variation was 0.6 % (n = 26).
2.5 Catecholamines
Catecholamines were extracted from the coronary effluent using alumina in the presence of an
internal standard - dihydroxybenzylamine (DHBA). The catechols were then eluted using HC1
and analysed by HPLC with electrochemical detection.
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2.5.1 Extraction Principle
The extraction principle is adapted from a published method (Howes et al., 1985) and exploits
the fact that catecholamines will bind tightly to alumina under alkaline conditions, but will be
eluted from it at low pH.
2.5.2 Reagents
a) Acid washed alumina, activity grade 1 (Sigma).
b) Tris EDTA buffer - 1 M Tris base (Sigma), 0.05 M disodium EDTA (BDH)
pH 8.8 with HC1.
c) Internal standard - 91 nM solution of DHBA (D4471, Sigma), diluted with
water, daily, from a 4.5 mM stock solution in 0.2 N HC1.
The stock solution was stored in brown glass at 4 °C.
d) 0.2N Hydrochloric acid (BDH).
All the reagents were of the highest grade available, to avoid interference from contaminants.
Water was double distilled and then deionised.
2.5.3 Extraction Procedure
Sample or standard (2 ml) was added to 15 ml polystyrene tubes (Elkay) containing 2 ng of
the internal standard solution and a small amount of alumina (approximately 20 mg).
Tris / EDTA buffer (2 ml) was added and the tubes were capped and mixed on a
rotary mixer (SB1, Stuart Scientific) for 10 min. The catecholamines were now tightly bound
to the alumina.
The alumina was allowed to settle and most of the water layer was aspirated to waste,
following which the alumina was washed twice with 10 ml of deionised water. Catecholamines
were eluted from the alumina by the addition of 150 pi of 0.2 N hydrochloric acid to the tubes,
followed by vortex mixing of the contents for 1 min.
Alumina was sedimented (1 min at 1700g), and the acid phase (130 pi) was analysed
by HPLC. Care was taken not to introduce any grains of alumina into the HPLC system as
they could cause blockages affecting peak shape and retention time.
A standard curve for noradrenaline and adrenaline was included with every run. Stock
solutions of noradrenaline and adrenaline (1 mM in 0.2 N HQ) were stored in the fridge. On
Materials and methods 35
the day of the assay they were diluted, first with 0.2N HC1 and then with water, to give final
concentrations of 1, 5, 10, 15 and 20 nM. Each batch of samples also contained a blank and a
zero.
The percentage recoveries for noradrenaline and adrenaline through the method,
determined from the 10 nM standard, were 91 and 89 % respectively. The within assay
coefficients of variation for 10 nM concentrations of noradrenaline and adrenaline were 2.0
and 1.9 % respectively. The between assay coefficients of variation for the same
concentrations were 4.9 and 4.5 %
When stored at -70 °C, a quantity of pooled samples and diluted standards were found
to be stable for up to 3 months. All the experimental samples generated were, however,
analysed within 6 weeks of collection.
2.5.4 HPLC Analysis of Catecholamines
The reverse phase HPLC separation followed by electrochemical detection of catecholamines
was adapted from the method ofMoyer and Jiang (1978).
2.5.5 HPLC Apparatus
The HPLC system consisted of an isocratic pump (LC250, Perkin Elmer), connected to an
autosampler (ISS200, Perkin Elmer) fitted with a 100 pi PTFE sample loop (Anachem). The
analytical column was an ODS2, 3 pm cartridge column (10 cm x 4 mm, Phase Separations)
fitted with a reverse phase guard cartridge. Compounds were detected electrochemically
(LC4C, Bioanalytical Systems) using a glassy carbon electrode at a potential of + 0.7 V. Data
handling was carried out with a 950 interface box (PE Nelson) and Turbochrom 3 software
(PE Nelson). Precolumn tubing was narrow bore PTFE tubing (0.005" internal diameter,
Anachem).
The mobile phase was 0.18 M potassium phosphate, pH 3.5, containing 0.2 mM
disodium EDTA and 2 mM heptane sulphonic acid (H8901, Sigma) as an ion pairing agent.
Double distilled and deionised water, mentioned already, was filtered and degassed under
vacuum through a 0.22 pm hydrophilic membrane (Durapore, Millipore). The flow rate was
1 mlmin'1.
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Figure 2.2 Chromatogram showing 10 pmoles, on column, of each of noradrenaline,
adrenaline andDHBA.
2.5.6 Analysis
Batches of approximately twenty samples and standards (100 pi per injection) were run
together. The system was calibrated with noradrenaline, adrenaline and DHBA (see
Figure 2.2). Standards were made up in 0.2 N HC1. Calibration curves were constructed for
amounts of: 1; 5; 10; 15 and 20 pmoles on column.
In the majority of samples, the only peaks to be observed were those which were due
to noradrenaline and DHBA. There was, however, a small peak which could not be identified
in a few samples, which ran approximately 40 s before noradrenaline. It did not interfere with
the assay and attempts to identify it with known metabolites were unsuccessful.
All standards were purchased from Sigma Chemical company. The inter- and
intra-assay coefficients of variation for 10 pmoles, on column, of noradrenaline were 3.5 %
and 1.8 % (n = 10) respectively. Standards were run in duplicate, but due to insufficient
volume, samples were run singly.
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2.6 Chemicals
All chemicals were purchased from MERCK-BDH, except where stated, and were analytical
grade. Water was double distilled and, for catecholamine extractions and analyses, was
deionised (UHQII, Elga.).
2.7 Statistical analysis
Data was checked for normality using frequency distribution charts in microsoft excel 5.0.
Other analyses were carried out using the MINITAB version 7 software (CLE.COM
Ltd.,Birminham).
Normally distributed groups were compared using one- or two-way analysis of
variance (ANOVA). Where a follow-up test was required, unpaired Student's T-tests were
performed and Bonferoni corrections were applied. All results are expressed as mean ± one
standard deviation. Statistical significance was accepted at p < 0.05.
Skewed data was analysed using the non-parametric Kruskal-Wallis test. Follow-up
testing was done with the Mann-Whitney test and appropriate Bonferoni correction.
The intra-assay coefficient of variation for the protein results was determined using
the following formula to calculate the standard deviation:
Standard deviation = V(Ix2 / 2n) where x is the difference in the duplicate values of the
samples and n is the number of duplicates.
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CHAPTER 3
Acetylcholine methodology
3.1 Introduction and methods
Measurement of noradrenaline levels in the coronary effluent of isolated, perfused hearts has
led to a greater understanding of the workings of the sympathetic nervous system.
Comparatively little is, however, known about the functioning of the parasympathetic nervous
system owing to the lack of a sufficiently sensitive acetylcholine assay with which to study it.
The aim of the study was to investigate the behaviour of the parasympathetic nervous
system in the in situ, perfused, innervated rat heart during several different severities of
ischaemia, by employing a recently developed HPLC assay to measure levels of acetylcholine
present in coronary effluent.
3.1.1 HPLC Assay
The assay kit was purchased from Biotech Instruments (Bioanalytical Systems).
• assay principle
Acetylcholine and choline in the sample were separated on a polymer analytical column
(Bioanalytical Systems Ltd) and passed as discreet, resolved bands into a reactor column
(Bioanalytical Systems Ltd). The reactor column contained enzymes which were covalently
bonded to the support phase and catalysed the following reactions:
acetylcholinesterase
a) Acetylcholine + H20 > Choline + Acetate
choline oxidase
b) Choline + 202 + H20 > Betaine + 2H202
Hydrogen peroxide was detected electrochemically (LC4C, BAS) using an oxidative reaction
at a platinum electrode held at +0.6 V vs Ag/AgCl. Within the effective concentration range,
the amount of hydrogen peroxide liberated was directly proportional to the amount of
acetylcholine or choline present in the sample.
The precolumn HPLC system was identical to that described in the preceding chapter
for catecholamine analysis (see Section 2.5.5). The run time for each sample was 20 min.
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Retention times for acetylcholine and choline were 6.2 ± 0.5 (n = 25 ) and 7.9 ± 0.6 (n = 25)
min respectively.
• mobile phase
The optimum mobile phase was found to consist of 0.1 M Tris (T6791, Sigma) containing
0.1 M sodium perchlorate monohydrate (10313 4Y, BDH) made up in double distilled,
deionised water. Kathon CG reagent, 0.005 % v/v (CF-2150, BAS) was present as an
anti-bacterial agent. The pH was adjusted to 8.50 ± 0.05 with HC1.
• standards
Acetylcholine and choline standards were made up in a solution of glacial acetic acid (0.3 %
v/v) adjusted to pH 5 with dilute sodium hydroxide and containing 0.005 % v/v Kathon CG
reagent. Standards and samples of perfusate 'spiked' with known amounts of acetylcholine and
choline, were stable at room temperature for at least 24 hours. All samples were analysed
within 8 hours of collectioa
Standard curves were constructed for acetylcholine and choline for on column
amounts of 5,10, 20, 30 and 40 pmole (see Figure 3.2). The injection volume was 100 pi.
The detection limit for acetylcholine was found to be 2 pmole on column which, with
an injection volume of 100 pi, equates to a sensitivity of 20 nM.
The intra-assay coefficient of variation for 20 pmole of acetylcholine in a 100 pi
injection was 4.8 % (n = 10). The inter-assay coefficient of variation for the same standard
was 6.0 % (n= 10).
• peak separation
This was a commercial assay and information regarding the nature of the solid phase was not
available to us. The fine-tuning of the separation was, therefore, limited by our lack of
knowledge of the chemistry involved. Nevertheless, it was possible to alter the ionic strength,
pH and flow rate of the mobile phase to optimise the separation. Despite this, baseline
separation of acetylcholine and choline was not quite achieved and both compounds exhibited
some peak-tailing, particularly at higher concentrations (see Figure 3.1 and 3.3).
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Figure 3.1 Separation of5 pmole ofacetylcholine and choline (100 \xl iniection)
Numbers denote the time after injection in minutes
Figure 3.2 Standard curve for acetylcholine (5 - 40 pmole).
Each acetylcholine standard was injected 3 times
Injection volume was 100 (H
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3.1.2 Protocol for pilot experiments
The basic model was the in situ, innervated, perfused rat heart as described in Section 2.1.2.
The flow rate was controlled at 5 ml g"1 min'1.
• use ofdrugs
To prevent the rapid hydrolysis of released acetylcholine, neostigmine methyl sulphate
(N2126, Sigma), a reversible acetylcholinesterase inhibitor, was included in the perfusate at a
concentration of 50 (iM. Neostigmine also interacted with the enzyme in the reactor column,
but at the concentration used in these experiments it has been demonstrated that the enzyme
present on the reactor column is in sufficient excess for pharmacological experiments (data
shown in manufacturer's literature). Moreover, neostigmine elutes after acetylcholine.
During initial experiments, choline chloride (C7017, Sigma) was also present in the
perfusate at a concentration of 10 pM in order to provide a substrate for acetylcholine
resynthesis (Dieterich et al., 1978; Wetzel and Brown, 1983). Despite attempts to improve the
separation of acetylcholine and choline (see Section 3.1.1), the compounds were not quite
baseline resolved. When choline chloride was present in the perfusate at the above
concentration, picomolar amounts of acetylcholine appeared as a shoulder on the choline peak
and the assay sensitivity was reduced by a factor of ten. During initial experiments, vagus
stimulation did not produce detectable amounts of acetylcholine in the presence of choline
chloride. Thus, to maximise the assay sensitivity for acetylcholine, choline chloride was
excluded from the perfusate for the remaining experiments.
• vagus nerve stimulation
Bilateral vagus nerve stimulations were carried out as described in Section 2.1.4. The duration
of each stimulation was 30 s and there was a 15 min recovery period between each episode of
nerve stimulation. Each preparation underwent four episodes of nerve stimulation at 45, 60, 75
and 90 min after aortic cannulation.
• sample collection
Total coronary effluent was collected in consecutive 30 s samples. Sampling began 30 s before
the onset of each nerve stimulation and continued for 180 s. A single aliquot (100 pi) from
each sample was injected directly onto the HPLC system.
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• treatment groups
In ten preparations there was a 45 min equilibration period followed by four vagus nerve
stimulations. The reproducibility of the response to vagus nerve stimulation was determined
and the coronary effluent was analysed for the presence of acetylcholine.
In a further five preparations, the functional response to a single vagus nerve
stimulation was determined at the end of the 45 min equilibration period. Atropine (AO132,
Sigma), a muscarinic antagonist, was then infused into the aortic cannula via a syringe
infusion pump (2400-001, Harvard Apparatus), to reach a final concentration of 1 (iM in the
perfusate. After 15 min, a second vagus nerve stimulation was carried out to confirm that the
functional changes observed during vagus nerve stimulation were indeed due to the action of
acetylcholine on muscarinic receptors and were therefore abolished by atropine.
3.2 Results and discussion
3.2.1 Haemodynamic response to vagus nerve stimulation
The effect of bilateral vagus nerve stimulation on the various measured haemodynamic
parameters is shown in Table 3.2.1. There was no significant change in any of the pre-
stimulation values during the 60 min measurement period (1 way ANOVA, p = NS). Heart
rate was significantly reduced by vagus stimulation during all four stimulations (2 way
ANOVA, followed by paired T-test, p < 0.05), although the response declined significantly
through the experiment (1 way ANOVA, p < 0.05). Vagus nerve stimulation caused a
significant reduction in both +dP/dt and -dP/dt during the first two, but not the subsequent two
stimulations (2 way ANOVA, followed by paired T-test, p < 0.05). Left ventricular pressure
was not significantly altered by vagus stimulation.
3.2.2 Use of atropine to verify vagus nerve stimulation
The results are shown in Table 3.2.2. In the absence of atropine, heart rate and dP/dt were
significantly reduced by nerve stimulation (Stim 1) when compared to pre-stimulation values.
The addition of 1 |iM atropine to the perfusate 15 min before a second nerve stimulation
(Stim 2) completely abolished this response.
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#Duringvagusstimulation,theminimumvalu sofHR,LVPa ddP/dtwerrecorded. *Significantlydifferentfromthpre-sti ulalionvalue(2wayANOVA,followedbypairT- e t,<0.05).
Table 3.2.2 The effect ofatropine on the cardiac response to vagus nerve stimulation
(n = 5). Values are mean ± SD.
FUNCTIONAL
PARAMETER
NO ATROPINE ATROPINE (luM)
PRE-STIM STIM 1 PRE-STIM STIM 2
HEART RATE max 255 120* 248 253
(beats min"1) ±11 ±25 ±8 ±15
+ dP/dt max (mm Hg s"1) 2010 1460* 1950 2100
±265 ±308 ±288 ±320
- dP/dt max (mm Hg s'1) 1000 700* 940 940
±148 ±69 ±92 ±92
* p < 0.05 vs pre-stimulation without atropine (paired t-test)
3.2.3 Presence of acetylcholine in coronary effluent
A typical HPLC chromatogram of coronary effluent collected during vagus stimulation is
shown in Figure 3.3. No traces of acetylcholine were detected in any of the samples of
coronary effluent which were analysed, although choline was detected, even in unstimulated
samples.
Figure 3.3 Analysis ofacetylcholine in coronary effluent collected during vagus nerve
stimulation
The inserted peak represents the peak resulting from 2 pmoles of acetylcholine (detection limit).
99.6 pmole of choline was detected, equivalent to 5.0 nmoles g"1 min"1.
The retention time for choline was 8.49 minutes.
The injection volume was 100 pi.
Acetylcholine methodology 45
3.2.4 Discussion
Vagus nerve stimulation was confirmed both by the reduction in heart rate and dP/dt and also
by the abolition of this response in the presence of 1 pM atropine.
The haemodynamic response to vagus nerve stimulation was reproducible for the first
two stimulations only. The deterioration in the response to the third and fourth stimulations
was possibly due to the absence of choline chloride in the perfusate. This may have led to the
progressive failure of ganglionic transmission as the ganglionic stores of acetylcholine were
exhausted (Dieterich et al., 1978). Alternatively, the relatively low flow rate (5 ml g'1 min'1),
may have caused a mild hypoxia, affecting the nerve function (see Chapter 4). Other
investigators have employed similarly low flow rates in experiments to look at sympathetic
nerve function (Du and Dart, 1993) and the interaction of the parasympathetic and
sympathetic nervous system (Du, Ph.D. thesis, University of Edinburgh, 1991). A low flow
rate was chosen for the experiments detailed in this chapter, in order to maximise the chances
of observing acetylcholine in the coronary effluent. Attempts to differentiate between the above
two mechanisms were not made as, at this stage, the experiments were not quantitative and the
haemodynamic responses were only used as a marker of acetylcholine release.
The apparent absence of acetylcholine in the coronary effluent raised three
possibilities:
a) The acetylcholinesterase on the reactor column of the HPLC system was inhibited by the
neostigmine present in the samples and, consequently, only choline was detected.
b) Myocardial acetylcholinesterase was not sufficiently inhibited by the concentration of
neostigmine used, to prevent the hydrolysis of released acetylcholine before it could be washed
out of the synaptic cleft.
c) The concentration of released acetylcholine was too low to be detected by the HPLC method
employed.
Further experiments were devised to differentiate among the above possibilities.
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3.3 Further experiments
3.3.1 Inhibition of reactor column acetylcholinesterase
The manufacturer's literature, supplied with the column, suggested that 50 pM neostigmine
would not affect the assay unless the column had deteriorated to such an extent that the
amount of enzyme present was seriously reduced. The following experiments were carried out
to see if this was the case.
• protocol
The following series of injections (100 pi) were carried out:
a) 200 nM acetylcholine standard made up in diluent (10 injections).
b) Coronary effluent from a stimulated heart (10 injections) but alternating with 10 injections
of a 200 nM acetylcholine standard made up in diluent.
c) 200 nM acetylcholine standard made up in coronary effluent from a stimulated heart
(10 injections).
The mean ± SD area for the 200 nM acetylcholine standard was calculated from the first set of
standard injections. This was compared with the same statistic from the other two sets of
standard injections to determine if there were any cany-over or direct effects from the presence
of neostigmine in the perfusate.
• results and discussion
There were no significant differences in the observed acetylcholine result between any of the
three groups of standards, indicating that neostigmine, or other substances in the coronary
effluent samples, did not interfere with the HPLC analysis of acetylcholine (see Table 3.3.1).
Table 3.3.1 Recovery of20 pmoles of added acetylcholine in the absence and presence of
50 pM neostigmine
STANDARD GROUP
a (n = 10) b (n = 10) c (n = 10)
MEAN SAMPLE ACETYLCHOLINE 19.3 20.1 19.7
CONTENT (pmoles) ±0.8 ±1.3 ±1.0
PERCENTAGE RECOVERY 96.5 100.5 98.5
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3.3.2 In vitro myocardial acetylcholinesterase activity
Myocardial acetylcholinesterase activity was measured in crude atrial and ventricular
homogenates as well as atrial and ventricular microsomal preparations. These measurements
were carried out both in the presence and the absence of an inhibitor.
Acetylcholinesterase activity was measured using a spectrophotometric assay, (Ellman
et al., 1961), modified for use on a centrifugal analyser (Cobas Bio, Roche).
• spectrophotometric assay ofacetylcholinesterase
Acetylthiocholine is hydrolysed by acetylcholinesterase to acetic acid and thiocholine. The
thiocholine then reacts with DTNB (Ellman's reagent) to form the yellow anion,
5-thio-2-nitrobenzoate, which is measured at 410 nm. The rate of formation of the coloured
compound is directly proportional to the amount of enzyme present in the sample.
acetylcholinesterase
a) Acetylthiocholine + H20 >Acetic acid + Thiocholine
b) Thiocholine + DTNB > 2-nitrobenzoate-5-mercaptothiocholine +
5-thio-2-nitrobenzoate
The following solutions were made up
1) Phosphate buffer, 100 mM, pH to 8.0 with NaOH.
2) Phosphate buffer, 100 mM, pH to 7.0.
3) Buffered Ellman's reagent, DTNB (D8130, Sigma) 10 mM, made up in solution 2) and
containing 17.85 mM sodium bicarbonate (S6014, Sigma).
4) Acetylthiocholine perchlorate (A7407, Sigma) 75 mM.
The freshly prepared reagent was a combination of 9 ml phosphate buffer (pH 8.0), 60 pi
acetylthiocholine (substrate) and 300 pi DTNB solution.
Each sample (5 pi) was analysed with 300 pi of the above reagent and the course of
the reaction was followed for 6 min. The linear portion of the reaction was used to calculate
the rate. The reaction took place at 37 °C. Samples were analysed in duplicate.
The intra-assay coefficient of variation for a sample with a mean activity of 254 Units
L"1 was 2.7 % (n = 10). The inter-assay coefficient of variation for the same sample was 7.5 %
(n = 10). The approximate range of sample activities measured on the Cobas was 100 to 600
Units L'1.
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• preparation of tissue homogenates
Hearts were perfused for 10 min to flush out blood.
In the case of crude membrane preparation, the hearts were excised into ice cold
phosphate buffer (100 mM, pH 8.0). The atria and ventricles were separated and any excess
fat or connective tissue was removed. The atria and ventricles were minced with scissors,
before being homogenised separately over ice, using ten strokes of a close fitting teflon plunger
(Dounce homogeniser). The ratio of tissue to phosphate buffer was 400 mg to 20 ml. The
homogenate was filtered through gauze before analysis.
Hearts for microsome preparation were excised into ice cold Tris / HC1 buffer
(50 mM Tris containing 25 mM sucrose, pH 7.4). They were treated in the same way as the
crude preparations but the ratio of tissue to buffer for the homogenisation was 1 g to 20 ml.
Following the gauze filtration step, the filtrate was centrifuged for 10 min at
16,000 gav, 4 °C (JA20 rotor). The pellet was discarded and the supernatant was centrifuged
for a further 25 min at 42,000 gaV. 4 °C in a Beckman rotor (45 Ti). The microsomal pellet
was gently resuspended in 2 ml phosphate buffer before analysis.
• protocol
Three different fractions of atrial and ventricular homogenates were analysed. These were
crude homogenate, a microsomal preparation and the post-microsomal supernatant.
Microsomal membranes were prepared from the pooled tissues of 15 hearts. Crude
homogenate was prepared from the pooled tissues of 3 hearts. Solutions of neostigmine methyl
sulphate, Eserine (E8375, Sigma), an irreversible acetylcholinesterase antagonist, and
Quinidine sulphate (Q0875, Sigma), an inhibitor of pseudocholinesterase were made up in
phosphate buffer.
Aliquots (180 pi) of the tissue fractions were pipetted into the Cobas sample cups. To
these were added 20 pi of one of the inhibitors or phosphate buffer such that the final




Duplicate samples (5 pi) were analysed for cholinesterase activity and protein content
(see Section 2.4). Results were expressed as Units mg'1 protein. A reagent blank of phosphate
buffer was also run.
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• results and discussion
In the control group, approximately 70 % of the observed enzyme activity was located
in the atria, with only 30 % of the activity attributable to the ventricles. The level of activity in
the crude homogenate was approximately 75 % of that in the microsomal fractions when the
results were corrected for protein concentration. Very little enzyme activity (<13 Units
mg"1 protein) was detected in the supernatant fractions (see Table 3.3.2).
The enzyme activity in samples treated with quinidine sulphate was not significantly
different from samples which only contained phosphate buffer, indicating that there was no
pseudocholinesterase present in the samples. If pseudocholinesterase activity had been
detected, it would have indicated that there was erythrocyte contamination in the homogenate.
Both eserine (100 pM) and neostigmine (50 pM) inhibited acetylcholinesterase
activity to a similar degree, causing 90 to 95 % inhibition in the crude homogenates and the
microsomal fractions.
Table 3.3.2 The effect of inhibitors on myocardial acetylcholinesterase activity
(Units mg'1 protein).
TREATMENT
TISSUE Control Quinidine Eserine Neostigmine
FRACTION 100 mM 20 pM 100 pM 50 pM
HA 91 77 7 6
HA 91 89 7 6
HV 38 38 4 4
HV 38 38 4 4
MA 120 120 10 10
MA 120 120 20 10
MV 60 50 3 3
MV 50 50 3 3
SA 12 12 5 5
SA 13 13 5 3
SV 6 6 4 4
SV 6 6 4 4
KFY
HA = Homogenised atria
HV = Homogenised ventricles
MA = Atrial microsomes
MV = Ventricular microsomes
SA = Atrial supernatant
SV= Ventricular supernatant
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These results show that in tissue homogenates, up to 95 % of myocardial
acetylcholinesterase activity is inhibited by a 50 pM concentration of neostigmine. A two
times higher concentration of eserine, a more efficacious anticholinesterase, caused a similar
degree of enzyme inhibition.
Naturally, these are in vitro results and may not be exactly representative of the
in vivo situation. It seems likely, however, that the relative amount of inhibitor to enzyme
would be more favourable in vivo, where the membrane surface area would be expected to be
smaller.
3.3.3 In vivo myocardial acetylcholinesterase activity
• protocol
Three hearts were perfused for 45 min from a 500 ml perfusion column containing oxygenated
Krebs-Henseleit buffer with 50 pM neostigmine. The flow rate was 5 ml min"1 and the
perfusion pressure was maintained at a constant 100 cm H20 by the use of a recirculating
system (as described in Section 2.1.2). Perfusion and superfusion were then switched to a
second, identical recirculating perfusion system containing the same Krebs-Henseleit buffer
and neostigmine solution spiked with 200 nM acetylcholine. A second group of three hearts
(control group) underwent the same protocol, but in the absence of neostigmine.
Samples of coronary effluent and superfusate were taken 5, 7 and 9 min after the
switch to acetylcholine infusion, and analysed for acetylcholine content.
The amount of acetylcholine recovered from the coronary effluent samples was
compared to that recovered from the samples of superfusate which had undergone the same
treatment, except that they did not pass through the myocardium.
• results and discussion
There was no observed difference between the amount of acetylcholine present in the
superfusate samples from the two groups (see Table 3.4.3).
In the group containing neostigmine, there was no observed difference between the
amount of acetylcholine present in the samples of coronary effluent or superfusate. The
coronary effluent samples from the control group, however, contained less acetylcholine than
the superfusate samples (paired T-test, p < 0.05).
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Table 3.3.3 effect of50 |xM neostigmine on mean±SD acetylcholine result (pmoles).
SAMPLE
TREATMENT GROUP
Control (n = 3) 50 pM Neostigmine (n = 3)
Superfusate (n = 3)





# Significantly lower than superfusate (paired T-test, p < 0.05).
The results show that 50 jiM neostigmine will prevent the significant hydrolysis of 200 nM
infused acetylcholine. Assuming that the infused acetylcholine partitions within the
myocardium in a similar manner to that released during nerve stimulation, a 50 |±M
concentration of neostigmine should also prevent the significant hydrolysis of acetylcholine
released during nerve stimulation.
3.3.4 The effect of stimulation frequency and voltage
• increase the efficacy of the nerve stimulus
The magnitude of the haemodynamic response to sympathetic nerve stimulation depends upon
the frequency and voltage of the stimulus (Du, unpublished observations). This is reflected in
the amount of noradrenaline overflow.
The frequency and voltage of the vagus nerve stimulus can also be observed to
influence the magnitude of the haemodynamic response and presumably, therefore, the amount
of acetylcholine release.
By changing, first the frequency (15-50 Hz) and then the voltage (10-40 Volts) of
the vagus nerve stimulus to elicit the maximum possible response, it was hoped to increase the
amount of acetylcholine released from the nerve terminal to a level that could be detected by
the HPLC assay.
Despite altering the stimulus to cause asystole, no acetylcholine was detected in any
samples (not shown).
• use ofatropine
It has been observed that atropine (1 |iM), a muscarinic antagonist, caused an approximately
four fold increase in acetylcholine overflow from stimulated preparations of cat superior
cervical ganglia and rat cortical slices (Kato et al., 1975). This was possibly as a result of the
inhibition of a negative feedback effect on acetylcholine release when the acetylcholine was
prevented from binding to the muscarinic receptors.
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Although the use of atropine would abolish any haemodynamic changes during vagus
nerve stimulation, it was decided to use it just to see if it could cause the overflow of a
detectable amount of acetylcholine.
In a total of eight hearts, the viability of the vagus nerves was tested by doing a 5 s
control stimulation at the end of the 45 min equilibration period. Atropine was then infused at
the rate of 100 pi min'1, to reach a final concentration in the perfusate of 1 pM. A second
bilateral vagus nerve stimulation (15 Hz, 20 V, 30 s) was then performed, and samples
collected and analysed as previously described.
In 5 out of 8 preparations, no acetylcholine was detected. In 3 preparations, however,
there was a very small baseline disturbance which coincided with the position of the
acetylcholine standard peak and looked as though it might be due to the presence of a tiny
amount of acetylcholine.
Assuming that the 'peak' was indeed due to acetylcholine and not to a contaminant,
and assuming too that a four fold increase in acetylcholine overflow was also caused by
atropine in this preparation, it would indicate that at least a 20 to 30 fold increase in the
concentration of acetylcholine in the samples was needed before this assay could be reliably
employed to measure acetylcholine overflow from the isolated rat heart during vagus nerve
stimulation.
3.3J Sample concentration
The basic samples consisted of a 100 pi injection of the perfusate. Previously, no attempt had
been made to clean them up as the method had been successfully employed by other
investigators to measure levels of acetylcholine in 100 pi samples of brain microdialysate
(Kendrick et al, 1992).
Assuming that acetylcholine was present in the samples, but in concentrations too low
to be detected by the HPLC system, the following methods were employed to concentrate
acetylcholine in the samples.
• reduction ofperfusion flow rate during nerve stimulation
The flow rate was reduced from 5 ml g"1 min'1 to 0.5 ml g'1 min'1 during, and for 3 min after
episodes of nerve stimulation, in an attempt to increase the concentration of acetylcholine in
the samples. Acetylcholine was not detected.
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• evaporation
A 100 nM standard solution of acetylcholine in perfusate was prepared. Aliquots (2 ml) of the
standard solution and perfusate were freeze dried overnight and then reconstituted in 200 pi of
double distilled water, 100 pi of which was injected onto the HPLC system.
Unfortunately, the resulting high salt concentration caused a massive baseline
disturbance when injected, and any acetylcholine peak would have been masked. As a result it
was decided to try and extract the acetylcholine from the salt matrix.
• solvent extraction
A solid phase extraction method for extracting acetylcholine from physiological salt solutions
could not be located, and so the following solvent extraction, (Kato et al., 1975) was used.
Aliquots (4 ml) of the 100 nM standard solution of acetylcholine in perfusate were
shaken with an equal volume of a 10 mg ml"1 solution of tetraphenylboron (T4125, Sigma) in
heptanone (H7883, Sigma) to extract the acetylcholine out of the aqueous layer.
After centrifugation, to separate the aqueous and organic layers, 3 ml of the organic
layer was removed and shaken with 1.5 ml of 1 N HC1 to back-extract the acetylcholine into
the aqueous layer.
Following a further centrifugation step, the organic layer was discarded and the
aqueous layer was dried down under a vacuum (Biichi Rotavapor-P, Orme Scientific). The
residue was redissolved in 300 pi of double distilled, deionised water. Aliquots (100 pi) of the
resulting solution were injected onto the HPLC.
Unfortunately, injection of the extracted samples caused an offscale response during
the solvent peak which did not return to baseline before the acetylcholine peak eluted. The
acetylcholine peak could not be detected.
3.3.6 Bioassay of acetylcholine
It was therefore decided that bioassay using a preparation of the leech dorsal muscle might be
a suitable and more sensitive assay system for acetylcholine (Feldberg and Gaddum 1934).
• protocol
Ten specimens of Hirudo medicinalis were obtained (Biopharm UK Ltd). They were stored at
4 °C in a muslin bag containing a commercial gel (Hirudogel, Biopharm UK) to keep them
moist. A longitudinal strip of dorsal muscle was dissected from each specimen and was set up
in an organ bath filled with cold frog Ringer's solution (containing in mM; 111 NaCl,
1.8 KC1, 0.4 NaH2P04.2H20, 11 glucose, 4.8 NaHC03, 1.08 CaCl2). The Ringer's solution
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also contained the acetylcholinesterase inhibitor eserine (30 |iM). The organ bath was
continuously bubbled with air. The top of each muscle section was tied with thread and
connected to the arm of a force transducer (see Figure 3.6). A small weight (approximately
2 g) was attached to the opposite end of the transducer arm, such that the muscle underwent
isotonic contractions.
Figure 3.4 Leech dorsal muscle preparation for acetylcholine bioassay.
Force
\ transducer
All preparations underwent a 2 hour equilibration period, during which time the organ
bath was regularly flushed with fresh frog Ringer's solution. At the end of this period, the
chart recorder was zeroed and a dose response curve was constructed for acetylcholine, using
four concentrations of acetylcholine made up in a 5 in 7 dilution of Krebs-Henseleit solution
with double distilled water. The Krebs buffer was diluted to be isotonic with the Ringer's
solution.
Standards and samples were 5 ml in volume. They remained in contact with the
muscle preparation for 60 s, after which the organ bath was flushed repeatedly with fresh
Ringer's solution. Sufficient time was left between additions to the organ bath to allow the
muscle to return to it's resting length (generally, around 10 min).
Samples of coronary effluent from perfused hearts containing neostigmine or eserine,
were collected for 60 s. The sampling period began 60 s before vagus nerve stimulation, and
continued for 180 s. Samples were diluted in the same way as the standards before addition to
the organ bath. A total of 10 experiments were carried out.
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• results and discussion
Blank samples consisting of diluted Krebs-Henseleit solution did not cause any significant
change to the baseline.
Sensitivity to acetylcholine varied between the preparations (see Figure 3.5 for
examples of dose response curves). A significant response was, however, observed in 75 % of
preparations, upon addition of 50 pmoles of acetylcholine to the organ bath. This would equate
to a sample sensitivity of 10 nM, twice the sensitivity achieved with the HPLC assay. Hie
most sensitive preparation exhibited a sensitivity to acetylcholine of 5 nM.
Figure 3.5 Dose response curves for bioassay of acetylcholine on leech dorsal muscle
(experiment numbers 1-4)
Acetylcholine (pmoles)
Despite the superior sensitivity of the assay, however, no acetylcholine was detected in
any of the samples of coronary effluent which were analysed.
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3.4 CONCLUSIONS
Taking all these experiments into account, it would seem that the most likely explanation for
the absence of acetylcholine in samples of coronary effluent, is that acetylcholine is only
released in very small quantities upon vagus nerve stimulation, and that as it washes out of the
myocardium it becomes too dilute to be detected by the HPLC assay.
Unlike the sympathetic innervation, which is predominantly ventricular (Jacobowitz et
al., 1967), the majority of the parasympathetic nerve terminals are located within the atria
(Kent et al., 1974, Pardini et al., 1987). The observed distribution of acetylcholinesterase
within the myocardium would also support this (LOffelholz and Pappano 1985). Thus,
acetylcholine has a much smaller target tissue than noradrenaline, and it is perhaps not
surprising that coronary effluent from stimulated hearts would appear to contain substantially
less acetylcholine than noradrenaline.
Avian and amphibian hearts demonstrate a larger evoked acetylcholine overflow than
those of mammals. Studies with isolated perfused chicken hearts have yielded measurable (by
bioassay) quantities of acetylcholine into the coronary effluent, even in the absence of vagus
nerve stimulation (Dieterich et al., 1977). It is possible that the perfused innervated chicken
heart may have been a more suitable preparation in which to perform these experiments. The
rat heart was chosen as we had considerable experience of the model and the sympathetic
ganglion stimulation-evoked overflow of noradrenaline during normoxia and ischaemia.
Furthermore, although avian hearts liberate substantially larger amounts of acetylcholine in
response to nerve stimulation, tissue acetylcholine concentrations do not differ from those
recorded in mammals. Furthermore, acetylcholinesterase activity may even be lower in avian
than mammalian hearts (Dieterich et al., 1977). This raises the possibility that the stimulus-
secretion coupling in avian hearts is different from that in mammals. Consequently,
information about the interaction of the parasympathetic and sympathetic branches of the
autonomic nervous system, obtained in an avian preparation, might not be applicable to the
mammalian situation, where it is of most interest. In recent years, the publication of several
reports of multiple muscarinic receptor subtypes in chick atrial and ventricular tissues (Tietje
and Nathanson, 1991; Gadbut and Galper, 1994), provides more concrete evidence that
cholinergic neurotransmission in avian hearts may indeed differ from that in mammalian
hearts. Mammalian atrial and ventricular tissues have been found to contain muscarinic
receptors of the m2 subtype alone.
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In conclusion, until such time as a good sample clean up and concentration method
becomes available, the HPLC analysis of acetylcholine in the coronary effluent of stimulated






In the past, investigators have employed a variety of different coronary flow rates when
studying autonomic nerve function in the buffer-perfused, isolated rat heart. Flow rates as low
as 3.5 ml g"1 min'1 have been used during experiments to examine sympathetic stimulation-
evoked noradrenaline overflow (Dart et al., 1983), although flow rates of 5 ml g'1 min"1 have
been reported more frequently (Kurz et al., 1995a; Du and Dart, 1993). Similarly, studies of
the haemodynamic response to vagus nerve stimulation in the in situ, innervated perfused rat
heart, have utilised flow rates of 5 ml g'1 min'1 (Du, Ph.D. thesis, University of Edinburgh,
1991). The perfusion buffers for these studies are based on Krebs-Henseleit solution. The
composition of these buffers does not vary greatly, except for the inclusion of pyruvate in
some, but not all of them. The early studies (Dart et al., 1983; Dart et al., 1984a and b;
contained pyruvate (1.8 mM), whereas pyruvate was not included in the perfusion buffer of
later studies where a flow rate of 5 ml g"1 min"1 was used (Du and Dart, 1993; Du, 1991; Kurz
et al., 1995).
Buffer flow rates of around 5 ml g"1 min"1 were justified by past investigators on the
basis that they were close to the flow rate of blood through the coronary arteries in vivo (Malic
et al., 1976). Perhaps more importantly, however, they were limited by the sensitivity of the
radioenzymatic assay for noradrenaline. Higher flow rates, similar in magnitude to those
achieved with free flow at a constant perfusion pressure of 100 cm H20 in the buffer perfused
heart (approximately 10 ml g'1 min"1), may have been preferable, but the assay could not cope
with the resulting sample dilution. This is not a problem with the superior sensitivity achieved
with the HPLC assay.
The experiments described in the previous chapter, were carried out with a buffer flow
rate of 5 ml g'1 min"1. The haemodynamic response to vagus nerve stimulation was not
maintained over the course of 4 consecutive stimulations. This effect persisted when
exogenous choline was provided for acetylcholine resynthesis (Dieterich et al., 1978). In
addition to the above observation, while the HPLC assay for catecholamines was being set up
and verified, a control group for sympathetic stimulation from a previously published
experiment, using a flow rate of 5 ml g"1 min"1, was repeated. Again, it was noted that the
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magnitude of the noradrenaline overflow was not maintained over the course of the four
stimulations, despite the fact that the in situ, isolated, innervated rat heart model has been
reported to be stable under these conditions (Results not shown). The reason for the
discrepancy in these results, with those of Du, was not apparent. The experimental conditions
were identical to those reported by Du, and the only difference was the assay method for
noradrenaline. In Du's experiments, a radioenzymatic method for determination of
catecholamine concentrations in coronary effluents was used (Da Prada and ZUrcher, 1976),
compared to the alumina extraction and HPLC analysis detailed in Section 2.5.
Studies have demonstrated the improved contractile performance of blood-perfused
compared to buffer-perfused hearts, owing to the superior myocardial oxygen supply (Masuda
et al„ 1994). We hypothesised that at buffer flow rates of 5 ml g"1 min"1, either the nerves may
already be slightly hypoxic, or the myocytes might be releasing factors that inhibit nerve
function. Despite their un-physiological nature, higher flow rates may be appropriate in the
buffer perfused, innervated heart to provide sufficient oxygen for the maintenance of function.
The following experiments were designed to investigate the model stability under different flow
and nerve stimulation conditions.
4.2 Protocol
4.2.1 Stability of nerve stimulation model
Animals were allocated to one of three experimental groups:
Group Ai, 5 ml g"1 min"1 flow rate, 60 s duration of nerve stimulation, (n = 6).
Group A2.5 ml g'1 min"1 flow rate, 30 s nerve stimulation, (n = 6).
Group Bi, 10 ml g"1 min"1 flow rate, 30 s nerve stimulation, (n = 6).
Hearts were cannulated and perfused as described in Section 2.1.2. Each preparation
underwent a 40 minute equilibration period followed by four consecutive left stellate ganglion
stimulations (5 Hz, 20 V), at t = 0,15, 30 and 45 minutes.
The coronary venous effluent was collected in two consecutive 120 s aliquots, starting
120 s before the beginning of the nerve stimulation. Duplicate 2 ml portions of each aliquot
were assayed for noradrenaline content using the HPLC method. Lactate concentrations were
analysed in duplicate in coronary effluent collected before the first ganglion stimulation (SI)
and during nerve stimulation, as described in Section 2.3.1. Left ventricular pressure, heart
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rate and dP/dt were continuously monitored as described in Section 2.2.1. Maximum
stimulation evoked changes were recorded.
4.3 Results
4.3.1 Model stability - baseline haemodynamic function and biochemical data
Baseline haemodynamic function was defined as the values of LVP, HR and ±dP/dt in the
absence of ganglion stimulation, measured immediately prior to each episode of stimulation.
Baseline haemodynamic function of the isolated rat heart preparation was stable in all three
experimental groups over the 45 minute observation period.
Table 4.3.1 Baseline haemodynamic function of the isolated rat heart perfused at 5 or

















0 250 ± 32 53 ±9 2071 ± 360 1044 ±175
At 5 15 258 ± 29 52 ±8 2159 ±378 1021 ±134
(n = 6) 30 249 ± 36 56 ±10 2206 ± 388 1032 ±151
45 245 ± 41 54 ±9 2176 ±375 994 ±153
0 269 ± 48 48 ±6 1763 ±364 850 ± 265
a2 5 15 270 ± 47 51 ±12 1975 ±457 988 ±184
(n = 6) 30 258 ± 60 56 ±12 1950 ±332 1000 ±163
45 278 ± 28 55 ±13 1900 ±327 925 ±150
0 318 ± 21 83 ±17 2588 ± 232 1625 ±350
Bt 10 15 304 ± 29 81 ±15 2588 ± 232 1713 ±307
(n = 6) 30 294 ± 34 83 ±18 2700 ± 294 1650 ±235













* units ofml g"1 min'1
# Minutes after the end of the equilibration period.
Baseline values of LVP, HR and ± dP/dt were all significantly enhanced (p < 0.01; p < 0.05;
and p < 0.01 respectively) at all time points in group Bi (10 ml g"1 min'1 flow rate), compared
to groups Ai and A2 (flow rate 5 ml g"1 min"1). Baseline haemodynamic parameters were not
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different in the two groups perfused at 5 ml g"1 min'1 (1 way ANOVA, p = NS). Unstimulated
lactate overflow in hearts perfused with 5 ml g'1 min"1 was 1.7 ± 0.8 and 1.5 ± 0.8
pmol g"1 min"1 in groups Ai and A2 respectively. In the hearts perfused at increased flow rate
(10 ml g1 min"1), lactate overflow was higher (2.9 ± 2.5 p. mol g"1 min'1). Owing to the
increased variation, the effect was not significant (unpaired T-test, p = NS).
Noradrenaline was not detected in any unstimulated samples (< 0.5 pmol ml"1; not
shown).
43.2 The effect of stimulus duration on the response to repetitive ganglion stimulation
Group Ai (60 s stimulus duration, 5 ml g'1 min"1) was compared with group A2 (30 s stimulus
duration, 5 ml g'1 min'1). Mean ± SD values were normalised by expressing them as a
percentage of the first ganglion stimulation SI. The results are summarised in Table 4.3.2.
Actual values of SI are mentioned in the text or presented in Table 4.3.3.
Table 4.3.2 The effect of stimulus duration (60 or 30 s) on the response to repetitive
ganglion stimulation (data are presented as percent ofSI (SI = 100 %).
*Stim Stim NA Delta Delta Delta Delta
Exp. Dur. No. Overflow HR LVP +dP/dt -dP/dt
Group (s) (% of SI) (% of SI) (% of SI) (% ofSI) (% of SI)
SI 100 100 100 100 100
Ai 60 S2 71 ±36 83 ±30 108 ± 33 79 ±29 81 ±22
(n = 6) S3 49 ±33 90 ±36 108 ± 42 76 ±40 72 ±26
S4 40 ±31 90 ±71 83 ±75 72 ±45 59 ±26
SI 100 100 100 100 100
a2 30 S2 94 ±29 74 ±37 71 ±22 68 ±25 80 ±30
IIs S3 65 ±9 75 ±33 71 ±35 65 ±17 70 ±22
S4 46 ± 11 55 ±19 64 ±45 41 ±14 58 ± 17
2 way 60 vs 30 s: p < 0.05 NS NS NS NS
ANOVA SI - S4: p < 0.001 NS NS p < 0.01 p < 0.01
* Stimulus duration.
• Noradrenaline overflow
Left stellate ganglion stimulation evoked a significant noradrenaline overflow during the two
minute collection period in all experiments. The amount of noradrenaline overflow during S1
was not significantly different in the two groups (145 ± 58 and 161 ± 40 pmol g"1 min"1 for
groups Ai and A2 respectively).
In both groups, noradrenaline overflow declined significantly over the course of the
four ganglion stimulations (ANOVA, p < 0.001). Ganglion stimulation evoked noradrenaline
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overflow declined more rapidly when the duration of the stimulation was 60 s rather than 30 s
(2 way ANOVA, p < 0.05; see Table 4.3.2 and Figure 4.1).
Figure 4.1 The effect of stimulus duration on noradrenaline overflow during four
consecutive left stellate ganglion stimulations.
S1 S2 83 84
Stimulation
Group Ai (60 s ganglion stimulation), is represented by dark grey bars.
Group A2 (30 s ganglion stimulation), is represented by light grey bars.
Each bar is the mean of 6 experiments.
For statistical analysis see Table 4.3.2.
• Haemodynamic function
The first left stellate ganglion stimulation increased heart rate, left ventricular pressure and
dP/dt (Table 4.3.3). The magnitude of the SI haemodynamic responses to ganglion stimulation
were not significantly effected by the duration of the stimulation.
Although there was a trend for heart rate and left ventricular pressure responses to decrease
over the course of the four ganglion stimulations, these changes failed to reach significance
owing to the large variability. Variability was higher in the group stimulated for 60 s (AO, and
tended to increase from SI to S4 (Figure 4.2). Stimulus duration did not have a significant
effect on the heart rate or left ventricular pressure responses.
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Figure 4.2 The effect of stimulus duration (60 or 30 s) on the haemodynamic response to
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Stimulation Stimulation
Dark grey bars represent group Ai (60 s ganglion stimulation).
Pale grey bars represent group A2 (30 s ganglion stimulation).
Each bar is the mean of 6 experiments.
Heart rate and left ventricular pressure responses were not significantly altered during SI to S4. The magnitude
of the +dP/dt and -dP/dt responses declined significantly during SI to S4 (2 way ANOVA, p < 0.01). Stimulus
duration had no effect on the rate of this decline.
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Left ventricular contractility did, however, demonstrate a significant decline during
SI- S4 (p < 0.01 for both +dP/dt and -dP/dt; Figure 4.2). Stimulus duration had no effect on
the rate of this decline.






















A! (n = 6) 5 60 63 ±24 12 ±5 717 ±223 808 ± 265
A2 (n = 6) 5 30 79 ± 13 12 ±5 883 ±169 825 ±204
B! (n = 6) 10 30 *40 ±11 12 ±5 *425±167 792 ±169
# Units ofml g'1 min'1.
Group Ai was compared to group A2, and group A2 was compared to group Bi using unpaired T-tests.
* Significantly lower than group A2 (unpaired T-test, p < 0.001).
• Lactate overflow
Lactate overflows measured during ganglion stimulation at SI were 2.6 ±1.2 and 2.5 ±1.2
(xmol g"1 min"1 in groups Ai and A2 respectively, and were not significantly different
(Table 4.3.4). Although lactate overflow during ganglion stimulation tended to decline from SI
to S4, this trend was not significant. Stimulus duration did not affect the amount of lactate
overflow during stimulation (2 way ANOVA, p = NS; Table 4.3.4).








(s) SI S2 S3 S4
A,(n = 6) 60 2.6 ± 1.2 2.2 ±1.3 2.2 ±1.3 2.1 ± 1.1
A2 (n = 6) 30 2.5 ± 1.2 2.8 ±1.1 2.3 ±1.0 1.8 ±0.7
* Stimulus duration
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4.3J The effect of perfusion flow rate on the response to repetitive ganglion stimulation.
The effect of flow on the effect of a 30 s ganglion stimulation, repeated 4 times, was further
analysed statistically by comparing group A2 (5 ml g"1 min'1) with group Bi (10 ml g"1 min'1).
Mean ± SD values were normalized by expressing them as a percentage of SI. The results are
summarised in Table 4.3.5. Note that the results for group A2 have already been given in
Table 4.3.2. Values of SI are stated in the text or presented in Table 4.3.3.
Table 4.3.5 The effect offlow rate on the response to repetitive 30 s ganglion stimulation
(data are presented as percent ofSI ± SD (SI = 100 %).
NA Delta Delta Delta Delta
Exp. Flow Stim overflow Heart rate LVP +dP/dt -dP/dt
Group Rate No. (% of SI) (% of SI) (% of SI) (% of SI) (% of SI)
SI 100 100 100 100 100
#a2 5 S2 94 ±29 74 ±37 71 ±22 68 ±25 80 ±30
(n = 6) S3 65 ±9 75 ±33 71 ±35 65 ± 17 70 ±22
S4 46 ± 11 55 ± 19 64 ±45 41 ± 14 58 ± 17
SI 100 100 100 100 100
Bi 10 S2 93 ±15 88 ±25 100 ±22 110 ±40 95 ±29
(n = 6) S3 95 ±15 122 ± 25 92 ±32 94 ±27 93 ±24
S4 93 ±16 123 ± 25 121 ±49 100 ± 40 98 ± 19
2 way Flow rate p < 0.001 p < 0.05 p < 0.05 p < 0.001 p < 0.05
ANOVA SI -S4 p < 0.01 NS NS p<0.01 NS
Interaction p < 0.05 NS NS p<0.01 NS
# The data of group A2 in this table is identical to that already shown in Table 4.3.2.
• Noradrenaline overflow
Left stellate ganglion stimulation evoked a significant noradrenaline overflow during the two
minute collection period in all experiments. The amount of noradrenaline overflow during S1
was significantly higher in the group perfused at a flow rate of 10 ml g'1 min"1 compared to
5 ml g'1 min"1 (229.5 ± 35.5 and 161.3 ± 39.9 pmoles g'1 min"1 respectively; p < 0.05).
At the lower flow rate (5 ml g"1 min'1), noradrenaline overflow decreased significantly
during SI to S4 (ANOVA, p < 0.001). When the flow rate was increased to 10 ml g"1 min"1,
however, the noradrenaline overflow was well maintained throughout all four stimulations.
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Figure 4.3 The effect of coronary flow rate (5 and 10 ml g'1 min1) on the noradrenaline




























Group A2, 5 ml g"1 min"1 is represented by dark grey bars.
Group Bi, 10 ml g'1 min'1 is represented by pale grey bars.
Each bar represents the mean of 6 observations.
Noradrenaline overflow declined in the group perfused at 5 ml g"1 min"1, but was stable in the high flow rate
group. For statistical analysis see Table 4.3.5.
• Haemodynamic function
Values at SI are presented in Table 4.3.3. The magnitude of left ventricular pressure and
-dP/dt responses were not significantly affected by the flow rate. The magnitude of the heart
rate and +dP/dt responses to ganglion stimulation was, however, significantly reduced in group
Bi (10 ml g'1 min'1) compared to A2 (5 ml g"1 min"1).
The haemodynamic responses to repetitive nerve stimulation were better maintained in the
higher flow rate group (see Figure 4.4).
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Figure 4.4 The effect of flow rate (5 or 10 ml g'J miri1) on the reproducibility of the
haemodynamic response to four identical 30 s ganglion stimulations.
Stlmulitlon Stimulation
Group A2 (5 ml g'1 min"1) is represented by the dark grey bars.
Group Bi (10 ml g"1 min"1) is represented by the pale grey bars.
Each bar is the mean of 6 experiments.
Haemodynamic responses were all stable in the higher flow rate group.
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• Lactate overflow
Lactate overflows during nerve stimulation are shown in Table 4.3.6. Lactate overflows tended
to be slightly higher in the group perfused at 10 ml g"1 min"1, possibly reflecting the higher
contractile function, although this difference was not significant (unpaired T-test, p = NS).
The lactate overflow was stable throughout the experiment.
Table 4.3.6 The effect offlow rate on lactate overflow (\xmol g' min1) during a repeated







SI S2 S3 S4
A2 (n =6) 5 2.5 ± 1.2 2.8 ±1.1 2.3 ±1.0 1.8 ±0.7
Bi(n = 6) 10 3.8 ±3.4 3.5 ±3.3 3.5 ±3.3 3.2 ±3.3
Unpaired T-test NS NS NS NS
# Units ofml g"1 min'1.
4.4 Discussion
The results demonstrate that a coronary flow rate of 5 ml g"1 min'1 is not sufficient to maintain
ganglion stimulation-evoked noradrenaline overflow in this model. Even when the duration of
the stimulation was reduced, the noradrenaline overflow declined, although the onset was
delayed. Interestingly, the haemodynamic responses were not always a good indicator of the
failing noradrenaline overflow. Heart rate and left ventricular pressure were particularly
poorly related to noradrenaline overflow, although it is possible that with greater numbers,
these parameters would have shown a significant decline in their response to repetitive
stimulations. When the stimulus duration was longer (60 s), the heart rate and left ventricular
pressure changes were better maintained, although the variability was very large. This
suggested that perhaps the magnitude of these responses could be maintained in some
preparations, but a longer period of nerve stimulation was required to achieve the maximal
response. When the flow rate was 5 ml g'1 min"1, left ventricular contractility responses were a
more sensitive marker of noradrenaline overflow, particularly -dP/dt. It is of interest that Du
found a good relationship between neurally mediated noradrenaline overflow and
haemodynamic responses in the innervated rat heart perfused at 5 ml g"1 min"1 (Du, 1991). His
experiments were in that case, however, limited to two ganglion stimulations.
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Although in the hearts perfused at 5 ml g'1 min'1 noradrenaline overflow undeniably
declined, and was assumed to reflect a corresponding reduction in presynaptic noradrenaline
release, it is possible that the failing dP/dt responses at this flow rate were actually due to
postsynaptic mechanisms. For example, small changes in intracellular pH could have affected
intracellular enzyme activity and the coupling of receptors to second messenger systems.
Adrenergic receptor binding characteristics may also have been altered. No attempt was made
to differentiate between a pre- and postsynaptic mechanism for this effect, although repeated
short noradrenaline or isoprenaline infusions, in place of the ganglion stimulations, could have
provided this information.
Increasing the flow rate to 10 ml g'1 min'1 caused significant increases in all the
haemodynamic parameters measured at baseline, confirming that at the lower flow rate, the
contractile function of the heart was already limited.
The reduction of the magnitude of the stimulation-evoked heart rate and +dP/dt
responses at the higher flow rate (see Table 4.3.3), was interesting. Despite the fact that the
magnitude of the stimulation induced increases were reduced, the actual values of heart rate
and -t-dP/dt reached during stimulation, were higher as they were superimposed onto higher
baseline values. This result probably reflects that the magnitude of the heart rate and +dP/dt
responses were nearing their maximum in the higher flow rate group, and the 'dose-response'
curves were no longer linear. Alternatively, the increased rate of washout of noradrenaline
from the synaptic cleft at the higher flow rate, reduced the concentration of noradrenaline in
contact with the postsynaptic receptors, even though the total amount of noradrenaline released
during the stimulation was greater.
Lactate overflow was not significantly different at the two flow rates although the
overflow tended to be greater in the hearts perfused at 10 ml g"1 min"1. Lactate overflow
measured during ganglion stimulation, was not a good indicator that the haemodynamic and
nervous function of the heart was compromised at the lower flow rate. It is likely that the
increase in lactate overflow lagged behind the haemodynamic response to ganglion stimulation,
and was not adequately represented in our 120 s sample. If lactate overflow had been sampled
for longer periods following a stimulation, it is possible that it would have resulted in a closer
relationship to noradrenaline overflow and haemodynamic function.
The reason that this lack of model stability at flow rates of 5 ml g"1 min"1 has only
been observed now, is difficult to determine. It is hard to compare these results with those of
experiments in which the conditions were not identical. It is possible, for example, that the
inclusion of pyruvate in the perfusion buffer by groups working in Germany during the 1980s,
may have stabilised the model. The use of pyruvate, however, has not been ubiquitous in
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experiments performed at a flow rate of 5 ml g'1 min"1 (Du, 1991; Du and Dart, 1993; Kurz,
1995). One possibility is that the improved sensitivity and precision of the assay procedures
used to analyse noradrenaline levels in the coronary effluent in these experiments, led to the
discrepancy. The radioenzymatic assay was a notoriously difficult assay to work with and
often produced aberrant results. For this reason, samples were run in triplicate and often had
to be repeated. Given an unexpectedly low result, it would have been very easy to assume that
the assay was at fault and discard or repeat the sample. This may have been even more likely
if the heart rate and left ventricular pressure responses were not demonstrating a
corresponding fall. Furthermore, if as a result of the exclusion criteria, preparations were
discarded if the haemodynamic response to ganglion stimulation began to fail at any point
throughout the experiment, the problem would have been exacerbated.
In conclusion, these results demonstrate the need to work with higher coronary flow
rates than have been used in the past, to study ganglion stimulation-evoked noradrenaline
overflow from the buffer perfused rat heart. A flow rate of 10 ml g"1 min'1 is sufficient to
provide model stability. The results emphasise the importance of measuring neurotransmitter
overflow when studying nerve function. Haemodynamic responses alone are not sufficiently
sensitive markers of nerve activity.




Brief episodes of ischaemia and reperfusion, which themselves do not cause myocardial
damage, preceding a longer, sustained period of myocardial ischaemia, delay the onset and
decrease the severity of cell injury (Murry et al., 1986). This phenomenon of 'ischaemic
preconditioning' has been observed in a wide range of species and models (see Section 1.2),
where in addition to its infarct size-limiting effect, it improves the post-ischaemic recovery of
contractile function (Cave, 1995) and reduces the incidence of post-ischaemic arrhythmias on
reperfusion (Parratt and Vegh, 1994).
The mechanism of ischaemic preconditioning has been extensively investigated (for
review, see Cohen and Downey, 1996). Adenosine appears to be a principal mediator of
ischaemic preconditioning in the majority of species which have been investigated including
the rabbit, dog and human heart (Liu et al., 1991; Grover et al., 1992; Claeys et al., 1996).
Adenosine, however, seems not to be involved in the adaptive response to ischaemic
preconditioning in the rat heart where the primary mediator remains to be elucidated (Asimakis
et al., 1993; Li and Kloner, 1993). A role for catecholamines in the mechanism of ischaemic
preconditioning in the rat heart was first investigated by Locke-Winter and co-woikers in
1991. They reported that ^-adrenoceptor stimulation facilitated ischaemic preconditioning in
the protection against contractile dysfunction during post-ischaemic reperfusion in the
buffer-perfused rat heart (Locke-Winter et al., 1991). They concluded that this effect was
achieved by increasing the presynaptic release of endogenous noradrenaline during the
transient preconditioning ischaemia (although noradrenaline release was not measured). The
endogenous noradrenaline was then proposed to mediate ischaemic preconditioning through an
effect on postsynaptic oti-adrenoceptors. Subsequently, other evidence supporting a role for
catecholamines as mediators of ischaemic preconditioning has been reported. Exogenously
infused noradrenaline (10 nmol min"1; 2 min) mimicked ischaemic preconditioning in the
globally ischaemic rat heart (Baneijee et al., 1993). The effect was blocked by depletion of
endogenous noradrenaline (reserpine), or an cci-adrenoceptor antagonist.
Although very limited endogenous noradrenaline release may occur during transient
global ischaemia in the isolated buffer-perfused heart (Baneijee et al., 1993), the magnitude of
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the release is small (approximately 150 pmol g"1 min"1). The situation in vivo is slightly
different. Reflex activation of sympathetic nerves occurs very quickly after the onset of acute
ischaemia (Malliani et al., 1969). Even so, this reflex-mediated release is small, and of a local
nature, compared to the unphysiologically high levels of exogenous noradrenaline which were
infused in the above experiments. The perfused, innervated in situ rat heart preparation
provides a more suitable model in which to investigate the role of noradrenaline in the
preconditioning response.
The following experiments aimed to establish whether direct sympathetic ganglion
stimulation could protect against post-ischaemic dysfunction and tissue enzyme depletion in




The in situ, innervated, Langendorff perfused rat heart model was used (as described in
Section 2.1.3). Free flow conditions were used and the mean ± SD flow rate was 9.6 ± 1.0
ml g'1 min"1. The coronary perfusion pressure was 100 cm H2O.
Animals were randomly assigned to three groups: A total of 27 animals completed the
study (see below). Mean wet heart weights between the groups were not significantly different
(1 way ANOVA, p = NS).
Group 1: control group (n = 9); wet heart weight 1.36 ± 0.04g.
Group 2: sympathetic ganglion stimulation (5 Hz, 5 min) (n = 9); 1.35 ± 0.05g.
Group 3: noradrenaline infusion (5 nmol min'1,5 min) (n = 9); 1.24 ± 0.06g.
Following a 45 min equilibration period, baseline haemodynamic values of heart rate,
left ventricular pressure and left ventricular contractility were recorded. Left ventricular
developed pressure (LVDP) was defined as the difference between end diastolic and peak
systolic pressure. Coronary flow rate, lactate and noradrenaline overflows were also recorded.
Groups 2 and 3 then underwent a 5 min preconditioning interventioa In group 2, this
was a period of sympathetic ganglion stimulation (GS). In order to prevent 'nerve fatigue',
ganglion stimulations were carried out in 30 s bursts, interspersed with 30 s recovery periods
for a total of 5 minutes. Group 3 underwent 5 minutes of exogenous noradrenaline infusion at
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the corresponding time. A 50 (iM noradrenaline solution was infused at a rate of 100 pi min'1,
(i.e. 5 nmol min"1). Coronary effluent was collected throughout this period for determination of
noradrenaline overflow. A total of twelve hearts underwent this procedure. Three of them
developed sustained ventricular fibrillation and could not be manually defibrillated. These
three preparations were discarded and did not complete the protocol. The remaining nine hearts
were all in sinus rhythm at the onset of global ischaemia.
Following the ganglion stimulation or noradrenaline infusion, the hearts were
normoxically perfused for a further 10 min, and the parameters were rerecorded immediately
before the onset of global ischaemia (BGI). Hearts in group 1 were normoxically perfused for
the entire 15 min period.
All three groups were then subjected to 30 min global stop-flow ischaemia. During
this time, the left ventricular apical cannula was removed and a thermostatic cup was placed
over the heart to maintain the temperature at 37 °C. Continuous superfusion with wanned
buffer ensured that the preparation remained moist. One minute before the end of the
ischaemic episode, the apical cannula was carefully replaced in the ventricle.
Figure 5.1 Schematic illustration of experimental protocol.
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GS represents ganglion stimulation.
NA represents exogenous noradrenaline infusion.
Perfusion was free-flow (100 cm H2O), except during global stop-flow ischaemia.
Haemodynamic recovery, noradrenaline and lactate overflows were monitored for the first 30 minutes of the
reperfusion period. Tissue creatine kinase was measured after 4 hours of reperfusion.
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5.2.2 Data collection and processing
The presence of arrhythmias throughout the first twenty minutes of reperfusion made analysis
of the progression of haemodynamic recovery impossible. Post-ischaemic recovery of
haemodynamic function was assessed after 30 minutes of reperfusion. At this time, most
hearts were beating in sinus rhythm and were free of arrhythmias. In 4 of the 27 preparations,
sustained, serious ventricular arrhythmias were present and these preparations were excluded
from the analysis of haemodynamic functional recovery. They were, however, included in the
analysis of post-ischaemic arrhythmias, tissue creatine kinase, lactate and noradrenaline
overflow.
Coronary effluent was collected into pre-weighed, chilled tubes for each of the first
5 minutes of the reperfusion period, and for every fifth minute thereafter. Recovery of
coronary flow rate was assessed from these samples and lactate and noradrenaline overflows
were assayed in the effluent. Lactate and noradrenaline overflows were expressed per gram
wet weight of heart tissue.
The presence of ventricular tachyarrhythmias could be identified from the left
ventricular pressure recording. Heart rates in excess of 500 beats per minute were classified as
tachycardia. All 27 hearts suffered sustained severe ventricular arrhythmias during the early
part of the reperfusion period. The incidence of these arrhythmias gradually declined
throughout the first 30 minutes of reperfusion. The duration of ventricular tachycardia or
fibrillation was measured between 20 and 30 minutes of reperfusion.
Tissue creatine kinase levels, as an indicator of cell damage, were assayed in
ventricular homogenate (see section 2.3), at the end of 4 hours of reperfusion.
5.23 Statistical analysis
Normally distributed data was analysed using one and two way analysis of variance where
appropriate. Where the first test was significant, follow up testing was done with paired and
unpaired Student's t-tests. Bonferoni corrections were applied.
Skewed data was analysed using the non-parametric Kruskal-Wallis test. Follow-up
testing was done with the Mann-Whitney test and appropriate Bonferoni correction.
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5.3 Results
53.1 Effect of ganglion stimulation or noradrenaline infusion on pre-ischaemic function
• Noradrenaline overflow
Noradrenaline was not detected in any samples of coronary effluent at baseline
(< 1 pmol g"1 min'1 ; Table 5.3.1). During intermittent left stellate ganglion stimulation (group
2), the mean ± SD overflow of noradrenaline in the coronary effluent was 249 ± 92
pmol g"1 min'1. In group 3, the concentration of noradrenaline in the effluent during
noradrenaline infusion reached 378 ± 16 nM, resulting in an apparent 'overflow' of 3712 ± 92
pmol g"1 min"1. This was significantly higher than during ganglion stimulation (unpaired T-test;
p < 0.001). Noradrenaline overflow was not detected ten minutes after the end of the ganglion
stimulation or noradrenaline infusion protocols (Table 5.3.1).
Table 5.3.1 Coronary flow and washout of lactate and noradrenaline at baseline and




(p mol g'1 min'1)
Baseline Treatment BGI
Control (n = 9) * ND ND ND
GS (n = 9) ND 8 249 ± 92 ND






(n moles g'1 min"1)
♦♦Baseline #BGI Baseline BGI
Control (n = 9) 9.3 ±0.9 9.3 ± 1.7 91 ±22 102 ± 22
GS (n = 9) 9.7 ± 1.3 9.9 ±1.5 86 ±27 70 ±21
NA (n = 9) 9.8 ± 0.4 10.2 ± 1.0 85 ±8 78 ± 15
2 way ANOVA






** Measured at the end of the 45 minute equilibration period.
# BGI represents measurements taken immediately before global ischaemia.
* ND represents not detected (< 1 pmol g"1 min'1).
8
Significantly higher than baseline (paired T-test; p < 0.001).
b
Significantly higher than GS (unpaired T-test; p < 0.001).
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• Haemodynamic function
Baseline values of coronaiy flow rate did not differ between the three groups (Table 5.3.1).
Coronary flow rate measured immediately before the onset of global ischaemia was not
different from baseline (2 way ANOVA, p = NS).
Heart rate, left ventricular pressure and dP/dt in groups 2 and 3 at baseline, were not
different from control (Table 5.3.2). Intermittent ganglion stimulation (5 Hz) and
noradrenaline infusion both caused significant increases in peak heart rate, left ventricular
pressure, +dP/dt and -dP/dt compared to baseline (Table 5.3.2). Noradrenaline infusion caused
a greater increase in the peak value of -dP/dt than intermittent ganglion stimulation (unpaired
T-test, p < 0.05). Noradrenaline infusion caused a sustained increase in haemodynamic
function during the 5 minute infusion period. Intermittent ganglion stimulation, however,
resulted in a cyclical response which corresponded to the periods of stimulation. The
haemodynamic response to ganglion stimulation was maintained over the course of all five
stimulations. Heart rate, left ventricular pressure and dP/dt had all returned to baseline before
the onset of global ischaemia (Table 5.3.2).
• Lactate overflow
Baseline lactate overflows did not vary significantly between the groups (Table 5.3.1). Lactate
overflow measured immediately before the onset of global ischaemia was not different from
baseline.
• Arrhythmias
Preparations suffering sustained, serious ventricular arrhythmias during the 60 min
pre-ischaemic period were abandoned. A total of three preparations were rejected during the
noradrenaline infusion protocol in group 3, after they developed sustained VF from which they
could not be manually defibrillated.
5.3.2 Effect of 30 minute, global stop-flow ischaemia on haemodynamic function.
At the onset of global, stop-flow ischaemia, haemodynamic variables declined progressively.
All preparations, reached asystole within the first three minutes of global ischaemia, and
remained so for the duration of the ischaemic episode.
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5.33 Post-ischaemic reperfusion.
• Post-ischaemic noradrenaline overflow
Reperfusion following 30 minutes of global ischaemia caused a significant overflow of
noradrenaline in the coronary effluent (Table 5.3.3). Post-ischaemic washout of noradrenaline
was complete within the first three minutes of reperfusion. The total noradrenaline recovered
in the effluent was not significantly different between the groups (Kruskal-Wallis; p = NS;
Table 5.3.3). The variability was high within all three groups, although this was particularly
so in the groups which received either ganglion stimulation or noradrenaline infusion in the
pre-ischaemic period.
Table 5.3.3 Total noradrenaline overflow (pmol gl) and coronary flow rate (% of baseline







Early reperfusion Early reperfusion Late reperfusion
Control (n = 9) 502 ± 73 68 ±4 78 ±5
GS (n = 9) 685 ±222 82 ±4 81 ±5
NA (n = 9) 742 ±261 "101 ±5 86 ±4
Significantly higher than control (1 way ANOVA followed by unpaired T-test; p < 0.01).
* Total post-ischaemic washout of noradrenaline (complete within first 3 minutes of reperfusion). This data
was not normally distributed and was analysed using the non-parametric Kruskal-Wallis test.
** Values during early reperfusion are the average coronary flow rate during the first 5 minutes of post-
ischaemic reperfusion. Values during late reperfusion are coronary flow rate measured in the 30th minute of
post-ischaemic reperfusion. Mean ± SD values are expressed as the percentage of baseline flow rate.
• Post-ischaemic haemodynamic function
Hearts which received pre-ischaemic noradrenaline infusion, reperfused better than control
hearts, demonstrating significantly higher average coronary flow rates during the first
5 minutes of post-ischaemic reperfusion (1 way ANOVA, followed up by unpaired T-test;
p < 0.01; Table 5.3.3). This effect was lost when coronary flow rates were compared at the
end of the 30 minute reperfusion period (Table 5.3.3).
Values of LVDP, +dP/dt and -dP/dt, measured after 30 minutes of post-ischaemic
reperfusion, were significantly depressed when compared to baseline (2 way ANOVA,
p < 0.001; Table 5.4; Figure 5.2). Left ventricular end diastolic pressure measured at the same
time, was significantly higher than baseline in all three groups (21 ± 12, 36 ± 16 and 21 ± 18
mm Hg in control, GS and NA group respectively; p < 0.05). Neither pre-ischaemic
noradrenaline infusion, nor intermittent ganglion stimulation, had any effect on the magnitude
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of the changes in post-ischaemic contractile function (2 way ANOVA, p = NS; Figure 5.2).
Heart rate measured after 30 minutes of reperfusion was not significantly different from
baseline in any of the groups (Table 5.3.4).
Table 5.3.4 The effect of intermittent ganglion stimulation or exogenous noradrenaline











Control (n=7) 105 ± 24 62 ±27 60 ±27 70 ±27
GS (n=8) 96 ±8 74 ± 10 65 ± 13 63 ±23












All parameters, except heart rate, were significantly reduced after 30 minutes of post-ischaemic normoxic
reperfusion compared to baseline.
Figure 5.2 The effect of ganglion stimulation or noradrenaline infusion on contractile
recovery after 30 minutes post-ischaemic reperfusion.
-gr 160 —




For statistical analysis see Table 5.3.4.
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• Lactate overflow
Lactate overflow after 30 minutes of post-ischaemic reperfusion was significantly higher than
baseline values in all three groups (paired T-test, p < 0.001). Neither pre-ischaemic ganglion
stimulation nor noradrenaline infusion had a significant effect on this value (1 way ANOVA,
p = NS; Table 5.3.5).
Table 5.3.5 The effect ofganglion stimulation or noradrenaline infusion on lactate overflow,










Control (n = 9) a 771 ±127 2.8 ± 0.9 32.2 ± 2.0
GS (n = 9) a 728 ±109 1.4 ± 1.7 32.9 ± 1.3
NA (n = 9) a 702 ±138 1.1 ±2.1 33.0 ±1.7
1 way ANOVA NS NS NS
* Measured in the 30th minute of reperfusion.
** Measured between 20 and 30 minutes of the reperfusion period.
# Tissue level, measured after 4 hours of reperfusion.
Significantly higher than baseline (paired T-test, p < 0.001).
• Post-ischaemic arrhythmias
The total time spent in either ventricular tachycardia or ventricular fibrillation, was analysed
between twenty and thirty minutes of reperfusion (Table 5.3.5). There was a trend towards
fewer post-ischaemic arrhythmias in groups which underwent pre-ischaemic ganglion
stimulation or noradrenaline infusion, although there was a very large variability and the trend
was not statistically significant.
• Creatine Kinase
In control hearts (see Table 5.3.5), the mean tissue creatine kinase level was 32.2 ± 2.0
units-mg"1 protein. This was significantly lower than the level observed in a group of 4 hearts
perfused with no interventions for 6 hours (38.2 ± 0.8 units mg"1 protein, p < 0.05, not shown).
Neither pre-ischaemic sympathetic ganglion stimulation, nor noradrenaline infusion
significantly effected the amount of tissue enzyme depletion after 4 hours of reperfusion (32.9
±1.3 and 33.0 ±1.7 units mg"1 protein, respectively).
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5.4 Discussion
This is the first study to show that a five minute left stellate ganglion stimulation does not
protect the buffer perfused rat heart against the development of post-ischaemic contractile
dysfunction following 30 minutes of global ischaemia. This result would indicate that under
physiological conditions, endogenous noradrenaline release is unlikely to play an important
role in the adaptive response to ischaemic preconditioning in the rat heart. As ever, there are
limitations involved in the use of a buffer perfused model. For example, the coronary flow
rates are unphysiologically high, resulting in the increased washout of metabolites and
neurotransmitters from the heart. The rate of glycolytic flux is also unnaturally high owing to
the absence of fatty acids for oxidative phosphorylation. Ideally, experiments should be carried
out under more physiological conditions such as the rat heart in vivo preparation to
substantiate this conclusion.
We were also unable to demonstrate that pre-ischaemic exogenous noradrenaline
infusion caused an improvement in post-ischaemic contractile function. This was unexpected
as the protocol described in these experiments was very similar to the one used by Banerjee
and co-workers, in which exogenous noradrenaline infusion resulted in a significant
improvement in post-ischaemic contractile function (Baneijee et ai, 1993). In that study, a
2 minute infusion of exogenous noradrenaline (10 nmol min"1) or phenylephrine, ten minutes
before a twenty minute global ischaemia, facilitated the recovery of post-ischaemic contractile
function in isolated rat hearts. Preconditioning produced with either noradrenaline infusion or
transient ischaemia was abolished with oti-adrenoceptor blockade. This led them to conclude
that ischaemic preconditioning in the isolated rat heart involves sympathetic neurotransmitter
release and (Xi-adrenoceptor activation. It is possible that slight differences in the methodology
may explain why noradrenaline infusion failed to precondition the globally ischaemic rat heart
in the experiments described here.
The exact amount of noradrenaline infused during the preconditioning stimulus was
not felt to be a critical factor in explaining the lack of any protective effect observed in these
experiments. Banerjee used a 2 minute preconditioning period during which noradrenaline was
infused at the rate of 10 nmol min"1. Unfortunately, it proved difficult to infitse this
concentration of noradrenaline for 5 minutes due to the appearance ofmany serious ventricular
arrhythmias which failed to resolve themselves after 10 minutes of normal perfusion. To
overcome this problem, the concentration of infused noradrenaline was reduced to
5 nmol min'1. The 5 minute preconditioning stimulus was, therefore, greater than that in
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Banerjee's experiments, but at a lower concentration. It is remarkable that Baneijee et al. do
not report that they experienced these difficulties. The concentration of potassium in their
perfusate was slightly higher than ours (4.7 vs 4.0 mM), although this alone would not seem to
be sufficient to explain the difference.
The primary difference in the methodology of the two studies was the severity of the
ischaemic insult. Banerjee's group used a twenty minute period of global ischaemia, whereas
thirty minutes was used here. The more severe ischaemic episode may have overcome any
protection conferred by the noradrenaline infusion. This is not a likely explanation for the
discrepancy, however, as a surprising feature of Banerjee's results is the relatively poor
recovery of his control group after such a short ischaemic episode. The final recovery of
developed pressure after 40 minutes of reperfusion in his control group was 57.4 ± 2.4 %
(mean ± s.e.m) of baseline pre-ischaemic function. In the experiments reported here, the
recovery of developed pressure in the control group was not different from that result
(62 ± 9 % mean± s.e.m) despite a longer (30 min) ischaemic insult, and a shorter reperfusion
period (30 min).
Other investigators were also unable to demonstrate such a magnitude of
post-ischaemic contractile dysfunction after only twenty minutes of global ischaemia
(Asimakis et al., 1994, Weselcouch et al., 1995). It has been demonstrated that enhanced rates
of glucose uptake and glycolysis during reperfusion, improve the post-ischaemic contractile
function of the isolated rat heart (Mochizuki and Neely, 1980; Fralix et al., 1992). Banerjee
used a lower perfusate glucose concentration (5.5 mM) compared to the glucose concentration
reported here, and by Asimakis and Weselcouch in their experiments (11 mM). Thus, a
proportion of the depression of post-ischaemic contractile function in Banerjee's experiments
may have been ascribed to a limitation of the rate of glucose uptake. Noradrenaline enhances
glucose uptake in the rat heart (Clark and Patten, 1984). If this effect had persisted, the
improvement that Baneijee observed with noradrenaline infusion, may have been due to
improved glucose uptake during reperfusion. Furthermore, Banerjee's hearts were paced
during the post-ischaemic reperfusion period. The pacing may have unmasked an effect by
forcing the hearts to contract during their recovery period and causing greater metabolic
demands. Under these circumstances, any intervention to improve the rate of glucose uptake
would have had been expected to result in an even more marked improvement in contractile
function. It would be interesting to repeat Banerjee's experimental protocol comparing the
effect of the two different concentrations of glucose on the contractile recovery and tissue
glycogen level during post-ischaemic reperfusion.
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In these experiments, monitoring of the recovery of contractile function was
complicated by a high incidence of arrhythmias during the first twenty minutes of
post-ischaemic reperfusion in all three groups (not shown). Heart rate, left ventricular pressure
and dP/dt were difficult to assess in these circumstances, as a period of at least one minute of
sinus rhythm was required to ensure that the contractile function was stable. Post-ischaemic
contractile recovery was assessed after 30 minutes of reperfusion. Preparations which still had
sustained serious ventricular arrhythmias at this time were excluded from the analysis of
contractile recovery. A total of four preparations were excluded in this manner (two from
control and one each from the other groups). It could be said that any hearts which did not
regain sinus rhythm within 30 minutes of reperfusion recovered less well and that excluding
them does not allow for this to be taken into account. In the event that they were included in
the analysis, however, they would have been scored as having zero percent recovery, which
also biases the data. Pre-ischaemic ganglion stimulation or noradrenaline infusion did not have
a significant effect on post-ischaemic contractile recovery if the arrhythmogenic preparations
in question were included in the analysis. Baneijee did not report having had problems with
arrhythmias, although hearts were defibrillated when necessary. It is not possible to say if this
could have been a contributing factor to the difference in the two sets of results. The use of a
slightly higher potassium concentration by them (4.7 mM) may have reduced the incidence of
arrhythmias and made monitoring of the contractile recovery somewhat easier.
Although Asimakis also reported that a five minute pre-ischaemic noradrenaline
infusion (1.5 nmol min"1) could protect the isolated rat heart against post-ischaemic contractile
dysfunction, these results were confounded by haemodynamic factors that may have been
responsible for the so-called ischaemic preconditioning (Asimakis et al., 1994). A rebound
decrease in haemodynamic function, immediately after the noradrenaline infusion, persisted
throughout the 5 minute washout period until the start of the 30 minute global ischaemia. At
the onset of ischaemia therefore, these hearts had reduced energy requirements which may
have led to a less severe metabolic acidosis. In the experiments reported here, a 10 minute
post-stimulus washout period was used and the haemodynamic function of the heart at the
onset of ischaemia was fully restored to baseline.
Since these experiments were completed, two other groups have reported being unable
to effect an improvement in post-ischaemic contractile function in the isolated rat heart with
exogenous noradrenaline (Weselcouch et al., 1995), or phenylephrine infusion (Moolman
et al., 1996. In the former study, denervation with either 6-hydroxydopamine or reserpine, did
not affect the improvement in post-ischaemic contractile recovery observed with ischaemic
preconditioning. This led them to conclude that endogenous catecholamine release was not
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involved in the adaptive response to ischaemic preconditioning in the isolated rat heart.
Moolman and colleagues reported that in their experiments, phenylephrine infused at several
concentrations in a repeated fashion during the pre-ischaemic period, was without effect on the
contractile recovery following 25 minutes of global ischaemia and 30 minutes reperfusion in
the isolated rat heart. They also observed that oil-adrenoceptor antagonisism was unable to
abolish the effect of ischaemic preconditioning on post-ischaemic contractile recovery.
One interesting observation from these experiments was that pre-ischaemic
noradrenaline infusion caused significantly improved coronary flow in the early stages of
reperfusion. This was presumably as a result of an effect on endothelial function, but of
relatively short duration (less than 25 min). Improved perfusion may have been expected to
lead to an overall improvement in contractile function. It is possible that the mechanisms
behind the preconditioning phenomena of improved post-ischaemic contractile recovery,
reduced infarct size and reduced incidence of arrhythmias are not the same. In this case, it
cannot be discounted that an improved reperfusion reflow would have caused a reduced infarct
size under appropriate conditions. The initial rate of coronary reflow after 30 minutes of
global ischaemia is, however, not important in determining the degree of post-ischaemic
contractile recovery.
Post-ischaemic washout of noradrenaline has been related to the duration of global
ischaemia (SchOmig, 1988), and could relate to ischaemic severity. Catecholamines are
associated with increased incidence of arrhythmias (Thandroyen 1983, Penny 1985), tissue
damage and poor outcome after ischaemia (Nayler 1985). Before the experiment was carried
out, it was hypothesised that if there was an effect of either noradrenaline infusion or ganglion
stimulation to improve post-ischaemic function, then it might be related to a reduction in
post-ischaemic noradrenaline overflow, resulting from a depletion of endogenous noradrenaline
stores before the onset of ischaemia. In the experiments reported here, neither of the
interventions caused an improvement in post-ischaemic contractile function. Interestingly,
however, it has recently been shown that preconditioning with transient ischaemia reduces
post-ischaemic noradrenaline overflow (Seyfarth et al., 1996), suggesting that post-ischaemic
noradrenaline overflow may, indeed, be another useful marker of preconditioning.
One observation from these experiments is that although post-ischaemic noradrenaline
overflow was not significantly different between the groups, the variance was much greater in
the noradrenaline infusion and ganglion stimulation groups compared to control. This
suggested heterogeneity within the groups that received a preconditioning stimulus. As a result
of this heterogeneity, the noradrenaline extraction and analysis procedure was checked. The
recovery of the internal standard was not different in those samples where a low or a high
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concentration of noradrenaline was present. The post-ischaemic acidosis may have selectively
reduced the adsorption of noradrenaline to the alumina. Although the sample pH was not
checked, there was nothing to suggest a relationship between high post-ischaemic lactate
overflow (as a marker of acidosis) and low noradrenaline overflow. Furthermore, lactate
overflow in the treated groups was not different to the control group, even during the first 5
minutes of reperfusion (not shown). The reason for the increased heterogeneity of
noradrenaline overflow in the ganglion stimulated and noradrenaline infusion groups in these
experiments was not able to be deduced.
In summary, endogenous noradrenaline release during a 5 minute sympathetic
ganglion stimulation did not protect the innervated, perfused rat heart against
ischaemia-induced contractile dysfunction following 30 minutes of global ischaemia and
reperfusion. Nor did exogenous noradrenaline infusion afford protection against the effects of
subsequent global ischaemia. Recent publications support the conclusion of this study that
adrenergic mechanisms are not involved in the protection afforded by ischaemic
preconditioning in the rat heart. The mechanisms involved in the mediation of the ischaemic
preconditioning response in the rat heart remain to be elucidated.
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CHAPTER 6
General discussion
In recent years, the development of baroreflex sensitivity and heart rate variability testing as
reliable, non-invasive techniques, has made the study of cardiac autonomic function in vivo
that much easier. As a result, the influence of autonomic activity on arrhythmogenesis and the
outcome of acute myocardial ischaemia has been brought more sharply into focus. A huge
amount is known about the cardiac sympathetic neuroeffector junction and its release of
neurotransmitters. Although the results reported here indicate that some of these experiments
may have been carried out under less than ideal conditions, the ability to measure
noradrenaline overflow in the coronary effluent of isolated hearts has been invaluable in
determining the presynaptic mechanisms which control that release. It has also permitted a
greater insight into the effect of ischaemia on those presynaptic mechanisms. There is
consensus among investigators that endogenous noradrenaline release occurs during acute
myocardial ischaemia. That the presence of catecholamines is deleterious to the ischaemic
myocardium, increasing the vulnerability to arrhythmias and promoting tissue damage, is also
not in dispute.
Two different mechanisms of noradrenaline release in the ischaemic myocardium of
the isolated heart have been identified- an early, reflex-mediated exocytotic release, which is
followed by a greater, non-exocytotic release after a longer period of ischaemia. Although the
reflex-evoked noradrenaline release fails after a relatively short period (1-3 minutes) of stop-
flow ischaemia in the isolated rat heart, this may not accurately reflect the situation in other
animal species, or in humans in vivo, where the reduction of myocardial blood flow within the
ischaemic territory is not absolute, owing to the presence of collaterals. During global low
flow ischaemia (95 % flow reduction) in the isolated buffer perfused rat heart, the mechanism
of exocytotic noradrenaline release may be maintained for long periods (Du, 1991). The
physiological significance of the non-exocytotic release has been questioned as it only occurs
with long periods of zero-flow ischaemia in isolated preparations. Thus, it is the reflex-evoked
noradrenaline release which is believed to increase the vulnerability to arrhythmias during the
early stages of acute ischaemia - the most dangerous, in terms of arrhythmogenesis and
mortality. It is apparent from studies of baroreflex sensitivity in the dog in vivo preparation,
that the presence of superior parasympathetic reflexes can protect against these early phase
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arrhythmias during acute ischaemia (Schwartz et al., 1988a). Numerous other studies, both
in vivo and in isolated heart preparations, support the view that parasympathetic nerve activity
is antiarrhythmic. Parasympathetic nerve function in the acutely ischaemic state is therefore of
great interest and importance. It is striking that there are very few publications in the literature
where cardiac acetylcholine overflow has been measured. In view of the difficulties which
seem to be associated with measuring such acetylcholine overflows in the mammalian heart,
perhaps this is not so surprising.
Negative findings are reported less frequently and may be more difficult to get
published than positive ones. It is possible that many other investigators have carried out
experiments to measure acetylcholine overflow from the mammalian heart but that their results
have not appeared in the literature. There appears to be only one published report where
HPLC with electrochemical detection was used to measure cardiac acetylcholine overflow -
also, it must be noted, without success. This emphasises the need for negative findings to be
reported. In many ways they may be equally as important as positive ones.
The experiments reported here, highlight the importance of measuring transmitter
overflow as an endpoint, even though the techniques involved may be difficult and
time-consuming to perform. Haemodynamic effects may not be sufficiently sensitive endpoints
on their own to reflect nerve activity and transmitter release. There is a great requirement for
someone to develop a method for measuring acetylcholine overflow from the perfused
mammaliam heart. Only then will it be possible to really understand the interaction of the
parasympathetic and sympathetic branches of the autonomic nervous system during ischaemia.
It has been reported that the vagally-mediated reduction in sympathetic stimulation-
evoked noradrenaline overflow is abolished very early in an ischaemic episode (Du, 1991).
Does this reflect a reduction in acetylcholine release? Alternatively, might ischaemia induce
changes in the muscarinic receptor binding or coupling characteristics at the presynaptic
sympathetic nerve terminal? The reduction of noradrenaline overflow produced by
methacholine infusion was also diminished after 10 minutes of low flow ischaemia in that
study, suggesting that the latter mechanism might indeed be responsible. The results, however,
were inconclusive as the rates of attenuation of the response to vagus stimulation and
methacholine infusion were different. The ability to measure stimulation-evoked acetylcholine
overflow would help to elucidate the mechanisms opperating under these circumstances.
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Other issues which would be of equal interest would be: whether parasympathetic and
sympathetic nerve terminals have different sensitivities for the factors associated with
ischaemia, such as lowered pH, adenosine release, tissue potassium efflux etc. Do pre- or
postsynaptic mechanisms fail first? Without the ability to measure acetylcholine overflow, the
answer to these questions pertaining to presynaptic effects will remain unanswered.
The HPLC assay for acetylcholine described here would provide a good starting point
for anyone who was interested in developing a method. Once set up, it is inexpensive to run,
sensitive and the samples are processed very quickly. What is required, however, is a method
of concentrating acetylcholine in the samples without concentrating substances such as salts,
which interfere with the electrochemical detection. The attempts to concentrate acetylcholine in
the samples by evaporation or solvent extraction mentioned previously, were rendered
unsuccessful as a result of interference of this nature. It is possible that solid phase extraction
might provide a solution, although here again there are likely to be methodological difficulties.
One of the main restrictions to developing an extraction method for this assay is that organic
solvents cannot be introduced into the HPLC system because they poison the enzymatic
reactor column. This obviously limits the choice of solvents available for solid phase
extraction procedures. Additionally, the extracted samples must be free of electrochemically
active compounds which might interfere with the detection of acetylcholine. Unfortunately,
limitations of time prevented the development of such a method for this thesis.
Of course, it cannot be ruled out from these experiments that acetylcholine released in
response to vagus stimulation in the rat heart is hydrolysed by acetylcholinesterase before it
can wash out of the heart. The results of the experiment in which acetylcholinesterase
inhibitors were used in homogenates during the measurement of acetylcholinesterase activity,
support the conclusion that the concentration of inhibitor used was sufficient to prevent the
significant hydrolysis of acetylcholine. This conclusion, however, is dependent upon the
assumption that when the inhibitor was infused at that concentration into an isolated heart, it
would have the same efficacy to inhibit acetylcholinesterase activity as in the homogenate,
where it presumably has greater access to the membrane bound enzyme. Although the inhibitor
did appear to prevent the significant hydrolysis of infused acetylcholine, this was a high
concentration of acetylcholine, and it cannot be discounted that small amounts of acetylcholine
would have been completely hydrolysed. In most biological systems it is realistically very
difficult to ensure that an inhibitor will block 100 % of enzyme activity, particularly when the
inhibition is reversible, as in this case. The use of an irreversible inhibitor such as
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physostigmine was not possible as it would have rendered the enzymatic reactor column
useless.
It is possible that the combination of a relatively small release of acetylcholine in
response to nerve activity in the mammalian heart, and an efficient clearance mechanism will
be a very hard one to overcome. It appears that evolution has been rigorous in ensuring that a
compound such as acetylcholine which is very capable of inducing cardiac arrest is never
present in excess. Another option would be to switch to a different model, such as the perfused
chicken heart, in which acetylcholine overflow has been demonstrated to be larger, and
therefore more easily measurable. The main drawback to this approach is that the physiology
of the cardiac autonomic nervous system differs from that present in mammalian species.
Mammalian hearts only contain the m2-muscarinic subtype of acetylcholine receptors. There
are now several reports in the literature, however, of the presence of more than one subtype of
muscarinic receptor in the chick heart (Tietje et al., 1991; Gadbut and Galper, 1994). In
addition, the very thing that may make the model attractive as an alternative to the rat heart, ie.
the comparatively large amount of acetylcholine overflow achieved with vagus nerve
stimulation, raises questions about how this may affect the interaction of the parasympathetic
and sympathetic branches of the autonomic nervous system. Thus, information obtained from
the chicken heart may not be readily applicable to the mammalian, and most particularly the
human, heart where it is potentially of greatest interest clinically.
The experiments reported in this thesis were performed in buffer-perfused hearts. The
importance of a high coronary flow rate in maintaining nerve function was highlighted. This
was presumably because the oxygen supply was not adequate. Although buffer perfused heart
preparations have been invaluable in the study of all aspects of heart function, there are
obvious drawbacks involved with their use. These concern the unphysiological nature of some
aspects of the model, in particular, the high oxygen tension, of around 600 mm Hg, which is
required to provide an adequate oxygen supply. Even at high flow rates, which themselves are
unphysiological, buffer-perfused hearts exhibit reduced contractile function compared to
blood-perfused preparations (Masuda et al., 1986). The high flow rates facilitate the wash out
metabolites and transmitters much faster than would naturally occur. This may have
implications for presynaptic control mechanisms, as substances such as noradrenaline,
acetylcholine, adenosine, and NPY have to diffuse over relatively large distances to exert their
presynaptic effects. Particularly where trans-synaptic modulation is involved, increased flow
rates could result in a markedly reduced modulatory effect. High flow rates are also liable to
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cause large sheer stresses on the endothelial walls. It is possible that this may have effects on
the production of substances such as nitric oxide, endothelin and prostaglandins some of which
may also exert presynaptic effects on autonomic neurotransmission. Finally, buffer-perfused
hearts have to generate most of their high energy phosphates from aerobic glycolysis, unlike
the situation prevailing in vivo, where oxidative phosphorylation of free fatty acids makes by
far the biggest contribution to the energy requirements. One of the consequences of this is that
the NADH plus H+ / NAD+ ratio is reduced when glucose instead of fatty acid is the
predominant substrate. If the heart becomes ischaemic, then it will take longer for such an
heart to reach a level of acidosis at which the glycolytic pathway is inhibited through inhibition
of the pH-sensitive enzyme glyceraldehyde-3-phosphate-dehydrogenase.
Some of the above problems are eliminated if a blood-perfused model is used. Oxygen
delivery is improved and so high flow rates are not necessary. In addition, contractile function
is enhanced compared to the buffer-perfused model (Masuda et al„ 1986). There are at least
two methods of carrying out blood perfusions. Although both have advantages over the buffer-
perfused model, they also have certain technical difficulties and disadvantages associated with
their use. In perhaps the most commonly used method, a genetically similar animal may be
used as a recirculating oxygenator or 'support' animal. As the support animal is anaesthetised,
endogenous substances or anaesthetic may have effects in the recipient. For example, blood
pressure fluctuations in the support animal may lead to reflex adrenaline release which can
affect the recipient heart. Another drawback is that the amount of blood is limited and so large
samples cannot be taken. If this model were used for nerve stimulation experiments,
measurement of transmitter overflow would be complicated by the reduced sample volumes.
Even then, a plasma expander needs to be given to avoid the support animal becoming
hypovolemic. Another method is to use washed red blood cells, often bovine in origin,
suspended in a physiological salt solution. With this method, larger volumes can be prepared,
avoiding the necessity of using a recirculating system. Oxygenation is carried out through the
use of a membrane or filament oxygenator. Problems can occur with haemolysis, which allows
free haemoglobin to infiltrate the endothelial lining of the blood vessel walls. Free haemoglobin
acts as a sponge to mop up nitric oxide, resulting in a profound vasoconstriction. Complement
activation can also be a problem in this model, and the failure rate of experimental
preparations can be very high. When the method was tested in this laboratory, as many as
50 % of all the preparations failed, despite very careful preparation of the blood cells
(R. Riemersma, personal communication).
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One approach which might be expected to avoid some of the difficulties associated
with the use of the above-mentioned methods is to use an artificial blood solution. These
solutions are being developed as an alternative to whole blood for blood transfusions as they
have a longer shelf-life, need less exacting storage conditions and do not have the same disease
risks as whole blood. During the course of this project, a prototype artificial blood solution
became available to us from the Scottish Blood Transfusion Service. The solution was a
glycoaldehyde cross-linked human haemoglobin solution formed by combining molecules of
free haemoglobin. This process resulted in the production of an oxygen-dissociation curve
which, with a p50 value of around 25-30 mm Hg, was very similar to that of red blood cells
(MacDonald and Middleton, 1992). The preparation had already been used successfully to
perfuse isolated liver preparations. When it was infused into the rat heart preparation in
solution with Krebs-Henseleit buffer, the heart progressively stopped beating over the course
of approximately 2 to 3 minutes and the coronary perfusion pressure became elevated to over
250 mm Hg, indicating that a profound vasoconstriction had occurred. If normal oxygenated
Krebs buffer was then perfused, they recovered completely, The vasoconstriction probably
resulted from the effect of free heamoglobin to bind nitric oxide (Marcus and Broekman,
1996). Perhaps in the future, if these molecules could be incorporated into liposomes, this
undesirable side-effect might be avoided. In addition, despite the fact that the solution was
fully oxygenated before entering the heart, it appeared that the heart could not extract
sufficient oxygen to maintain its haemodynamic function, although whether this was as a
consequence of severe vasoconstriction preventing nutritive flow was not determined. This
effect was not likely to have been so apparent in other isolated organ preparations as they do
not have such a large metabolic requirement for oxygen as the heart. It would thus appear that
glycoaldehyde cross-linked haemoglobin was not a suitable alternative to either buffer, whole
blood or suspensions of washed red blood cells in the perfusion of isolated heart models.
A second type of artificial blood solution - perfluorocarbons - may be of potentially
more use in this field. Indeed, they have already been successfully used to perfuse isolated
heart preparations (Freeman et al., 1987). Unfortunately, their cost may well prohibit their use
for experiments of this kind. The in situ, innervated buffer-perfused rat heart model was
initially developed as an alternative to in vivo nerve stimulation experiments in larger animals
such as dogs. Not only was the rat heart preparation substantially cheaper, but it also avoided
the complication of anaesthetic effects on the nerves. With the improvement in techniques to
quantify noradrenaline release, however, it may be preferable for future experiments to utilise
flow rates of 10 ml g'1 min'1 instead of the more 'traditional' 5 ml g"1 min"1 . The presence of
pyruvate in the perfusate during some of the earlier experiments may have ameliorated the
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effect of the low flow rates by stimulating aerobic glycolysis and removing hydrogen ions in
the process (Liedke et al., 1976).
Interestingly, the importance of the choice of experimental model is also highlighted in
the study of the influence of noradrenaline on post-ischaemic contractile recovery. It appears
that one of the principle reasons why the results reported here may differ from those of
Baneijee et al., is that different glucose concentrations were used in the two studies. It is
possible that Baneijee observed an effect of pre-ischaemic noradrenaline infusion to improve
post-ischaemic contractile function because the glucose concentration used in that study was
below the optimum level. When noradrenaline was infused, an increase in glucose uptake may
have occurred. Pacing of the hearts during the post-ischaemic reperfusion period may have
unmasked an effect of improved glycolytic flux in these hearts compared to control. Unlike
Banerjee, the results reported here do not support a role for pre-ischaemic noradrenaline in
improving the post-ischaemic contractile recovery in the rat heart. This result, and others
published since these experiments were completed, would indicate that it is unlikely that
noradrenaline is involved in the mechanism of ischaemic preconditioning in the rat heart. Even
if the noradrenaline infusions carried out in the published studies had resulted in a reliable
improvement in post-ischaemic contractile function, it would have been difficult to relate the
result to the situation in vivo, owing to the unphysiologically high concentrations of
noradrenaline which were infused (up to 10 nmol g"1 min"1). This amount of noradrenaline
would never be released endogenously from the rat heart. Indeed, during the first ten minutes
of acute myocardial ischaemia it is very difficult to demonstrate an enhanced release of
endogenous noradrenaline at all, despite evidence that sympathetic reflexes are activated.
Infusions of such unphysiologically high concentrations of agonist into any system is liable to
result in an increased chance of non-specific effects such as the non-specific binding of agonist
to other receptors. Even if the non-specific binding does not result in activation of that
receptor, it may still act as a competitive antagonist.
In contrast to the situation in the rat, it appears that pre-ischaemic noradrenaline or
tyramine infusion may protect the rabbit heart against infarction. A reduction of infarct size
was observed in the rabbit in vivo model when a five minute infusion of either tyramine
(Thornton et al., 1993; Bankwala et al., 1994) or noradrenaline (Bankwala et al., 1994) was
carried out ten minutes before a 30 minute coronary occlusion. The noradrenaline was shown
to act via ai-adrenoceptors, as a-adrenergic blockade abolished the effect in both studies. A
non-specific adenosine antagonist also abolished the effect in Thornton's study it is thus
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possible that noradrenaline was actually acting on a-adreneigic receptors to cause an increase
in myocardial adenosine release (although adenosine levels were not measured). In addition,
there may have been a cooperative effect of the tyramine infusion to raise adenosine levels in
the synaptic cleft by causing the co-release of purines with the endogenous noradrenaline from
the presynaptic vesicles. Adenosine has been repeatedly demonstrated to be involved in the
mechanism of ischaemic preconditioning in the rabbit heart (Liu et al., 1991 and 1996;
Tsuchida et al., 1994; Armstrong and Ganote, 1994). Further evidence that noradrenaline
release was not solely responsible for the preconditioning effect was provided when
a-adrenergic blockade failed to abolish preconditioning with transient ischaemia, (Thornton
et al., 1993). This inability of adrenergic receptor antagonists to prevent the infarct-limiting
effect of ischaemic preconditioning has also been reported by other investigators working with
this model (Haessler et al., 1996).
It was always extremely unlikely that endogenous noradrenaline release would turn
out to be of primary importance in mediating the ischaemic preconditioning response in any
animal model, as the phenomenon of ischaemic preconditioning is clearly demonstrable in
isolated hearts. A single episode of 5 minutes of ischaemia, which is sufficient to cause
preconditioning, is insufficient to cause substantial noradrenaline overflow in the isolated
heart. The duration of global ischaemia would have to be at least 10 to 15 minutes before
significant noradrenaline release would occur (Schdmig, 1988). It is, however, possible that
the situation opperating in vivo with reflex sympathetic activation occurring within the first
few minutes of ischaemia, may contribute to the mechanism of preconditioning by facilitating
the accumulation of purines in the synaptic cleft. The purines which are co-released from
presynaptic vesicles with noradrenaline are degraded by ecto-ATPase to form adenosine. In
addition, endogenous noradrenaline acting via the ocr adrenoceptor stimulates haemodynamic
function, resulting in the increased use of ATP. Some of the resulting ADP will be degraded to
adenosine and will diffuse out of the muscle. Thus, in species such as the rabbit, dog, human
and pig, in which adenosine is clearly involved in the mechanism of ischaemic preconditioning,
reflex-evoked noradrenaline release could play a facilitatory role in the in vivo situation by
increasing the ischaemia-evoked adenosine accumulation. It would be interesting to look at the
effect of acute and chronic cardiac denervation on adenosine release during transient ischaemia
in an in vivo model
At the time of writing, the mechanism(s) responsible for producing the beneficial
effects of ischaemic preconditioning remain unresolved. It appears, however, that the situation
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in the rat heart differs from that of other species such as the dog, pig, rabbit and human, where
the involvement of adenosine at some level is not disputed. It may turn out that no single
pathway is responsible for the effect, but that multiple pathways are involved and act in a
cooperative fashion.
Finally, in relation to the objectives of the study (Introduction, p27), although
stimulation of the perfused innervated rat heart had the expected negative chronotropic and
inotropic effects, acetylcholine overflow in the coronary effluent was not detected when a
novel HPLC method was used to quantify the neurotransmitter. The apparent absence of
acetylcholine in the coronary effluent could not be attributed to biodegradation of the
acetylcholine by myocardial acetylcholinesterase activity. Bioassay of acetylcholine using the
leech dorsal muscle preparation confirmed the lack of detectable acetylcholine in the coronary
effluent samples following vagus stimulation. As a consequence, it was not possible to
determine either the extent to which the severity and duration of global ischaemia affect the
vagally mediated overflow of acetylcholine or the relative importance of the various
concomitants of ischaemia on this overflow. Likewise, it was not possible to investigate the
effect of the severity and duration of global ischaemia on the presynaptic interaction of the
parasympathetic and sympathetic nervous system with respect to the overflow of acetylcholine
and noradrenaline. The importance of an adequate coronary flow rate in the maintenance of
stimulation-evoked noradrenaline overflow in buffer perfused rat hearts was highlighted. A
five minute sympathetic ganglion stimulation or infusion of noradrenaline increased heart rate
and contractility. All parameters returned to baseline within ten minutes. These adrenergic
stimuli to the normoxic heart did not result in improved haemodynamic recovery following a
subsequent thirty minute period of global, stop-flow ischaemia. Other markers of ischaemia -
induced damage such as noradrenaline release on reperfusion or myocardial creatine kinase
content, were also unaffected by these interventions.
General discussion 95
References
Abrahamsson T, Almgren O, Carlsson L. Wash-out of noradrenaline and its metabolites by
calcium-free reperfusion after ischaemia: Support for the concept of ischaemia-induced
noradrenaline release. British Journal ofPharmacology (1984);81:22-24.
Abrahamsson T, Almgren O, Carlsson L. Ischemia-induced noradrenaline release in the
isolated rat heart: Influence of perfusion substrate and duration of ischemia. Journal of
Molecular and Cellular Cardiology (1983); 15:821-830.
Adamson P, Huang M, Vanoli E, Foreman R, Schwartz P, Hull S. Unexpected interaction
between beta-adrenergic blockade and heart rate variability before and after myocardial
infarction: A longitudinal study in dogs at high and low risk for sudden death. Circulation
(1994);90:976-982.
Adler-Graschinsky E, Langer SZ. Possible role of a Beta-adrenoceptor in the regulation of
noradrenaline release by nerve stimulation through a positive feedback mechanism. British
Journal ofPharmacology (1975);53:43-50.
Armstrong A, Duncan B, Oliver M, Julian D, Donald K, Fulton M, Lutz W, Morrison S.
Natural history of acute coronary heart attacks: A community study. British Heart Journal
(1972);34:67-80.
Armstrong S, Downey J, Ganote C. Preconditioning of isolated rabbit cardiomyocytes:
induction by metabolic stress and blockade by the adenosine antagonist SPT and calphostin C,
a protein kinase C inhibitor. Cardiovascular Research (1994);28:72-77.
Asimakis G, Inners McBride K, Conti V. Attenuation of postischaemic dysfunction by
ischaemic preconditioning is not mediated by adenosine in the isolated rat heart.
Cardiovascular Research (1993);27:1522-1530.
Baneijee A, LockeWinter C, Rogers KB, Mitchell MB, Brew EC, Cairns CB, Bensard DD,
Harken AH. Preconditioning againstmyocardial dysfunction after ischemia and reperfusion by
an alphal-adrenergic mechanism. Circulation Research (1993);73:656-670.
Bankwala Z, Hale SL, Kloner RA. alpha-Adrenoceptor stimulation with exogenous
norepinephrine or release of endogenous catecholamines mimics ischemic preconditioning.
Circulation (1994);90:1023-1028.
Barbe P, Millet L, Galitzky J, Lafontan M, Berlan M. Situ assessment of the role of the
betal-, beta2- and beta3-adrenoceptors in the control of lipolysis and nutritive blood flow in
human subcutaneous adipose tissue. British Journal ofPharmacology (1996); 117:907-913.
Barber M, Mueller T, Davies B, Gill R, Zipes D. Interruption of sympathetic and
vagal-mediated afferent responses by transmural myocardial infarction. Circulation
(1985);72:623-631.
Barron H, Lesh M. Autonomic nervous system and sudden cardiac death. Journal of the
American College ofCardiology (1996);27:1053-1060.
References 97
Baumgarten C, Fozzard H. The resting and pacemaker potentials. In: Fozzard H, et al, eds.
The Heart and Cardiovascular System. Raven Press: New York, 1986:601-626.
Beavo J, Hardmann J, Sutherland E. Stimulation of adenosine -3',5'-monophosphate hydrolysis
by guanosine-3',5'-monophosphate. Journal ofBiological Chemistry (1971);246:3841-3846.
Bennett S. Socioeconomic inequalities in coronary heart disease and stroke mortality among
Australian men, 1979-1993. International Journal ofEpidemiology (1996);25:266-275.
Berger R, Akselrod S, Gordon D, Cohen R. An efficient algorithm for spectral analysis of
heart rate variability. IEEE Trans Biomedical Engineering (1986);33:900-904.
Billman G. Effect of the cholinergic against carbachol and cyclic guanosine monophosphate on
sudden cardiac death: protection from ventricular fibrillation. Journal of the American
College ofCardiology (1989); 13:91A (Abstract).
Blair R, Shimizu T, Bishop V. The role of vagal afferents in the reflex control of the left
ventricular refractory period in the cat. Circulation Research (1980);46:378-386.
Bligh J. The level of free choline in plasma. Journal ofPhysiology (1952); 117:234-240.
Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic
acetylcholine receptor genes. Science (1987);237:527-532.
Boyett MR, Kodama I, Honjo H, Arai A, Suzuki R, Toyama J. Ionic basis of the chronotropic
effect of acetylcholine on the rabbit sinoatrial node. Cardiovascular Research (1995);29:
867-878.
Breitwieser GE, Szabo G. Uncoupling of cardiac muscarinic and beta-adrenergic receptors
from ion channels by a guanine nucleotide analogue. Nature (1985);317:538-540.
Brown AM, Birnbaumer L. Direct G protein gating of ion channels. American Journal of
Physiology - Heart and Circulatory Physiology (1988);254:H401-H410.
Brown O. Cat heart acetylcholine: structural proof and distribution. American Journal of
Physiology (1976);231:781-785.
Brown SL, Brown JH. Muscarinic stimulation of phosphatidylinositol metabolism in atria.
Molecular Pharmacology (1983);24:351-356.
Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP,
MolinoffPB, Ruffolo RR, Trendelenburg U. IV. International union of pharmacology
nomenclature of adrenoceptors. Pharmacological Reviews (1994);46:121-136.
Cannon W. A law of denervation. American Journal ofMedicine (1939); 198:737-750.
References 98
Carlsson L. Mechanisms of local noradrenaline release in acute myocardial ischemia. Acta
Physiologica Scandinavica (1987); 129:S559;85.
Cave A. Preconditioning induced protection against post-ischaemic contractile dysfunction:
characteristics and mechanisms. Journal of Molecular and Cellular Cardiology (1995);27:
969-979.
Charest R, Blackmore PF, Berthon B, Exton JH. Changes in free cytosolic Ca2+ in
hepatocytes following alpha1-adrenergic stimulation. Studies on Quin-2-loaded hepatocytes.
Journal ofBiological Chemistry (1983);258:8769-8773.
Claeys M, Vrints C, Bosmans J, Conraads V, Snoeck J. Aminophylline inhibits adaptation to
ischaemia during angioplasty. Role of adenosine in ischaemic preconditioning. European
Heart Journal (1996); 17:539-544.
Clark MG, Patten GS. Adrenergic regulation of glucose metabolism in rat heart. A calcium-
dependent mechanism mediated by both alpha- and beta-adrenergic receptors. Journal of
Biological Chemistry (1984);259:15204-15211.
Clifton PM, Chang L, Mackinnon AM. Development of an automated Lowry protein assay for
the Cobas-Bio centrifugal analyzer. Analytical Biochemistry (1988); 172:165-168.
Cockroft S. Polyphosphoinositide phosphodiesterase: Regulation by a novel guanine nucleotide
binding protein, G(p). Trends in Biochemical Sciences (1987); 12:75-78.
Cohen MV, Downey JM. Myocardial preconditioning promises to be a novel approach to the
treatment of ischemic heart disease. Annual Review ofMedicine (1996);21-29.
Cohen MV, Yang X, Downey J. Conscious rabbits become tolerant to multiple episodes of
ischaemic preconditioning. Circulation Research (1994);74:998-1004.
Corr P, Yamada K, Witkowski F. Mechanisms controlling cardiac autonomic function and
their relation to arrhythmogesis. In: Fozzard H, et al, eds. The Heart and Cardiovascular
System. Raven Press: New York, 1986:1343-1403.
Corradetti R, Lindmar R, Loffelholz K. Physostigmine facilitates choline efflux from isolated
heart and cortex in vivo. European Journal ofPharmacology (1982);85:123-124.
Cramb G, Banks R, Rugg EL, Aiton JF. Actions of atrial natriuretic peptide (ANP) on cyclic
nucleotide concentrations and phosphatidylinositol turnover in ventricular myocytes.
Biochemical and Biophysical Research Communications (1987); 148:962-970.
Da Prada M, Ziircher G. Simultaneous radioenzymatic determination of plasma and tissue
adrenaline, noradrenaline and dopamine within the femtomol range. Life Sciences
(1976); 19:1161-1174.
References 99
Dart AM, Du XJ. Unexpected drug effects on autonomic function during myocardial
ischaemia. Cardiovascular Research (1993);27:906-914.
Dart AM, Dietz R, Hieronymus K, Kiibler W, Mayer E, Schdmig A, Strasser R. Effects of
alpha- and beta-adrenoceptor blockade on the neurally evoked overflow of endogenous
noradrenaline from the rat isolated heart. British Journal of Pharmacology (1984a);81:
475-478.
Dart AM, Schtimig A, Dietz R, Mayer E, Kiibler W. Release of endogenous catecholamines in
the ischemic myocardium of the rat. Part B: Effect of sympathetic nerve stimulation.
Circulation Research (1984b);55:702-706.
Dart AM, Dietz R, Kiibler W, Schomig A, Strasser R. Effect of cocaine and desipramine on
the neurally evoked overflow of endogenous noradrenaline from the rat heart. British Journal
ofPharmacology (1983);79:71-74.
Das P, Bhattacharya S. Studies on the effect of physostigmine on experimental cardiac
arrhythmias in dogs. British Journal ofPharmacology (1972);44:397-403.
De Boer REP, Brouwer F, Zaagsma J. Noradrenaline-induced relaxation of rat oesophageal
muscularis mucosae: Mediation solely by innervated beta3-adrenoceptors. British Journal of
Pharmacology (1995);116:1945-1947.
De Ferrari GM, Salvati P, Grossoni M, Ukmar G, Vaga L, Patrono C, Schwartz PJ.
Pharmacologic modulation of the autonomic nervous system in the prevention of sudden
cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs
with a healed myocardial infarction. Journal of the American College of Cardiology
(1993);22:283-290.
De Ferrari GM, Vanoli E, StrambaBadiale M, Hull SS, Foreman RD, Schwartz PJ. Vagal
reflexes and survival during acute myocardial ischemia in conscious dogs with healed
myocardial infarction. American Journal ofPhysiology - Heart and Circulatory Physiology
(1991);261:H63-H69.
De Ferrari G. Vagal stimulation and sudden death in conscious dogs with a healed myocardial
infarction. Circulation (1987);76 (supplement IV):IV-107(Abstract).
Deighton NM, Motomura S, Borquez D, Zerkowski HR, Doetsch N, Brodde OE. Muscarinic
cholinoceptors in the human heart: Demonstration, subclassification, and distribution.
Naunyn-Schmiedeberg's Archives ofPharmacology (1990);341:14-21.
Delhaye M, De Smet JM, Taton G, De Neef P, Camus JC, Fontaine J, Waelbroek M,
Robberecht P, Christophe J. A comparison between muscarinic receptor occupancy, adenylate
cyclase inhibition, and inotropic response in human heart. Naunyn-Schmiedeberg's Archives
ofPharmacology (1984);325:170-175.
References 100
Dempsey P, Cooper T. Ventricular cholinergic receptor systems: interaction with adrenergic
systems. Journal ofPharmacology and Experimental Therapeutics (1969); 167:282-290.
Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann JC, Laskey WK. Adaptation
to ischaemia during percutaneous transluminal coronary angioplasty: clinical, haemodynamic,
and metabolic features. Circulation (1990);82:2044-2051.
Dieterich H, Lindmar R, Ldffelholz K. The role of choline in the release of acetylcholine in
isolated hearts. Naunyn-Schmiedeberg's Archives ofPharmacology (1978);301:207-215.
Dieterich H, Ldffelholz K, Pompetzki H. Acetylcholine overflow from isolated perfused hearts
of various species in the absence of cholinesterase inhibition. Naunyn-Schmiedeberg's
Archives ofPharmacology (1977);296:149-152.
Di Francesco D, Tromba C. Inhibition of the hyperpolarization-activated current i(f) induced
by acetylcholine in rabbit sino-atrial node myocytes. Journal of Physiology (1988);405:
477-491.
Du XJ, Dart AM. Mechanism of noradrenaline release in the anoxic heart of the rat.
Cardiovascular Research (1993);27:2011-2015.
Du XJ. Modulation of sympathetic neurotransmitter release in acute myocardial ischaemia.
Ph.D. Thesis, University ofEdinburgh. (1991).
Ducceschi V, Di Micco G, Sarubbi B, Russo B, Santangelo L, Iacono A. Ionic mechanisms of
ischemia-related ventricular arrhythmias. Clinical Cardiology (1996);19:325-331.
Ellman G, Courtney K, Andres V, Featherstone R. A new and rapid colorimetric determination
of acetylcholinesterase activity. Biochemical Pharmacology (1961);7:88-95.
Endoh M. Correlation of cyclic AMP and cyclic GMP levels with changes in contractile force
of dog ventricular myocardium during cholinergic antagonism of positive inotropic actions of
histamine, glucagon, theophylline and papaverine. Japanese Journal of Pharmacology
(1979);29:855-864.
Farnebo L, Hamberger B. Drug induced changes in the release of 3H noradrenaline from field-
stimulated rat iris. British Journal ofPharmacology (1971);43:97-106.
Farrell TG, Odemuyiwa O, Bashir Y, Cripps TR, Malik M, Ward DE, Camm AJ. Prognostic
value of baroreflex sensitivity testing after acute myocardial infarction. British Heart Journal
(1992);67:129-137.
Feldburg W, Gaddum J. The chemical transmitter at synapses in a sympathetic ganglion.
Journal ofPhysiology (1934);81:305-319.
References 101
Ferrari M, Vanoli E, Curcuruto P, Tommasini G, Schwartz P. Prevention of life-threateneing
arrhythmias by pharmacological stimulation of the muscarinic receptors with oxotremorine.
American Heart Journal (1992); 124:883
Fields J, Roeske W, Morkin E, Yamamura H. Cardiac muscarinic cholinegic receptors:
biochemical identification and characterisation. Journal of Biological Chemistry
(1978);253:3251-3258.
Forfar JC, Riemersma RA, Russell D, Oliver MF. Relationship of neurosympathetic
responsiveness to early ventricular arrhythmias in ischaemic myocardium. Cardiovascular
Research (1984); 18:427-437.
Forfar JC, Riemersma RA, Oliver MF. alpha-Adrenoceptor control of norepinephrine release
from acutely ischaemic myocardium: Effects of blood flow, arrhythmias, and regional
conduction delay. Journal ofCardiovascular Pharmacology (1983);5:752-759.
Fralix T, Steenbergen C, London R, Murphy E. Metabolic substrates can alter postischemic
recovery in preconditioned ischemic hearts. American Journal of Physiology
(1992);263:C17-C23.
Fredholm BB, Sollevi A. The release of adenosine and inosine from canine subcutaneous
adipose tissue by nerve stimulation and noradrenaline. Journal of Physiology
(1981);313:351-367.
Freeman D, Mayr H, Schmidt P. Advantages of perfluorochemical perfusion in the isolated
working rabbit heart preparation using 31P-NMR. Biochimica et Biophysica Acta -
Molecular Cell Research (1987);927:350-358.
Fuder H, Muscholl E, Wolf K. Cholinesterase activity and exposure time to acetylcholine as
factors influencing the muscarinic inhibition of (3H)-noradrenaline overflow from guinea-pig
isolated atria. British Journal ofPharmacology (1985);86:905-914.
Gadbut AP, Galper JB. A novel m3 muscarinic acetylcholine receptor is expressed in chick
atrium and ventricle. Journal ofBiological Chemistry (1994);269:25823-25829.
George W, Poison J, O'Toole A, Goldberg W. Elevation of 3',5'- cyclic phosphate in rat heart
after perfusion with acetylcholine. Proceedings of the National Academy of Science USA
(1970);66:398-403.
Gilmour R, Zipes D. Abnormal automaticity and related phenomena. In: Fozzard H, et al„
eds. The Heart and Cardiovascular System. Raven Press: New York, (1986):1239-1258.
Gilmour R, Heger J, Prystowsky E, Zipes D. Cellular Electrophysiological abnormalities of
diseased human ventricular myocardium. American Journal of Cardiology (1983);51:
137-144.
References 102
Ginsborg B, Jenkinson D. Transmission of impulses from nerve to muscle. In: Zaimis E, ed.
Handbook of Experimental Pharmacology: Neuromuscular Junction. Berlin: Springer,
(1976):229-364.
Glitsch H, Pott L. Effect of divalent cations on acetylcholine release from cardiac
parasympathetic nerve endings. Pfliigers Archiv European Journal of Physiology
(1978);377:57-63.
Goldstein D, Brush J, Eisenhofer G, Stull R, EslerM. In vivo measurement of neuronal uptake
of norepinephrine in the human heart. Circulation (1988);78:41-48.
Goldstein D. Plasma norepinephrine as an indicator of sympathetic neural activity in clinical
cardiology. American Journal ofCardiology (1981);48:1147-1154.
Gothert M, Nawroth P, Neumeyer H. Inhibitory effects of verapamil, prenylamine and D600
on calcium-dependent noradrenaline release from the sympathetic nerves of isolated rabbit
hearts. Naunyn-Schmiedeberg's Archives ofPharmacology (1979);310:11-19.
Goto M, Miura T, Itoya M, Sakamoto J, Limura O. Reduction of regional contractile function
by preconditioning ischaemia does not play a permissive role in the infarct size limitation by
preconditioning. Basic Research in Cardiology (1993);88:594-606.
Gross G, Auchampach J. Blockade of ATP-sensitive potassium channels prevents myocardial
preconditioning in dogs. Circulation Research (1992);70:223-233.
Graver G, Sleph P, Dzwonczyk S. Role of myocardial ATP-sensitive potassium channels in
mediating preconditioning in the dog heart and their possible interaction with adenosine A1
receptors. Circulation (1992);86:1310-1316.
Graver G, Dzwonczyk S, Parham C. The protective effects of chromakalim and pinacidil on
reperfusion function and infarct size in isolated perfused rat hearts and anaesthetised dogs.
Cardiovascular Drugs and Therapy (1990);4:465-474.
Haass M, Cheng B, Richardt G, Lang RE, Schdmig A. Characterization and presynaptic
modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropeptide Y in
guinea pig heart. Naunyn-Schmiedeberg's Archives ofPharmacology (1989);339:71-78.
Haddad GE, Sperelakis N, Bkaily G. Regulation of the calcium slow channel by cyclic GMP
dependent protein kinase in chick heart cells. Molecular and Cellular Biochemistry
(1995);148:89-94.
Haessler R, Kuzume K, Wolff RA, Chien GL, Davis RF, Van Winkle DM. Adrenergic
activation confers cardioprotection mediated by adenosine but is not required for ischemic
preconditioning. Coronary Artery Disease (1996);7:305-314.
References 103
Hall GT, Potter EK. Attenuation of vagal action following sympathetic stimulation is
modulated by prejunctional alpha2-adrenoceptors in the dog. Journal of the Autonomic
Nervous System (1990);30:129-137.
Han J, Moe G. Non uniform recovery of excitability in ventricular muscle. Circulation
Research (1964); 14:44-60.
Harrison L, Kent K, Epstein S. Enhancement of electrical stability of acutely ischaemic
myocardium by edrophenium. Circulation (1974);50:99-102.
Hartzell H, Fischmeister R. Opposite effects of cyclic GMP and cyclic AMP on calcium
current in single heart cells. Nature (1986);323:273-275.
Hawthorne JN, Simmonds SH. Second messengers involved in the muscarinic control of the
heart: The role of the phosphoinositide response. Molecular and Cellular Biochemistry
(1989);89:187-189.
Henry P, Demolombe S, Puceat M, Escande D. Adenosine A1 stimulation activates
delta-protein kinase C in rat ventricular myocytes.. Circulation Research (1996);78:161-165.
Herbaczynska-Cedro K, Galkowska B. Effect of magnesium on myocardial damage induced
by epinephrine. Ultrastructural and cytochemical study. Cardioscience (1992);3:197-203.
Herre J, Wetstein L, Lin Y, Mills A, Dae M, Thames M. Effect of transmural versus
nontransmural myocardial infarction on inducibility of ventricular arrhythmias during
sympathetic stimulation in dogs. Journal of the American College of Cardiology
(1988); 11:414-421.
Hescheler J, Kameyama M, Trautwein W. On the mechanism of muscarinic inhibition of the
cardiac Ca2+ current. Pfliigers Archiv European Journal ofPhysiology (1986);407:182-189.
Hoffman B, Suckling E. Cardiac cellular potentials: Effect of vagal stimulation and
acetylcholine. American Journal ofPhysiology (1953);173:312-320.
Hohnloser S, Verrier R, Lown B. Effects of adrenergic and muscarinic receptor stimulation on
serum potassium concentrations and myocardial electrical stability. Cardiovascular Research
(1986);20:891-896.
Holmgren S, Abrahamsson T, Almgren O, Eriksson BM. Effect of ischaemia on the
adrenergic neurons of the rat heart: A fluorescence histochemical and biochemical study.
Cardiovascular Research (1981);15:680-689.
Hoshida S, Kuzuya T, Nishida M, Yamashita N, Oe H, Hori M, Kamada T, Tada M.
Adenesine blockade during reperfusion reverses the infarct limiting effect in preconditioned
canine hearts. Cardiovascular Research (1994);28:1083-1088.
References 104
Howes LG, Miller S, Reid JL. Simultaneous assay of 3,4-dihydroxyphenylethylene glycol and
norepinephrine in human plasma by high-performance liquid chromatography with
electrochemical detection. Journal of Chromatography - Biomedical Applications
(1985);338:401-403.
Hull S, Evans A, Vanoli E, Adamson P, Stramba-Badiale M, Albert D, Foreman R,
Schwartz PJ. Heart rate variability before and after myocardial infarction in conscious dogs at
high and low risk of sudden death. Journal of the American College of Cardiology
(1990); 16:978-985.
Ikegaya T, Nishiyama T, Haga K, Ichiyama A, Kobayashi A, Yamazaki N. Interaction of
atrial muscarinic receptors with three kinds of GTP-binding proteins. Journal ofMolecular
and Cellular Cardiology (1990);22:343-351.
Imanishi S, Surawicz B. Automatic activity in depolarized guinea pig ventricular myocardium:
Characteristics and mechanisms. Circulation Research (1976);39:751-759.
Immonen-RSiha P, Arstila M, Tuomilehto J, Haikio M, Mononen A, Vuorenmaa T, Torppa J,
Parvinen I. 21 year trends in incidence of myocardial infarction and mortality from coronary
disease inmiddle-age. European Heart Journal (1996); 17:1495-1502.
Inoue H, Skale B, Zipes D. Effects of myocardial ischaemia and infarction on cardiac afferent
sympathetic and vagal reflexes in the dog. American Journal of Physiology (1988);255:
H26-H35.
Inoue H, Zipes D. Increased afferent vagal responses produced by epicardial application of
nicotine on the canine posterior left ventricle. American Heart Journal (1987a);l 14:757-764.
Inoue H, Zipes D. Results of sympathetic denervation in the canine heart: supersensitivity that
may be arrhythmogenic. Circulation (1987b);75:877-887.
Irons C, Murray S, Glembotski C. Identification of the receptor subtype responsible for
endothelin-mediated protein kinase C activation and atrial natriuretic factor secretion from
atrial myocytes. Journal ofBiological Chemistry (1993);268:23417-23421.
Iversen L. Catecholamine uptake process. British Medical Bulletin (1973);29:130-135.
Jacobowitz D, Cooper T, Bamer H. Histochemical and chemical studies of the localization of
adrenergic and cholinergic nerves in normal and denervated cat hearts. Circulation Research
(1967);20:289-298.
Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from
myocardial ischemia and infarction. Physiological Reviews (1989);69:1049-1169.
References 105
Janse MJ, Van Capelle FJL, Morsink H, K16ber AG, Wilms-Shopman F, Cardinal R,
D'Alnoncourt CN, Durrer D. Flow of 'injury' current and patterns of excitation during early
ventricular arrhythmias in acute regional myocardial ischemia in isolated porcine and canine
hearts. Evidence for two different arrhythmogenic mechanisms. Circulation Research
(1980);47:151-165.
Jones C, Beck L, Dupont E, Barnes G. Effects of coronary ligation on the chronically
sympathectomized dog ventricle. American Journal ofPhysiology (1978);235:H429-H434.
Josephson I, Sperelakis. On the ionic mechanism underlying adrenergic-cholinergic
antagonism in ventricular muscle. Journal ofGeneral Physiology (1982);79:69-86.
Kaku T, Lakatta E, Filbum C. Alpha-adrenergic regulation of phosphoinositide metabolism
and protein kinase C in isolated cardiac myocytes. American Journal of Physiology
(1991);260:C635-C642.
Kameyama A, Shearman MS, Sekiguchi K, Kameyama M. Cyclic AMP-dependent protein
kinase but not protein kinase C regulates the cardiac Ca2+ channel through phosphorylation of
its alpha 1 subunit. Journal ofBiochemistry (1996); 120:170-176.
Kato A, Collier B, Ilson D, Wright J. The effect of atropine upon acetylcholine release from
cat superior cervical ganglia and rat cortical slices: Measurement by a radio-enzymatic
method. Canadian Journal ofPhysiology (1975);53:1050-1057.
Kaumann AJ, Molenaar P. Differences between the third cardiac beta-adrenoceptor and the
colonic beta3-adrenoceptor in the rat. British Journal of Pharmacology (1996); 118:
2085-2098.
Kendrick K, HintonM. Microdialysis sampling of in vivo neurotransmitter release in the brain
of the conscious sheep: measurement of acetylcholine, amino acid and monoamine
concentrations by high performance liquid chromatography (HPLC). Journal of Physiology
(1992);446:66P
Kent KM, Epstein S, Cooper T, Jacobowitz D. Cholinergic innervation of the canine and
human ventricular conducting system. Anatomic and electrophysiologic correlations.
Circulation (1974);50:948-955.
Kent KM, Smith ER, Redwood DR, Epstein SE. Electrical stability of acutely ischemic
myocardium. Influences of heart rate and vagal stimulation. Circulation (1973);47:291-298.
Kerzner J, Wolf M, Kosowsky B, Lown B. Ventricular ectopic rhythms following vagal
stimulation in dogs with acute myocardial infarction. Circulation (1973);47:44-50.
Kilbinger H. The autonomic cholinergic neuroeffector junction. In: Whittaker V, ed. The
Cholinergic Synapse. Springer Verlag: Berlin, (1988):581-595.
References 106
Kilbinger H, LOffelholz K. The isolated perfused chicken heart as a tool for studying
acetylcholine output in the absence of cholinesterase inhibition. Journal of Neural
Transmission (1976);38:9-14.
Kirkepar S, Puig M. Effects of stop flow on noradrenaline release from normal spleens treated
with cocaine, phentolamine or phenoxybenzamine. British Journal of Pharmacology
(1971);43:359-369.
Kleiger RE, Miller JP, Bigger JT, Moss AJ, Moss MD. Decreased heart rate variability and its
association with increased mortality after acute myocardial infarction. American Journal of
Cardiology (1987);59:256-262.
Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews RV, Burstein S, Gibson M,
Poole WK, Cannon CP, McCabe CH, Braunwald E. Previous angina alters in-hospital
outcome in TIMI4. A clinical correlate to preconditioning?. Circulation (1995);91:37-45.
Knight D, Von Grafenstein H, Maconochie D. Intracellular requirements for exocytotic
noradrenaline release. In: Brachmann J, Schdmig A, eds. Adrenergic system and ventricular
arrhythmias in myocardial infarction. Springer-Verlag: Berlin, (1989):3-20.
Komori S, Parratt JR, Szekeres L, Vegh A. Preconditioning reduces the severity of ischaemia
and reperfusion- induced arrhythmias in both anaesthetized rats and dogs. Journal of
Physiology (1990);423:16P
Koumi S, Sato R, Hayakawa H. Characterization of the acetylcholine-sensitive muscarinic K+
channel in isolated feline atrial and ventricular myocytes. Journal of Membrane Biology
(1995);145:143-150.
Kubo T, Fukuda K, Mikami A, Maeda A, Takahashi H, Mishina M, Haga T, Haga K,
Ichiyama A, Kangawa K, Kojima M, Matsuo H, Hirose T, Numa S. Cloning, sequencing and
expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature
(1986);323:411-416.
Kurachi Y, Tung RT, Ito H, Nakajima T. G protein activation of cardiac muscarinic K+
channels. Progress in Neurobiology (1992);39:229-246.
Kurz T, Offner B, Schreieck J, Richardt G, Tolg R, Schtjmig A. Nonexocytotic noradrenaline
release and ventricular fibrillation in ischemic rat hearts. Naunyn-Schmiedeberg's Archives of
Pharmacology (1995a);352:491-496.
Kurz T, Richardt G, Hagl S, Seyfarth M, Schbmig A. Two different mechanisms of
noradrenaline release during normoxia and simulated ischemia in human cardiac tissue.
Journal ofMolecular and Cellular Cardiology (1995b);27:l 161-1172.
La Rovere MT, Specchia G, Mortara A, Schwartz PJ. Baroreflex sensitivity, clinical
correlates, and cardiovascular mortality among patients with a first myocardial infarction: A
prospective study. Circulation (1988);78:816-824.
References 107
Lavallde M, De Charaplain J, Nadeau R, Yamaguchi N. Muscarinic inhibition of endogenous
myocardial catecholamine liberation in the dog. Canadian Journal of Physiology and
Pharmacology (1978);56:642-649. .
Levy MN. Cardiac sympathetic-parasympathetic interactions. Federation Proceedings
(1984);43:2598-2602.
Levy MN, Blattberg B. Effect of vagal stimulation on the overflow of norepinephrine into the
coronary sinus during cardiac sympathetic nerve stimulation in the dog. Circulation Research
(1976);38:81-85.
Levy MN. Sympathetic-parasympathetic interactions in the heart. Circulation Research
(1971);29:437-445.
Li G, Vasquez B, Gallagher K, Lucchesi B. Myocardial protection with preconditioning.
Circulation (1990);82:606-619.
Li Y, Kloner RA. The cardioprotective effects of ischemic "preconditioning' are not mediated
by adenosine receptors in rat hearts. Circulation (1993);87:1642-1648.
Liedke JA, Nellis SH, Neely JR, Hughes HC. Effects of treatment with pyruvate and
tromethamine in experimental myocardial ischemia. Circulation Research (1976);39:378-387.
Limas C. Phosphorylation of cardiac sarcoplasmic reticulum by a calcium-activated
phospholipid-dependent protein kinase. Biochemical Biophysical Research Communications
(1980);96:1378-1383.
Limas CJ, Limas C. Phorbol ester- and diacylglycerol-mediated desensitization of cardiac
beta-adrenergic receptors. Circulation Research (1985);57:443~449.
Limbird LE. Receptors linked to inhibition of adenylate cyclase: Additional signaling
mechanisms. FASEB Journal (1988);2:2686-2695.
Lindmar R, Loffelholz K, Weide W. Interstitial washout and hydrolysis of acetylcholine in the
perfused heart. Naunyn-Schmiedeberg's Archives ofPharmacology (1982);318:295-300.
Lindmar R, Ldffelholz K, Weide W. Inhibition by pentobarbital of the acetylcholine release
from the postganglionic parasympathetic neuron of the heart. Journal of Pharmacology &
Experimental Therapeutics (1979);210:166-173.
Litovsky S, Antzelevitch C. Differences in the electrophysiological responses of canine
ventricular subendocardium and subepicardium to acetylcholine and isoproterenol. A direct
effect of acetylcholine in ventricular myocardium. Circulation Research (1990);67:615-627.
References 108
Liu GS, Jacobson KA, Downey JM. An irreversible Al-selective adenosine agonist
preconditions rabbit heart. Canadian Journal ofCardiology (1996);12:517-521.
Liu GS, Richards S, Olsson RA, Mullane K, Walsh R, Downey JM. Evidence that the
adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated
rabbit heart. Cardiovascular Research (1994);28:1057-1061.
Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson RA, Downey JM. Protection
against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit
heart. Circulation (1991);84:350-356.
Liu Y, Downey JM. Ischemic preconditioning protects against infarction in rat heart.
American Journal ofPhysiology (1992);263:H1107 - HI 112.
Locke-Winter C, Winter C, Nelson D, Baneijee A. cAMP stimulation facilitates
preconditioning against ischaemia reperfusion through norepinephrine and alphal mechanisms.
Circulation (1991);84 (suppl 2):II-433 (Abstract).
Ldffelholz K, Pappano AJ. The parasympathetic neuroeffector junction of the heart.
Pharmacological Reviews (1985);37:l-24.
Ldffelholz K, Brehm R, Lindmar R. Hydrolysis, synthesis, and release of acetylcholine in the
isolated heart. Federation Proceedings (1984);43:2603-2606.
LOffelholz K, Muscholl E. A muscarinic inhibition of the noradrenaline release evoked by
postganglionic sympathetic nerve stimulation. Naunyn-Schmiedeberg's Archives of
Pharmacology (1969);265:1-15.
Lombardi F, Sandreone G, Pemprurer S, Sala R, Garimoldi M, Cerutti S, Baselli G,
Pagani M, Malliani A. Heart rate variability as an index of sympathovagal interaction after
acute myocardial infarction. American Journal ofCardiology (1987);60:1239-1245.
Lombardi F, Casalone C, Bella P, Malfatto G, Pagani M, Malliani A. Global versus regional
myocardial ischaemia differences in cardiovascular and sympathetic responses in cats.
Cardiovascular Research (1984); 18:14-23.
Losano G, Gattullo D, Pagliaro P. Myocardial, neural and vascular aspects of ischemic
preconditioning. Life Sciences (1996);59:1185-1192.
Lowry O, Rosebrough N, Farr A, Randall R. Protein measurement with the Folin Phenol
reagent. Journal ofBiological Chemistry (1951); 193:265-275.
Lundberg JM. Pharmacology of cotransmission in the autonomic nervous system: Integrative
aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide.
Pharmacological Reviews (1996);48:113-178.
References 109
MacDonald SL, Middleton SM. Haemoglobin and albumin. In: Prowse CV, ed. Plasma and
Recombinant Blood Products inMedical Therapy. John Wiley and Sons: (1992).
Maeda A, Kubo T, Mishina M, Numa S. Tissue distribution of mRNAs encoding muscarinic
acetylcholine receptor subtypes. FEBS Letters (1988);239:339-342.
Malic A, Kaplan J, Saba T. Reference sample method for cardiac output and regional blood
flow determination in the rat. Journal ofApplied Physiology (1976);40:472-475.
Malliani A, Schwartz P, Zanchetti A. A sympathetic reflex elecited by experimental coronary
occlusion. American Journal ofPhysiology (1969);217:703-709.
Marcus AJ, Broekman MJ. Cell free hemoglobin as an oxygen carrier removes nitric oxide,
resulting in defective thromboregulation. Circulation (1996);93:208-209.
Martin C, Meesmann W. Antiarrhythmic effect of regional myocardial chemical
sympathectomy in the early phase of coronary artery occlusion in dogs. Journal of
Cardiovascular Pharmacology (1985);7:S76-S80.
Masuda M, Chang C, Cho B, Flameng W. Coronary reserve and contractile reserve in
crystalloid- and blood-perfused rabbit hearts. Heart and Vessels (1994);9:175-182.
McCance A, Forfar JC. Cardiac and wholebody (3H) noradrenaline kinetics in ischaemic heart
disease: contrast between unstable angina syndromes and pacing induced ischaemia. British
Heart Journal (1989);61:238-247.
McGrath BP, Lim SP, Leversha L, Shanahan A. Myocardial and peripheral catecholamine
responses to acute coronary artery constriction before and after propranolol treatment in the
anaesthetised dog. Cardiovascular Research (1981);15:28-34.
McGrattan PA, Brown JH, Brown OM. Parasympathetic effects on in vivo rat heart can be
regulated through an alpha1-adrenergic receptor. Circulation Research (1987);60:465-471.
Minneman KP. alpha1-Adrenergic receptor subtypes, inositol phosphates, and sources of cell
Ca2+. Pharmacological Reviews (1988);40:87-119.
Minshall R, Nakamura F, Becker RP, Rabito SF. Characterisation of bradykinin B2 receptors
in adult myocardium and neonatal rat cardiomyocytes. Circulation Research (1995);76:
773-780.
Mitchell MB, Parker CG, Meng X, Brew EC, Lihua A, Brown JM, Harken AH, Baneijee A.
Protein kinase C mediates preconditioning in isolated rat heart. Circulation (1993);88
(suppl I):I-633(Abstract).
Miura T, Adachi T, Ogawa T. Myocardial infarct size-limiting effect of ischaemic
preconditioning: its natural decay and the effect of repetitive preconditioning. Cardiovascular
Pathology (1992); 1:147-154.
References 110
Mizamura T, Nithipatikom K, Gross G. Bimakalim, an ATP-sensitive potassium channel
opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release
and neutrophil function in dogs. Circulation (1995);92:1236-1245.
Mochizuki S, Neely J. Energy metabolism during reperfusion following ischemia. Journal of
Physiology (1980);76:805-812.
Moolman J, Genade S, Trompe E, Lochner A. No evidence for mediation of ischemic
preconditioning by alphal-adrenergic signal transduction pathway or protein kinase C in the
isolated rat heart. Cardiovascular Drugs and Therapy (1996);10:125-136.
Moyer T, Jiang N. Optimized isocratic conditions for analysis of catecholamines by high-
performance reversed-phase paired-ion chromatography with amperometric detection. Journal
ofChromatography (1978); 153:365-372.
Mubagwa K, Carmeliet E. Effects of acetylcholine on electrophysiological properties of rabbit
cardiac Purkinje fibers. Circulation Research (1983);53:740-751.
Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy
metabolism and delays ultrastructural damage during a sustained ischemic episode.
Circulation Research (1990);66:913-931.
Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell
injury in ischemic myocardium. Circulation (1986);74:1124-1136.
Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: Structure, function, and
time-dependence of risk. Circulation (1992); 85:1-2 -1-10.
Myers R, Pearlman A, Hyman R, Goldstein R, Kent K, Epstein S. Beneficial effects of vagal
stimulation and bradycardia during experimental acute myocardial ischaemia. Circulation
(1974);49:943-947.
Nadeau R, De Champlain J. Plasma catecholamines in acute myocardial infarction. American
Heart Journal (1979);98:548-554.
Nichols AJ, Motley ED, Ruffolo RR. Differential effect of pertussis toxin on pre- and
postjunctional alpha2-adrenoceptors in the cardiovascular system of the pithed rat. European
Journal ofPharmacology (1988); 145:345-349.
Nikolic G, Bishop RL, Singh JB. Sudden death recorded during Holter monitoring.
Circulation (1982);66:218-225.
Ninomiya I, Matsukawa K, Honda T, Nishimura N, Shirai M. Cardiac sympathetic nerve
activity and heart rate during coronary occlusion in awake cats. American Journal of
Physiology (1986);251:H528-H537.
References 111
Noble D. The surprising heart: a review of recent progress in cardiac electrophysiology.
Journal ofPhysiology (1984);353:1-50.
Odemuyiwa O, Poloniecki J, Malik M, Farrell T, Xia R, Staunton A, Kulakowski P, Ward D,
Camm J. Temporal influences on the prediction of postinfarction mortality by heart rate
variability: A comparison with the left ventricular ejection fraction. British Heart Journal
(1994);71:521-527.
Opie L, Thandroyen F, Muller C, Daries P. Catecholamines, cyclic AMP and arrhythmias.
Role for Ca2+ and Ca2+ - antagonist agents. In: Riemersma R, Oliver M, eds.
Catecholamines in the non-ischaemic and ischaemic myocardium. Elsevier Biomedical Press:
Amsterdam, (1982):203-224.
Osterrieder W, Yang QF, Trautwein W. The time course of the muscarinic response to
ionophoretic acetylcholine application to the S-A node of the rabbit heart. Pfliigers Archiv
European Journal ofPhysiology (1981);389:283-291.
Pardini B, Patel K, Schmid P, Lund D. Location, distribution and projections of intracardiac
ganglion cells in the rat. Journal of the Autonomic Nervous System (1987);20:91-101.
Parratt J, Vegh A. Pronounced antiarrhythmic effects of ischemic preconditioning.
Cardioscience (1994);5:9-18.
Paton W, Vizi E. The inhibitory action of noradrenaline and adrenaline on acetylcholine output
by guinea pig ileum longitudinal muscle strip. British Journal of Pharmacology
(1969);35:10-28.
Pelzer S, Shuba YM, Asai T, Codina J, Birnbaumer L, McDonald TF, Pelzer D. Membrane-
delimited stimulation of heart cell calcium current by beta- adrenergic signal-transducing G(s)
protein. American Journal of Physiology - Heart and Circulatory Physiology
(1990);259:H264-H267.
Penny WJ. The deleterious effects of myocardial catecholamines on cellular electrophysiology
and arrhythmias during ischaemia and reperfusion. European Heart Journal (1984);5:
960-973.
Pfaffinger PJ, Martin JM, Flunter DD, Nathanson NM, Hille B. GTP-binding proteins couple
cardiac muscarinic receptors to a K channel. Nature (1985);317:536-538.
Philippu P, Matthaei H. Transport and storage of catecholamines in vehicles. In:
Trendelenberg U, Weiner N, eds. Handbook ofExperimental Pharmacology. Springer-Verlag:
Berlin, (1988): 1-42.
Podzuweit T, Binz KH, Nennstiel P, Flaig W. The anti-arrhythmic effects of myocardial
ischaemia. Relation to reperfusion arrhythmias? Cardiovascular Research (1989);23:81-90.
References 112
Potter E. Presynaptic inhibition of cardiac vagal postganglionic nerves by neuropeptide Y.
Neuroscience Letters (1987);83:101-106.
Prystowsky EN, Jackman WM, Rinkenberger RL, Heger JJ, Zipes DP. Effect of autonomic
blockade on ventricular refractoriness and atrioventricular nodal conduction in humans.
Evidence supporting a direct cholinergic action on ventricular muscle refractoriness.
Circulation Research (1981);49:511-517.
Quist EE. Evidence for a carbachol stimulated phosphatidylinositol effect in heart.
Biochemical Pharmacology (1982);31:3130-3133.
Rand MJ, Majewski H, WongDusting H, Story DF, Loiacono RE, Ziogas J. Modulation of
neuroeffector transmission. Journal ofCardiovascular Pharmacology (1987); 10:S33-S44.
Rardon D, Bailey M. Parasympathetic effects on electrophysiologic properties of cardiac
ventricular tissue. Journal of the American College ofCardiology (1983);2:1200-1209.
Richardt G, Lumpp U, Haass M, Schdmig A. Propranolol inhibits nonexocytotic
noradrenaline release in myocardial ischemia. Naunyn-Schmiedeberg's Archives of
Pharmacology (1990);341:50-55.
Riemersma RA, Forfar JC. Effects of experimental ischaemia on myocardial catecholamines.
In: Riemersma RA, Oliver MF, eds. Catecholamines in the Non-ischaemic and Ischaemic
Myocardium. Elsevier biomedical press, (1981):139-155.
Roden D. Early after depolarizations and torsade de pointes: implications for the control of
cardiac arrhythmias by prolonging repolarization. European Heart Journal (1993); 14
(suppl H):56-61.
ROmer B, Uptmoor H, Meesmann W, Sautter R, Martin C, Krosigk SV, Neumann M.
Reduced coronary collateral resistance during acute coronary occlusion after regional chemical
myocardial sympathectomy. Pfliigers Archiv European Journal ofPharmacology (1981);391
(suppl) :R6.
Rosenshtraukh L, Danilo P, Anyukhovsky EP, Steinberg SF, Rybin V, BrittainValenti K,
MolinaViamonte V, Rosen MR. Mechanisms for vagal modulation of ventricular
repolarization and of coronary occlusion-induced lethal arrhythmias in cats. Circulation
Research (1994);75:722-732.
Roskoski R, Schmid P, Mayer H, Abboud F. In vitro acetylcholine biosynthesis in normal and
failing guinea pig hearts. Circulation Research (1975);36:547-552.
Sack S, Mohri M, Arras M, Schwarz ER, Schaper W. Ischaemic preconditioning - Time
course of renewal in the pig. Cardiovascular Research (1993);27:551-555.
References 113
Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II - induced c-fos gene
expression in cardiac myocytes in vitro; roles of phospholipid - derived second messengers.
Circulation Research (1993);73:424-438.
Scherlag B, El-Sherif N, Hope R, Lazzara R. Characterisation of ventricular arrhythmias
resulting from myocardial ischaemia and infarction. Circulation Research (1974);35:
372-383.
Scherlag B, Helfant R, Haft J, Damato A. Electrophysiology underlying ventricular
arrhythmias due to coronary ligation. American Journal of Physiology (1970);291:
1665-1671.
Schjott J, Jynge P, Holten T, Brurok H. Ischaemic episodes of less than 5 minutes produce
preconditioning but not stunning in the isolated rat heart. Acta Physiologica Scandinavica
(1994); 150:281 -291.
Schdmig A. Catecholamines in myocardial ischemia. Systemic and cardiac release.
Circulation (1990);82:II-13 -11-22.
Schdmig A. Adrenergic mechanisms in myocardial infarction: Cardiac and systemic
catecholamine release. Journal ofCardiovascular Pharmacology (1988); 12 (suppl 1):S1-S7.
Schdmig A, Kurz T, Richardt G, Schdmig E. Neuronal sodium homeostasis and axoplasmic
amine concentration determine calcium-independent noradrenaline release in normoxic and
ischemic rat heart. Circulation Research (1988);63:214-226.
Schdmig A, Fischer S, Kurz T, Richardt G Schdmig E. Nonexocytotic release of endogenous
noradrenaline in the ischemic and anoxic rat heart: Mechanism and metabolic requirements.
Circulation Research (1987);60:194-205.
Schdmig A, Dart AM, Dietz R. Paradoxical role of neuronal uptake for the locally mediated
release of endogenous noradrenaline in the ischemic myocardium. Journal of Cardiovascular
Pharmacology (1985);7 (suppl 5):S40-S44.
Schott RJ, Rohmann S, Braun ER, Schaper W. Ischemic preconditioning reduces infarct size
in swine myocardium. Circulation Research (1990);66:1133-1142.
Schwartz PJ, Vanoli E, Stramba-Badiale M, De Ferrari GM, Billman GE, Foreman RD.
Autonomic mechanisms and sudden death: New insights from analysis of baroreceptor reflexes
in conscious dogs with and without a myocardial infarction. Circulation (1988a);78:969-979.
Schwartz PJ, Zaza A, Pala M, Locati E, Beria G, Zanchetti A. Baroreflex sensitivity and its
evolution during the first year after acute myocardial infarction. Journal of the American
College ofCardiology (1988b); 12:629-636.
References 114
Schwartz PJ, Zaza A. The rational basis and clinical value of selective cardiac sympathetic
denervation in the prevention of malignant arrhythmias. European Heart Journal (1986);7
(suppl A): 107-118.
Schwartz PJ. Idiopathic long QT syndrome: Progress and questions. American Heart Journal
(1985);109:399-410.
Schwartz PJ, Motolese M, Pollavini G, Malliani A, Bartorelli C, Zanchetti A. Surgical and
pharmacological antiadrenergic interventions in the prevention of sudden death after a first
myocardial infarction. Circulation (1985);72 (suppl III):III-358 (Abstract).
Schwartz PJ, Stone HL. Left stellectomy in the prevention of ventricular fibrillation caused by
acute myocardial ischemia in conscious dogs with anterior myocardial infarction. Circulation
(1980);62:1256-1265.
Schwartz PJ, Stone HL, Brown A. Effects of unilateral stellate ganglion blockade on the
arrhythmias associated with coronary occlusion. American Heart Journal (1976a); 92:
589-599.
Schwartz PJ, Snebold N, Brown A. Effects of unilateral cardiac sympathetic denervation on
the ventricular fibrillation threshold. American Journal of Cardiology (1976b);37:
1034-1040.
Seyfarth M, Richardt G, Mizsnyak A, Kurz T, Schdmig A. Transient ischaemia reduces
norepinephrine release during sustained ischaemia: Neural preconditioning in isolated rat
heart. Circulation Research (1996);78:573-580.
Sheridan DJ, Penkoske PA, Sobel BE, Corr PB. Alpha adrenergic contributions to
dysrhythmia during myocardial ischemia and reperfusion in cats. Journal of Clinical
Investigation (1980);65:161-171.
Singer D, Baumgarten C, Ten Eick R. Cellular electrophysiology of ventricular and other
dysrhythmias: Studies on diseased and ischemic heart. Progress in Cardiovascular Diseases
(1981);24:97-156.
Slavikova J, Tucek S. Choline acetyltransferase in the heart of adult rats. Pflugers Archiv
European Journal ofPhysiology (1981);392:225-229.
Sleight P. A cardiovascular depressor reflex from the epicardium of the left ventricle of the
dog. Journal ofPhysiology (1964);173:321-343.
Spear J, Kronhaus K, Moore E, Kline R. The effect of brief vagal stimulation on pacemaker
activity and conduction within the atrioventricular conduction system of the dog. Circulation
Research (1979);44:75-88.
Starke K. Presynaptic a-autoreceptors. Review of Physiology Biochemistry and
Pharmacology (1987); 107:73-146.
References 115
Stiles GL, Taylor S, Lefkowitz RJ. Human cardiac beta-adrenergic receptors: Subtype
heterogeneity delineated by direct radioligand binding. Life Sciences (1983);33:467-473.
Szabo G, Otero AS. G protein mediated regulation of K+ channels in heart. Annual Review of
Physiology (1990);52:293-305.
Tate KM, Briend-Sutren MM, Emorine LJ, Delavier-Klutchko C, Marullo S, Strosberg AD.
Expression of three human beta-adrenergic-receptor subtypes in transfected Chinese hamster
ovary cells. European Journal ofBiochemistry (1991); 196:357-361.
Thames M, Klopfenstein H, Abboud F, Mark A, Walker J. Preferential distribution of
inhibitory cardiac receptors with vagal afferents to the inferoposterior wall of the left ventricle
activated during coronary occlusion in the dog.. Circulation Research (1978);43:512-519.
Thandroyen FT, Worthington MG, Higginson LM, Opie LH. The effect of alpha- and
beta-adrenoceptor antagonist agents on reperfusion ventricular fibrillation and metabolic status
in the isolated perfused rat heart. Journal of the American College of Cardiology
(1983); 1:1056-1066.
Thornton JD, Daly JF, Cohen MVVV, Yang XM, Downey JM. Catecholamines can induce
adenosine receptor-mediated protection of the myocardium but do not participate in ischemic
preconditioning in the rabbit. Circulation Research (1993);73:649-655.
Thornton JD, Striplin S, Liu GS, Swafford A, Stanley AWH, Van Winkle DM, Downey JM.
Inhibition of protein synthesis does not block myocardial protection afforded by
preconditioning. American Journal of Physiology - Heart and Circulatory Physiology
(1990);259:H1822-H1825.
Hetje KM, Nathanson NM. Embryonic chick heart expresses multiple muscarinic
acetylcholine receptor subtypes. Isolation and characterization of a gene encoding a novel m2
muscarinic acetylcholine receptor with high affinity for pirenzepine. Journal of Biological
Chemistry (1991);266:17382-17387.
Toombs CF, Wiltse AL, Shebuski RJ. Ischemic preconditioning fails to limit infarct size in
reserpinized rabbit myocardium: Implication of norepinephrine release in the preconditioning
effect. Circulation (1993);88:2351-2358.
Tsuchida A, Thompson R, Olsson R, Downey JM. The anti-infarct effect of an adenosine
A1-selective agonist is diminished after prolonged infusion as is the cardioprotective effect of
ischemic preconditioning in rabbit heart. Journal of Molecular and Cellular Cardiology
(1994);26:303-311.
Turrens JF, Thornton J, Barnard ML, Snyder S, Liu G, Downey JM. Protection from
reperfusion injury by preconditioning hearts does not involve increased antioxidant defences.
American Journal ofPhysiology (1992);262:H585-H589.
References 116
Vander Heide RS, Hill ML, Steenbergen C, Reimer KA, Jennings RB. Effect of reversible
ischemia on mitrochondrial ATPase activity in canine myocardium. Circulation (1991); 84
(Suppl II):II-192(Abstract).
Van Winkle DM, Thornton JD, Downey DM, Downey JM. The natural history of
preconditioning: Cardioprotection depends on duration of transient ischemia and time to
subsequent ischemia. Coronary Artery Disease (1991);2:613-619.
Vatner D, Lavallde M, Amano J. Mechanisms of supersensitivity to sympathomimetic amines
in the chronically denervated heart of the conscious dog. Circulation Research (1985);57:
55-64.
Verrier R, Lown B. Behavioural stress and cardiac arrhythmias. Annual Review of
Physiology (1984);46:155-176.
Warner MR, Levy MN. Neuropeptide Y as a putative modulator of the vagal effects on heart
rate. Circulation Research (1989);64:882-889.
Webb S, Adgey A, Pantridge J. Autonomic disturbance at onset of acute myocardial
infarction. British Medical Journal (1972);3:89-92.
Weselcouch E, Baird A, Sleph P, Dzwonczyk S, Murray H, Grover G. Endogenous
catecholamines are not necessary for ischaemic preconditioning in the isolated perfused rat
heart. Cardiovascular Research (1995);29:126-132.
Wessler I. Acetylcholine release at motor endplates and autonomic neuroeffector junctions: a
comparison. Pharmacological Research (1996);33:81-94.
Wetzel GT, Brown JH. Presynaptic modulation of acetylcholine release from cardiac
parasympathetic neurons. American Journal of Physiology - Heart and Circulatory
Physiology (1985);17:H33-H39.
Wetzel GT, Goldstein D, Brown JH. Acetylcholine release from rat atria can be regulated
through an alphal-adrenergic receptor. Circulation Research (1985);56:763-766.
Wetzel GT, Brown JH. Relationships between choline uptake, acetylcholine synthesis and
acetylcholine release in isolated rat atria. Journal of Pharmacology and Experimental
Therapeutics (1983);226:343.
Yamaguchi N, De Champlain J, Nadeau R. Regulation of norepinephrine release from cardiac
sympathetic fibres in the dog by presynaptic alpha and beta-receptors. Circulation Research
(1977);41:108-117.
Yang ZK, Boyett MR, Janvier NC, McMorn SO, Shui Z, Karim F. Regional differences in the
negative inotropic effect of acetylcholine within the canine ventricle. Journal of Physiology
(1996);492:789-806.
References 117
Yatani A, Imoto Y, Codina J, Hamilton SL, Brown AM, Birnbaumer L. The stimulatory
G protein of adenylyl cyclase, G(s), also stimulates dihydropyridine-sensitive Ca2+ channels.
Evidence for direct regulation independent of phosphorylation by cAMP-dependent protein
kinase or stimulation by a dihydropyridine agonist. Journal of Biological Chemistry
(1988);263:9887-9895.
Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet
(1993);342:276-277.
Yellon DM, Alkhulaifi AM, Browne EE, Pugsley WB. Ischaemic preconditioning limits
infarct size in the rat heart. Cardiovascular Research (1992);26:983-987.
Yokota R, Fujiwara H, Miyamae M, Tanaka M, Yamasaki K, Itoh S, Koga K. Transient
adenosine infusion before ischemia and reperfusion protects against metabolic damage in pig
hearts. American Journal ofPhysiology (1995);268:H1149-H1157.
Ytrehus K, Downey JM, Liu Y. Preconditioning protects ischaemic rabbit heart by protein
kinase C activation. American Journal ofPhysiology (1994);266:H1145-H1152.
Zimmermann H. Cholinergic synaptic vesicles. In: Whittaker V, ed. The Cholinergic Synapse.
Handbook ofExperimental Pharmacology. Springer-Verlag: Berlin, (1988):349-375.
References 118
